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VAbstract
Piano-stool iodido Os(II) arene complexes containing AZPY (phenylazopyridine)
π-acceptor bidentate ligands have been previously shown to exhibit potent anti-
cancer activity and mechanisms of action that involve ROS generation, and
differ greatly from early Os(II) arene complexes baring σ-donor bidentate 
ligands. The aim of this thesis was to explore Os(II) complexes containing other
types of azo-ligands as well as continue our studies into AZPY complexes.
Develop methods for improving the solubility of complexes, explore their
intracellular activation, and further understand the mechanisms in which ROS
levels are elevated inside cells.
Firstly I explored Os(II) arene complexes with AZBTZ (phenylazobenzothiazole)
bidentate liagnds. It was found that AZBTZ ligands can undergo unaided cyclo-
metallation with Os(II) to form N,C-coordinated osmacycles as well as N,N-
coordination. The amount of cyclo-metallation taking place seemed to be
dependent on steric factors and occurred more for iodido complexes than
chlorido and bromido analogues. The osmacycles were more stable than N,N-
coordinated species and exhibited unique properties such as regio-specific
deuteration of the aniline ring, but were too hydrophobic for biological
evaluation.
A total of 31 new Os(II) arene AZPY complexes were synthesised using the
previously determined structure-activity relationships as a basis. The majority
contained alkoxy and glycolic side chain substituents on the AZPY ligand, which
was achieved via a novel synthesis protocol. Their trends in anti-cancer activity,
solubility, lipophilicity and cell uptake were explored. It was found that varying
the anion was the best method for improving aqueous solubility without affecting
activity, lipophilicity or uptake. Key complexes were found to be very active
against OE19 oesophageal cancer cells, were capable of inducing apoptosis
and elevating ROS levels in A2780 cells, as well as causing cell cycle arrest in
different phases of the cell cycle.
VI
Complexes [Os(ɳ6-p-cym)(5-EtO-AZPY)I]+ and [Os(ɳ6-p-cym)(AZPY-NMe2)I]+
were labelled with radioisotope 131I (β-/γ emitter, t½ 8.02 d) in Kings College
London. They were relatively stable in human blood serum and cell culture
medium over 24 h. However, in the presence of MCF-7 cells, rapid dissociation
of the iodide monodentate ligand was observed in the supernatants. Cell uptake
studies revealed a spike in 131I uptake after 5-10 min, which proceeds to
steadily decline. The complexes seemed to undergo intracellular activation
involving dissociation of the iodide ligand, and uptake of the complex is in
competition with a rapid rate of iodide efflux, probably involving chloride
transport channels.
The aqua species, [Os(ɳ6-p-cym)(5-EtO-AZPY)H2O]2+, was synthesised and its
pKa was determined as 4.55, meaning it exists predominantly as a +1 charged
hydroxido species under physiological conditions. Using UV-Vis spectroscopy
and EPR (DEPMPO spin trap), [Os(ɳ6-p-cym)(5-EtO-AZPY)OH]+, and its
chlorido and iodido analogues were found to catabolise H2O2, generating
HO· radicals in the process that were capable of cleaving lysozyme protein with
effectiveness in the order OH>Cl>I. Interestingly it was discovered that iodido
complexes are activated by iodide ligand dissociation in the presence of low
concentrations of GSH (75 µM) to form the more active hydroxido species.
However, in higher concentrations (7.5 mM), they formed Os-SG and Os-SOG
adducts. Likewise, [Os(ɳ6-p-cym)(5-EtO-AZPY)OH]+ and its iodido analogue
were both capable of oxidising NADH to NAD+ with effectiveness in the order
OH>I. NADH was also capable of activating iodido species in a similar manner
and generating the hydroxido species was required for NADH oxidation to
proceed.
VII
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1.1. Cancer and cancer treatments
1.1.1. What is cancer?
Cancer is the collective term for a group of diseases characterised by
unregulated cell growth and the spread of unhealthy cells from their site of
origin. There are over 200 different types of cancer as there are over 200 cell
types in the human body. Cancer occurs when the genes of normal cells
become damaged or mutated, causing them to escape the many biological
regulations that make them behave normally.1 Typical abnormal behaviours of
cancerous cells include the following characteristics: 1) cell proliferation in an
uncontrolled manner, 2) an ‘anchorage independence’ of cells, enhancing their
ability to spread to other parts of the body, and 3) immortality, whereby
cancerous cells bypass apoptosis (the programmed cell death mechanism)
which is otherwise normally triggered in unhealthy cells.2 The progression of a
cancer typically results in the formation of a malignant tumour (Figure 1.1).3
These are physical obstructions in the human body that compromise the
function of vital organs and compete fiercely with healthy tissues for nutrients
and oxygen. If left untreated, the growth of a malignant tumour will spiral out of
control, spreading to other parts of the body and eventually resulting in the
death of the host. However, unlike many other diseases such as the human
immunodeficiency virus (HIV), cancer does not behave with malicious intent; it
is not a foreign invader infecting and destroying its host for self benefit. Cancer
is a disease that arises from the tissue of its host. It gains no benefit from the
host’s demise and is not passed onto a new host for future survival.1
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Figure 1.1. The anatomy of a tumour in normal tissue. Diagram taken from reference.3
Cancer is one of the most life threatening diseases of the modern era, second
only to heart disease. According to Cancer Research UK in 2012 in the UK,
338,623 people were diagnosed with cancer and 161,823 people lost their lives
to cancer.3 A startling new projection according to Macmillan Cancer Support
reveals that by 2020, almost half of Britons will be diagnosed with cancer at
some stage in their life time.4 Despite the increasing rates of incidence, the
survival rates of cancer patients for 10 years or more is 50%, which has seen
an increase over the past 40 years from 24%. This increased survival rate can
be attributed to the introduction of improved treatments for cancer patients and
early diagnosis.
1.1.2. Conventional treatments for cancer
1.1.2.1. Surgery
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For several millennia surgery has long been a stable form of treatment for many
cancers. Even as far back as 3000 – 1500 BC, an ancient Egyptian medical
manuscript known as the Edwin Smith Papyrus recalls the use of early surgical
techniques to remove ‘growths’ that today would likely be classified as breast
cancers.1 Surgery is still used today to remove malignant tumours, relieving the
patient from the bulk of a cancer with immediate effect. There is no guarantee
that surgery can remove every cancerous cell from the body, especially
considering the nature of cancer is to spread. This is why in the modern era
surgery is normally accompanied with radio therapy and/or chemotherapy.
1.1.2.2. Radiotherapy
Radiotherapy is a very powerful technique in cancer treatment. It utilises the
energy of high powered ionising radiation to shrink or destroy tumours.3
Paradoxically, sources of ionising radiation are known to cause cancer.
However, the levels of radiation required to cause mutations that may lead to
cancers are low in comparison to levels used in radiotherapy, where high levels
of radiation are directed at a tumour in a uniform beam.4 The idea being that the
damage sustained by cancerous tissue is so extensive that it cannot survive,
and any mutations caused are not passed into the next generation of cells. The
downside of radiotherapy is that ionising radiation cannot distinguish between
cancerous cells and normal cells. It will damage or destroy normal cells within
its path.1 Strategies must be employed to minimise the exposure of normal cells
to such powerful radiation. One such method is to irradiate a tumour using a
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rotating beam that consistently intersects the tumour from different angles,
hence providing a much greater absorbed dose to the tumour than the
surrounding normal tissues.
1.1.2.3. Chemotherapy
Of all the therapies used to treat cancer, chemotherapy has the greatest
likelihood of reaching every cancerous cell inside the patient. A patient is
injected with a chemical substance which accesses all areas of the body as it is
absorbed and distributed.1 DNA, proteins and cellular redox systems are the
three main targets of anti-cancer therapeutics. Many cytotoxic agents work by
attacking or inhibiting essential cell functions. This is usually achieved by
damaging/binding to DNA, or by causing oxidative stress in cells.5 Targeted
therapies work by inhibiting specific proteins that are essential for the growth
and proliferation of cancer cells. Unfortunately, as with radiotherapy, many anti-
cancer drugs are non-selective and target normal cells as well as cancerous
cells, leading to detrimental side effects. It is a great challenge for today’s
researchers to design novel and potent chemotherapies that favour the
destruction of cancerous cells over normal cells.
1.2. Cellular targets in chemotherapy
1.2.1. DNA
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Drugs that target DNA are considered to be the conventional approach for
targeting cancer in chemotherapy. Such drugs work by forming strong
interactions with DNA nucleobases, either by binding to the nitrogen donor
groups (Figure 1.2), or via π-π stacking interactions which distort the DNA’s 
geometry and structure.6,7 Both examples will typically lead to S-phase cell
cycle arrest and subsequent cellular processes that result in apoptosis. Metal-
based DNA binders usually rely on the replacement of labile ligands (such as
chloride) with water, which is crucial for their activity and toxicity. The obvious
disadvantage of targeting DNA is that it is a non-selective approach, affecting
the DNA of both normal and cancerous cells.8 This type of treatment relies on
the drug being absorbed more rapidly into cancer cells than normal cells based
on their faster proliferation rates. G. Sava and P. J. Dyson have published a call
to arms, to abandon the targeting of DNA with metallo-drugs in favour of more
novel and selective approaches in what is now described as the 'genomic era',
where present understanding of the various biochemical pathways responsible
for the maintenance of tumours has vastly expanded.9
Figure 1.2. Schematic depiction of the bi-functional DNA binding modes of well known anti-
cancer drug, cis-platin. (A) 1,2-Intrastrand cross-link. (B) 1,3-Intrastrand cross-link. (C)
Interstrand cross-link. Picture taken from reference.6
(A) (B) (C)
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1.2.2. Proteins involved in proliferation
Targeted therapy involves the targeting and inhibition of particular proteins that
are associated with cancer cell proliferation. This is a much more selective
approach for destroying cancer cells over normal cells. In particular, kinase
inhibitors have become an important branch of therapeutics in recent years.
Kinases are enzymes that are responsible for mediating the transfer of
phosphate moieties from higher energy phosphate donating molecules (such as
adenosine triphosphate, ATP) to specific substrate molecules. They are
involved in the regulation of most cellular processes such as metabolism,
proliferation, damage repair, and apoptosis.10 Disturbances in the signalling
pathways of these processes are common in cancer cells, and so efforts are
made to intervene therapeutically with kinases. Erlotinib is an example of a
tyrosine kinase inhibitor that acts on the epidermal growth factor receptor
(EGFR), which is highly expressed and sometimes mutated in some forms of
cancer (Figure 1.3, A). It is commercially available and commonly used in the
treatment of pancreatic cancer and non-small cell lung cancer, working by
reversibly binding to the ATP binding site of EGFR.11
Likewise, targeting pro-survival proteins is a novel and more recent approach
towards targeting cancer cells. The ability to evade apoptosis is a key
characteristic of cancerous cells and overcoming this barrier is a compelling
therapeutic goal. The major gateway to apoptosis is guarded by the BCL-2
protein family, which regulate cell death and are often over-expressed in
tumours, rendering cancerous cells resistant to some chemotherapies.
Intervening therapeutically to inhibit BCL-2 proteins can allow the apoptotic
pathways in cancer cells to be restored. To date, only a few compounds that
target BCL
currently developing a selective inhibitor of the BCL
which contains a lipophilic benzothiazole moiety that is capable of docking into
a key hydrophobic pocket of the protein, rendering it
Figure 1.3.
WEHI-539 in complex with BCL
1.2.3. Cellular redox systems
All cells require strict
proper redox signalling.
occurs mainly in the mitochondria, the most redox ac
component. ROS play an important role in the normal functioning of
metabolism, signal transduction and other cellular functions, but the high
reactivity of ROS makes their tight regulation necessary for cell survival.
cancer cells, the redox balance is disturbed resulting in enhanced levels of
ROS. The most common physiologically relevant ROS include; O
-2 proteins have reached clinical trials.
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HO·.15 In particular, it has been well established that production and secretion of
H2O2 in an uncontrolled manner is a very characteristic biological feature of
cancerous tumours. H2O2 acts as a 'fertiliser', driving processes such as DNA
alterations, cell proliferation, apoptosis resistance and metastasis, hence
advancing tumour development and providing the ideal micro-environment for
tumours to thrive.16 Interestingly, cancer cells adapt to increased levels of
oxidative stress by up-regulating antioxidant systems. This counteracts the
damaging effects caused by excessive ROS levels that lead to cell death.17 It is
therefore postulated that cancer cells are closer to a ROS threshold whereby
cell death can occur.
A novel approach for anti-cancer therapeutics is to perturb redox processes in
such a manner that leads to a significant elevation of ROS. This is known as
‘oxidative therapy’.17 Since cancer cells operate in abnormally high levels of
ROS, such an increase can push cancerous cells beyond the threshold where
ROS-induced damages lead to cell cycle arrest and apoptosis (Figure 1.4).18
The most important ROS-induced damages include: 1) DNA single strand
breaks, 2) mitochondrial dysfunction caused by disruption of the mitochondrial
inner membrane, 3) disturbed cell membranes caused by lipid peroxidation, and
4) oxidation of cysteine protein residues that result in changes to protein
structures.14,15 One way in which ROS increases are achieved is by targeting
ROS detoxification systems such as glutathione (GSH), which is responsible for
scavenging O2·- and HO·.19 The role of GSH is explained in greater depth in
Chapter 6, Section 6.1.20 Another approach involves exploiting the over
production of H
HO·, a considerably more reactive ROS.
Figure 1.4.
higher levels of ROS than normal cells (represented in black) and there is a threshold of ROS in
which cells cannot survive. Increasing the levels of ROS (represented in st
selectively produce cell death for cancer cells. Picture taken from reference.
1.3. Metal
In comparison to traditional organic
complexes can offer greater versatility in terms of electronic and structural
features. This is owing to their capacity to achieve a variety of oxidation states,
incorporate multiple types and numbers of ligands, and adopt diff
coordination geometries around their metal centres.
complexes can offer a variety of novel chemistry, such as redox and catalytic
reactions that are not widely accessi
can be exploited for medicinal purposes. Furthermore, drug activity can be fine
tuned by making subtle changes to the electronic
2O2
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bound ligands,24 or varying the metal and its oxidation state. There now exists
vast libraries of transition metal complexes exhibiting promising anti-cancer
activity, incorporating metal centres of; titanium,24,25 vanadium,26 iron,21,24,27
ruthenium,24,27 rhodium,28,29 silver,30 tin,24 osmium,23,24,27 iridium,27,31,32
platinum27,33 and gold.24,27,33,34 However, it was not until the discovery of cis-
platin as an anti-tumour agent that this field of drug discovery was so widely
explored.
1.3.1. The discovery of cis-platin
One of the greatest milestones in chemotherapy history was the discovery of
the classical non-selective DNA binder, cis-platin. Its structure and synthesis
has been known since 1893,35 however, the discovery of its anti-tumour
properties occurred much later when interest was sparked over an unusual
observation. In 1965, during a panel of experiments to determine the effects of
electric fields on E. coli, Rosenberg et al discovered that normal cell growth was
inhibited and cells grew up to 300 times their normal length.36 Further studies
revealed the presence of Pt(II) and Pt(IV) ammine chloride complexes in the
electrolyte, generated in situ by electrolysis. The generated Pt(II) complex, cis-
platin, was found to be one of the species responsible for the filamentation of E.
coli cells. Animal testing revealed cis-platin to be a very effective anti-tumour
agent, and once the transition was made to human trials it proved effective
against testicular, ovarian, lung, bladder, head, neck and cervical cancers.3,6
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The mechanism of action of cis-platin involves hydrolysis of the Pt-Cl bonds
followed by binding to nitrogen donors of DNA nucleobases. Such binding
causes structural distortions in DNA that lead to S-phase cell cycle arrest.6,37
This non-selective targeting of DNA in both normal and cancerous cells has
been associated with many toxic side effects. In particular, irreversible kidney
damage is a major concern and limits the dosage that can be administered.3
Second generation platinum drugs, carboplatin and oxaliplatin, have since been
produced and exhibit lesser side effects (Figure 1.5).37 Interestingly, it has been
discovered more recently that only a tiny fraction of cis-platin reaches nuclear
DNA because of the ability of platinum(II) to bind more favourably to sulphur
donors such as cysteines, than to the nitrogen donors in DNA. Glutathione
(GSH, a tripeptide containing L-cysteine) binds irreversibly to cis-platin and is
now known to be a cellular detoxifier of cis-platin and other platinum drugs.38,39
The efficacy of cis-platin is limited by the occurrence of platinum drug
resistance, caused by cells expressing elevated levels of GSH and up-
regulation mechanisms of DNA repair. There is now greater demand to discover
new anti-cancer therapeutics with alternative mechanisms of activity to
overcome cis-platin resistance.
Figure 1.5. The structures of (A) cis-platin, and second generation platinum drugs; (B)
carboplatin, and (C) oxaliplatin.
(A) (B) (C)
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1.3.2. Titanocene dichloride and its derivatives
Along with cis-platin, titanocene dichloride (Figure 1.6) will be remembered in
history as a major milestone in the discovery of metal-based anti-cancer
complexes. In the 1970s, Köpf-Maier et al explored the anti-cancer activity of a
series of metallocenes and reported on the anti-cancer activity of titanocene
dichloride on various cancer cell lines in 1979.24 It successfully progressed into
phase II clinical trials for the treatment of renal and breast cancers. Similarly to
cis-platin, titanocene dichloride undergoes hydrolysis in intracellular conditions,
but DNA does not appear to be the target. Moreover, Ti(IV) binds strongly to
human serum transferrin, which could be involved in the delivery of Ti(IV) into
cancer cells.24 This involves hydrolysis of the Ti-Cl bonds alongside cleavage of
the Ti-Cp bonds, followed by binding of Ti(IV) to the specific iron sites of
transferrin.
Unfortunately, attempts to formulate titanocene dichloride for clinical use were
halted due to issues with instability, resulting from fast hydrolysis rates and low
efficacy rates in Phase II trials.6 However, a new generation of titanocene
derivatives were later explored, which exhibit improved aqueous stability and
anti-cancer activity comparable to that of cis-platin. Improvements to structures
include: bridging of the Cp rings to prevent Ti-Cp bond cleavage (Tacke et al),25
exchanging the chloride ligands with a more suitable oxalate ligand (Tacke et
al),24 and ionic titanocene complexes synthesised by McGowan et al, which
improved aqueous solubility and activity40 (Figure 1.6).
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Figure 1.6. Molecular structures of (A) titanocene dichloride, (B) an ansa-titanocene bridged
derivative, (C) an oxalate derivative, and (D) an ionic titanocene derivative.
1.3.3. Ruthenium anti-cancer complexes
1.3.3.1. Ru(III) complexes
Anti-cancer ruthenium complexes have been explored for many years, as far
back as 1977 when Clarke et al reported pentaamino-ruthenium(III) purine
complexes that were capable of inhibiting DNA and protein synthesis in human
nasopharyngeal carcinoma cells in vitro.41 This discovery initiated a strong
interest and ruthenium anti-cancer complexes have been studied extensively by
various research groups ever since. The success of ruthenium has led to two
octahedral Ru(III) based anti-cancer drugs reaching clinical trials; NAMI-A
(Sava et al),42 and KP1019 (Keppler et al),43 see Figure 1.7.
(A) (B) (C) (D)
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Figure 1.7. The molecular structures of (A) NAMI-A, and (B) KP1019.
1.3.3.2. Ru(II) η6-arene complexes
As Ru(II) is believed to be the oxidation state responsible for anti-cancer activity
in ruthenium complexes, there has been much interest in exploring Ru(II)
complexes (and Os(II) complexes shown in Section 1.3.4).24 Consequently,
piano-stool arene complexes of Ru(II) have attracted much interest for their
promising activity, which is comparible to that of cis-platin and carboplatin.
Figure 1.8 shows the general structure of ruthenium(II) piano-stool complexes
with ɳ6-arene ligands, where X is a monodentate ligand and Y-Z is a bidentate
ligand. These have been explored in much depth by the Sadler group.24 Owing
to the high crystal field splitting energy prevalent in heavier transition metals,
these pseudo-octahedral d6 complexes are low-spin and diamagnetic.
(A) (B)
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Figure 1.8. (A) The general structure of pseudo-octahedral 3-legged piano-stool complexes
synthesised by the Sadler group, where R refers to alkyl/aryl substituents on the arene, X is a
monodentate ligand (typically a halide), and Y-Z is a bidentate ligand. (B) The diamagnetic d6
electron configuration of the ruthenium pseudo-octahedral low-spin state.
The ɳ6-arene plays an important role in stabilisation of the Ru(II) state by
preventing oxidation to Ru(III) from readily occurring, and their lies a delicate
balance between electron donation from the arene into the empty eg orbitals,
and back donation from the filled t2g into the arene π* anti-bonding orbitals.24
Arene ligands such as p-cymene (p-cym) and hexamethylbenzene (hmb) are
known to be stronger electron donors, owing to the presence of electron
donating alkyl substituents. In contrast, biphenyl (bip) may act as an electron
acceptor. Numerous N,N-, and O,O-coordinating bidentate ligands have been
explored for these systems, which play a role in stabilising the Ru(II) metal
centre with the added advantage of being able to tailor the electronic properties
of the metal centre through the choice of substituents.44 The choice of chelating
ligand dictates how labile the monodentate ligand will be and ultimately the
mechanism of anti-cancer activity of the complex.24 The monodentate ligand (X)
(A) (B)
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is important in defining the reactivity of the complex. Complexes with
monodentate ligands that are too labile tend to show little or low no anti-cancer
activity, likely because the complex becomes inactivated before reaching target
sites.
Scheme 1.1. RAPTA complexes of the Dyson group and their proposed activation method
involving hydrolysis then protonation of the PTA ligand.
Ruthenium(II) piano-stool complexes have also attracted interest in other
groups such as Dyson’s. Dyson et al have synthesised Ru(II) ɳ6-arene
complexes with 3 monodentate ligands making up the three legs of the piano-
stool, known as RAPTA complexes.45 The three legs consist of two labile
chloride ligands and a novel 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane
(PTA) ligand, which has been attributed to providing good aqueous solubility.
RAPTA complexes have indicated high selectivity towards cancerous cells over
normal cells, however, their cytotoxicity towards cancer cells in vitro is relatively
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low. Such complexes are known to undergo pH dependent binding to DNA
nucleobases in their hydrolysed (active) form (Scheme 1.1).46
1.3.3.2.1. Sadler group complexes with σ-donor bidentate ligands 
Early ruthenium piano-stool complexes of the Sadler group contain chloride
monodentate ligands and simple chelating σ-donor ligands, such as N,N-
chelating ethylenediamine (en),47,48 and O,O-chelating acetylacetone (acac),49
see Figure 1.9. These complexes have labile chloride ligands and are believed
to bind to DNA inside cells, involving a mechanism of action similar to cis-platin.
Outside the cell where chloride concentrations are high (c.a. ~103 mM),
hydrolysis of the Ru-Cl bond is suppressed. However, once inside the cell
where chloride concentrations are much lower (c.a. ~23 mM and ~4 mM for
intracellular and intranuclear conditions, respectively) the Ru-Cl bond
hydrolyses readily to form an aqua species (see Scheme 1.2).24 Owing to the
strong σ-donor nature of these bidentate ligands, electron density is pushed 
onto the Ru(II) centre rendering it more electronegative in character. As a
consequence, their corresponding aqua species are basic and high pKa* values
were observed for their monodentate H2O ligands (pKa* 7.7-9.4, pKa* refers to
the pKa measurement of a complex in D2O solution using a pH-meter calibrated
with H2O standard solutions).24 Under physiological conditions, the aqua
species exist predominantly with the labile Ru-OH2 bond as opposed to the
more stable Ru-OH bond, thus enabling easier binding to DNA nucleobases.24
The complex [Ru(ɳ6-p-cym)(en)Cl]+ was shown experimentally to bind
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selectively to guanine bases on DNA oligonucleotides in aqueous solution (see
Scheme 1.2).50 It is proposed that when the aqua species enters the cellular
nuclei it can bind to DNA and inhibit DNA synthesis.
Scheme 1.2. Proposed mechanism of DNA binding for [Ru(ɳ6-p-cym)(en)Cl]+. The complex is
stable in extracellular conditions where chloride concentrations are high. Fast hydrolysis occurs
in intracellular conditions where chloride concentrations are considerably lower. In intranuclear
conditions, binding to the guanine bases in DNA occurs.
Extracellular conditions
(~103 mM NaCl)
Intracellular conditions
(~23 mM NaCl)
pKa* = 8.3
Intranuclearconditions
(~4 mM NaCl)
(Fast)
(Guanine
base)
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Figure 1.9. Ru(II) arene complexes with monodentate chloride ligands and bidentate σ-donor 
ligands. (A) with an ethylenediamine (en) ligand, and (B) with an acetylacetonate (acac) ligand.
Ru(II) arene complexes with σ-donor (acac and en) are also capable of 
targeting the NADH/NAD+ redox system in the presence of formate51 (the
NADH/NAD+ system is explained in greater depth in Chapter 6, Section 6.1).
After hydrolysis, the complexes can transfer hydride from formate to NAD+.
Such synergistic effects can induce reductive stress on cancer cells. Later
Ru(II) arene complexes capable of NAD+ reduction contain bidentate
sulfonamido-ethylenediamine ligands,52 and were found to be considerably
more active (Figure 1.10). The anti-cancer activity of such complexes is
enhanced by up to 50x in the presence of low non-toxic doses of formate, and
the extent of NAD+ oxidation is dependent on formate concentration. This novel
reductive stress mechanism of cell death does not involve apoptosis and may
prove to be effective in overcoming cis-platin resistance.53
(A) (B)
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Figure 1.10. Ru(II) arene complexes containing sulfonamido-ethylenediamine bidentate ligands
that are capable of reducing NAD+ to NADH in the presence of low doses of formate.
1.3.3.2.2. Sadler group complexes with π-acceptor AZPY ligands 
Phenylazopyridine (AZPY) ligands consist of a pyridyl moiety and a phenyl
moiety linked together by an azo-bond (see Figure 1.11). The pyridine ring is an
intermediate π-acceptor and its nitrogen is a weak σ-donor. The nitrogens of 
the azo-bond are also weak σ-donors but are capable of strong π-acceptor 
ability due to the presence of the azo π* orbital.54
Figure 1.11. Phenylazopyridine (AZPY) ligands with a pyridyl and phenyl moiety linked together
by an azo-bond. Electron-donating groups can be incorporated onto the phenyl ring para to the
azo-bond.
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In contrast to the ruthenium complexes described previously with strong σ-
donor ligands, Ru(II) arene complexes with halide monodentate ligands and
bidentate AZPY ligands exhibit entirely different properties. Owing to the strong
π-acceptor capability of AZPY ligands, they withdraw electron density away 
from the Ru(II) metal centre which in turn renders their corresponding aqua
species more acidic. The aqua species, [Ru(ɳ6-p-cym)(AZPY-NMe2)H2O]2+, has
a pKa* of 4.6 and predominantly exists in water with the more stable Ru-OH
bond.54 As a consequence, such species do not bind as readily and as
extensively to DNA nucleobases as their σ-donor bidentate ligand bearing 
counterparts. Interestingly, the anti-cancer activity of these species is not
dependent on the lability of the monodentate ligand and their readiness to
hydrolyse in intracellular conditions. In fact, complexes containing iodido
monodentate ligands are more active than their chlorido analogues despite
being more stable towards hydrolysis, suggesting that entirely different
mechanisms of activity are involved.
Ru(II) complexes of the type [Ru(ɳ6-arene)(AZPY-R)I]PF6 (where arene = p-cym
or bip, and R = OH or NMe2) were found to increase ROS levels in cancer cells
and hence cause cell death via oxidative stress. On the basis that GSH is the
primary cellular antioxidant defence, they raise ROS by catalytically oxidising
GSH to glutathione disulfide (GSSG).19 The mechanism of GSH oxidation is
speculated to be mediated through the azo-bond of the AZPY ligand in a
catalytic cycle, whereby the azo-bond is reduced by GSH (forming a hydrazo
intermediate), followed by the formation of GSSG and regeneration of the azo-
bond (see Scheme 1.3). Ru(II) arene AZPY complexes and free AZPY ligands
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have two reduction potentials corresponding to the addition of two electrons into
the azo-bond's π*-orbital, when analysed by cyclic voltammetry. Interestingly, 
coordination of an AZPY ligand to an electropositive Ru(II) arene centre shifts
the first reduction potential within the biologically relevant range (-0.50 to +0.40
V),55 which may account for ligand based reductions caused by GSH under
physiological conditions.19
Scheme 1.3. Proposed catalytic cycle for the oxidation of GSH to GSSG by Ru(II) arene AZPY
complexes, where arene = p-cym or bip and R = OH or NMe2. Initially X is iodide, which is
displaced by GS- in the early stages of reaction. Released iodide can catalyse the
decomposition of H2O2.19
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1.3.4. Osmium anti-cancer complexes
1.3.4.1. Introduction to osmium
Osmium has an atomic number of 76 and belongs to a group of six elements on
the periodic table that make up the 'platinum group' elements (ruthenium,
rhodium, palladium, osmium, iridium and platinum), defined by having similar
physical and chemical properties and tending to occur together in the same
mineral deposits (Figure 1.12). Osmium is the rarest stable element in the
periodic table with an average abundance in the Earth's crust of around 1 g per
200 tonnes,56 and is commonly found in nature as an alloy with iridium, known
as 'osmiridium'. Neighbouring metals, osmium and iridium, have long been
known as the densest of all metals, both being over twice as dense as lead. It
was not until 1995 that a more accurate study confirmed osmium's density is
just slightly greater with a value of 22.587 g/cm3 at 20°C.57 Despite its rarity the
blue-grey hard and brittle metal is less valuable than gold and platinum, lacking
the desired visual and physical properties for commercial applications.
Furthermore, osmium has a total of seven stable naturally occurring isotopes:
184Os, 186Os, 187Os, 188Os, 189Os, 190Os, 192Os, one of which (186Os) is a
radioisotope with an extremely long half-life of 2.011 x 1015 years and α-decay 
mode, which for practical purposes is considered as stable.58 Figure 1.13 shows
each naturally occurring isotope and its % abundance.
Figure 1.12.
transition metals in the periodic table.
Figure 1.13.
Although lacking the desired properties for commercial uses in metallic form, its
chemical behaviour is rather interesting. The element was first discovered in
1802 by Smithson Tennant when preparing the volatile osmium tetroxide by
acid distillation of th
The platinum group elements, consisti
Seven naturally occurring isotopes of osmium and their isotopic abundances.
e black residues remaining from digestion of native platinum
ng of groups 8-10 of the 2nd and 3rd row
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in aqua regia.59 Osmium is highly versatile and capable of adopting up to 11
different oxidation states (ranging from -2 to +8) in its various compound forms.
An oxidation state of +8 is the highest possible state reached by any element
under normal circumstances, a feat shared only with iron, ruthenium and
xenon.56
Osmium tetroxide (oxidation state +8) has been the most useful of all osmium
compounds. It is used as a stain in microscopy and in fingerprint detection, as
well as a catalyst for a few industrial processes such as the production of some
anti-obesity and anti-diabetic drugs.60 The clinical applications of osmium
compounds are currently limited, however osmium tetroxide has been used
clinically for the treatment of arthritis. For 56 years it has been injected into
arthritic knee joints on a limited basis to chemically destroy diseased tissue in a
process known as 'chemical synovectomy'.61 Due to the highly toxic nature of
osmium tetroxide this procedure has been considered very controversial. A
class of osmium carbohydrate polymers known as 'osmarins' have been
proposed to replace osmium tetroxide as an anti-arthritic drug due to their
significantly lower toxicity. Osmarins are prepared from osmium tetroxide with
the final product containing between 30-40% of osmium(IV) in a water soluble
gel consisting of glucose and gluconate.61
1.3.4.2. The extension from ruthenium to osmium
As they belong to the same periodic group, it was not long before various
research groups began making the extension from ruthenium to osmium in anti-
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and reactivities were observed.24 Os(II) is inherently more electropositive than
Ru(II) and their complexes tend to exhibit lower pKa values for coordinated H2O
molecules in their aqua-adducts. The rate of hydrolysis for [Os(ɳ6-bip)(en)Cl]+ is
100x slower than its Ru(II) counterpart and unlike Ru(II), its aqua-species exists
predominantly in the more stable Os-OH form under physiological conditions.64
Initially, [Os(ɳ6-bip)(en)Cl]+ was found to be inactive against A2780 cells which
was attributed to its kinetic inertness and lower reactivity towards guanine
nucleobases in solution. However, a later study confirmed that its activity was
comparable to that of the Ru(II) analogue and the previous erroneous finding
was due to partial decomposition of the complex in stock solutions containing
DMSO.65
In contrast, chlorido Os(II) arene complexes of acac hydrolyse very rapidly.
They lack cytotoxicity towards cancer cells due to a lack of stability and a
tendency to form an un-reactive hydroxide-bridged dimer in solution.64,66 N,O-
coordinating picolinate ligands provide a good compromise for Os(II), between
the inert complexes of N,N-coordinating en ligands and the over-reactive
complexes of O,O-coordinating acac ligands.67,68 Chlorido Os(II) arene
picolinate complexes hydrolyse readily, but do not form unreactive hydroxido
dimers and are active towards A2780 cancer cells (Figure 1.15).
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Figure 1.15. Chlorido osmium(II) arene complexes with picolinate ligands and their IC50 values
for the A2780 cancer cell line.
1.3.4.3.1. Os(II) complexes with peptide side chains
One of the many problems to overcome in anti-cancer complex design is the
efficient passage of drugs into cells. Many complexes fail due to insufficient
cellular uptake. One interesting and novel method to improve the biological
properties of a metallo-drug and help alleviate this problem is the attachment of
cell penetrating peptides (CPPs) to complexes. A CPP is a short peptide chain
which, when chemically linked, facilitates the cellular uptake of molecular ‘cargo’
into the cell. This idea was explored by Van Rijt et al in the Sadler group for
Os(II) bip picolinate complexes.69 Peptide conjugates of the osmium complex
were synthesised with different arginine chain lengths. The picolinate ligand has
a carboxylic acid group at the 4-position on the ring that provides a binding site
for which peptides can be attached (Figure 1.16). It was found that the
conjugation of five arginine monomers doubled cellular uptake of the complex
into A2780 human ovarian cancer cells, and a 10-fold increase in cellular
uptake was observed when complexes were conjugated to eight arginine
(IC50 = 8 µM)
(IC50 = 4.2 µM)
Arene
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monomers. The 10-fold increase was also accompanied with a 15-fold increase
in the binding of osmium to DNA.
Figure 1.16. Structures of chlorido Os(II) bip picolinate complexes; (A) with a carboxylic acid
side chain which provides a platform for the attachment of peptides, (B) with an attached
arginine molecule, and (C) with an attached arginine peptide conjugate of varying chain length.
1.3.4.3.2. Os(II) complexes with AZPY ligands
A large and diverse range of 40 Os(II) arene AZPY complexes was synthesised
by Ying et al in the Sadler group with a variety of different electron
(A) (B)
(C)
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withdrawing/donating substituents on the AZPY ligand (see Figure 1.17),
providing further opportunity to tailor the electronic properties of the
complex.5,23,70 All of the complexes were tested against A2780 cancer cells for
anti-cancer activity and only three were found to be inactive (>100 µM IC50
values), and eight had IC50 values in the nano-molar range. Some of the most
active complexes were also active in other human cancer cell lines: A549 lung
cancer cells, HCT-116 colon cancer cells, PC-3 prostate cancer cells, MCF-7
breast cancer cells, and cis-platin resistant A2780cis ovarian cancer cells. In
general, a considerable increase in activity was observed on switching from
ruthenium to osmium for these species.
Figure 1.17. General structure of Os(II) arene AZPY complexes, where arene = p-cym or bip, X
is a monodentate halide ligand (Cl or I), and RA-RB are either electron donating/withdrawing
groups or H on the AZPY ligand.
Arene =
X = Cl or I
RA = H, Cl or CF3
RB = H, OH, F, Cl, Br or I
RC = H, or Cl
RD = H or Cl
RE= H, OH, NO2 or NMe2
or
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Structure-activity relationships (SARs) were determined for these complexes
and the following trends were found (Figure 1.18). (1) Iodido complexes have
much higher activity than chlorido complexes. This is owing to the strong
covalent nature of the Os-I bond, which in turn allows for strong back-donation
of electron density from the metal centre to the phenylazopyridine ligand. (2) In
general bip complexes are 10-times more active than p-cym complexes. Bip is
more lipophilic than p-cym and the observed increase in activity is due to better
cellular accumulation of bip complexes.71 (3) When an electron donating group
is introduced to the phenyl ring para to the azo-bond, a substantial increase in
activity is observed compared to when no substituent is introduced. This is likely
due to improved stability of the complex.70 (4) When a chloro-substituent is
introduced to the pyridyl ring, the activity depends on its position (RB>RA>RC).
Addition at the position para to the azo-bond gives the greatest activity. (5)
Changing the halo-substituent at the para-position (RB) on the pyridyl ring
increases the activity of the complex in the following order; Cl<Br≤F<I. 
Furthermore, complexes which have an electron donating OH group at RB and
an electron withdrawing NO2 group at RE (both para to the azo-bond) have very
potent activity.23
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Figure 1.18. Structure-activity relationships of Os(II) arene AZPY complexes against A2780
cancer cells. (A) Effect of the monodentate ligand. (B) Effect of the arene ligand. (C) Effects of
electron withdrawing/donating substituents on the AZPY ligands.
In comparison to their ruthenium analogues, Os(II) arene AZPY complexes are
very stable towards hydrolysis and hence not capable of binding to DNA
nucleobases such as guanine. Even the chlorido species, [Os(ɳ6-p-cym)(AZPY-
NMe2)Cl]+, is stable and attempts to remove the chloride ligand using AgNO3
(A)
(B)
(C)
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proved unsuccessful.70 These findings led to the conclusion that, like their Ru(II)
analogues, hydrolysis is not critical for activation and the AZPY ligand may play
a role in anti-cancer activity. However it still remains unknown as to whether the
monodentate ligand stays bound to Os(II) inside cells. Similarly to their
ruthenium analogues, Os(II) arene AZPY complexes are also capable of raising
ROS levels in cancer cells which is believed to be the primary mechanism of
activity.23 In stark contrast to its ruthenium analogue, [Os(ɳ6-p-cym)(AZPY-
NMe2)I]+ (FY026) does not raise ROS levels by catalytically oxidising GSH to
GSSG and therefore must operate by other means.70 The mechanism by which
Os(II) arene AZPY complexes raise ROS levels is still an area that requires
further investigation.
Interestingly, the active complex [Os(ɳ6-bip)(5-F-AZPY)I]+ which contains an
electron withdrawing fluoro-substituent on the pyridyl ring (para to the azo-
bond), was found to cause S-phase and G2/M-phase cell cycle arrest. Further
studies showed that it is capable of inhibiting tubulin polymerisation process by
up to 21%.5 The polymerisation of microtubules is vital for the cells’ ability to
form mitotic spindles appropriately in order for normal cell division to occur.72
This is a novel mechanism of activity for which there are currently no reports for
organometallic complexes, and highlights the ability of Os(II) arene AZPY
complexes to exert multiple mechanisms of anti-cancer activity inside cancer
cells.
1.3.4.3.3. FY026
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Complex FY026 (see Figure 1.19) is one of the most promising osmium anti-
cancer drugs in the Sadler group and a potential candidate for clinical trials. It
contains a p-cym arene ligand, a monodentate iodide ligand, and an AZPY
ligand with an electron donating NMe2 group on its phenyl ring.70 The +1 charge
on the cation is balanced with a PF6- anion, which plays no role in the anti-
cancer activity of the overall complex.
Figure 1.19. The molecular structure of potent osmium anti-cancer complex FY026, [Os(ɳ6-p-
cym)(AZPY-NMe2)I]PF6.
FY026 has potent nano-molar activity against a variety of human cancer cell
lines; A2780 (IC50 = 0.18 ±0.01 µM), A2780cis (IC50 = 0.23 ±0.05 µM), A549
(IC50 = 0.38 ±0.07 µM), HCT-116 (IC50 = 0.22 ±0.02 µM), MCF-7 (IC50 = 0.20
±0.01 µM), PC-3 (IC50 = 0.62 ±0.12 µM) and RT-112 (IC50 = 0.25 ±0.02 µM).70
Furthermore, it is 49x more potent than cis-platin in the 809-cell line screen of
the Sanger Institute (Mean GI50 of FY026 is 0.75 µM vs. 36.7 µM for that of cis-
platin).73 Preclinical development has shown that FY026 is capable of delaying
the growth of HCT-116 human colon cancer xenographs in mice.74 Furthermore,
in the same xenograph model and at concentrations 6x higher than that of the
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maximum tolerable dose of cis-platin (40 mg/Kg), FY026 caused negligible
deleterious effects to mice, suggesting a comparative lack of toxicity to the
host.70
The selectivity of FY026 also makes it a desirable drug candidate as studies
have shown it to be 28.4x more selective towards A2780 cells than MCR-5
normal lung fibroblast cells. Interestingly, its selectivity factor was further
improved to 63.5 when cells were treated synergistically with non-toxic levels of
L-buthionine-sulfoximine (L-BSO, 5 µM).75 L-BSO reduces GSH levels, hence
undermining cellular detoxification pathways and compromising their ability to
respond to the oxidative stress brought about by FY026. As stated earlier,
FY026 does not catalytically oxidise GSH. Its first reduction potential (involving
the addition of 1 electron into the π*-orbital of the azo-bond) is at -0.64 V,74
lower than that of its ruthenium analogue (-0.40 V)19 and is therefore less
biologically accessible. This may account for the low reactivity of FY026
towards GSH. The mechanism by which FY026 increases ROS levels within
cancer cells remained uncertain until studies involving mitochondria were
explored. FY026 alters the mitochondrial transmembrane potential in both
A2780 and A549 cells (explained in greater detail in Chapter 7, Section 7.4).71,75
Furthermore, FY026 causes S-phase cell cycle arrest in A549 cells, which may
be advantageous in slowing the proliferation of cancer cells.
1.3.4.3.4. Os(II) complexes with IMPY ligands
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Phenyliminopyridine (IMPY) ligands are structurally similar to their AZPY
counterparts but possess an imino-bond in place of an azo-bond. Their use was
inspired by previous work in the Sadler group involving Ru(II) complexes55 and
the general structure of Os(II) arene IMPY complexes is shown in Figure 1.20.5
Figure 1.20. General structure of Os(II) arene IMPY complexes, where arene = p-cym or bip, X
is a monodentate halide ligand (Cl or I), and RA and RB are either electron-donating groups or H
on the IMPY ligand.
In contrast to AZPY complexes, Os(II) arene IMPY complexes hydrolyse in
aqueous media. After 24 h incubation at 37°C in D2O, the extent of hydrolysis
for [Os(ɳ6-p-cym)(IMPY-NMe2)I]+ reached 50%, and 99% for its chlorido
analogue. Furthermore, the pKa* of the water molecule in the corresponding
aqua-adduct is 5.2, characteristic of a complex containing a π-acceptor 
bidentate ligand and therefore existing predominantly as the more stable
hydroxido-species, [Os(ɳ6-p-cym)(IMPY-NMe2)OH]+, under physiological
conditions.76 Similarly to Ru(II) arene AZPY complexes they are capable of
binding to guanine derivatives. They were also found to raise ROS levels in
Arene =
X = Cl or I
RA = H or OMe
RB = H, OH or NMe2
or
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cancer cells, but in contrast to Ru(II) arene AZPY complexes, are not capable of
catalytically oxidising GSH which may be explained by greater negative values
observed for their reduction potentials. Moreover they were found to target the
NADH/NAD+ redox system, causing catalytic oxidation of NADH to NAD+.76 A
mechanism of action was proposed, whereby hydride is transferred from NADH
to the complex to form NAD+. The hydride is then transferred to O2 leading to
regeneration of the catalyst and formation of H2O2 (Scheme 1.4). Table 1.1
shows a comparison chart of the currently known capabilities of osmium IMPY
and AZPY complexes, and ruthenium AZPY complexes.
Scheme 1.4. Proposed catalytic cycle for the oxidation of NADH with [Os(ɳ6-p-cym)(IMPY-
NMe2)X]+, where X = I-, Cl- or OH-.5
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X
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+
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Table 1.1. List of chemical and biological capabilities that are currently known for Ru(II) arene
complexes of AZPY and Os(II) arene complexes of AZPY and IMPY.
Ru(II) arene
AZPYs
Os(II) arene
AZPYs
Os(II) arene
IMPYs
Hydrolysis Yes No Yes
Binding with Guanine Yes No Yes
Increase in ROS Yes Yes Yes
Oxidation of GSH Yes No No
Oxidation of NADH n.d. No Yes
Inhibit polymerisation of tubulin n.d. Yes No
1.3.4.4. Osmium complexes of other research groups
Various other prominent research groups such as those of Keppler, Meggers,
Sava and Dyson, have also made the extension from ruthenium to osmium with
varied results. Osmium analogues of NAMI-A,77 KP101978 and RAPTA
(OsAPTA) complexes29 have been synthesised and were found to exhibit
slightly lower or comparable biological activities to their ruthenium counterparts.
The search for further osmium anti-cancer complexes continues and has led to
a variety of novel and promising structures.
1.3.4.4.1. Osmium complexes with pharmacophoric fragments
The combination of metal complexes with ligands containing protein targeting
groups is becoming an increasingly popular field in anti-cancer research. It
typically allows for better cancer cell selectivity as well as incorporating further
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mechanisms of anti-cancer activity.8 Kinases are involved in the regulation of
most cellular processes and so their therapeutic inhibition has particularly
attracted a lot of attention. The Keppler group have produced novel chlorido
Ru(II) and Os(II) complexes with bidentate ligands containing quinoxalinone
groups.10 The ligand exhibits a pharmacophoric feature of several ATP
competitive protein kinase inhibitors, and the chloride is a labile leaving group
which could provide a site for coordinative interaction with targets (see Figure
1.21). The solubility of the free ligands is generally very poor, but their
coordination to a metal centre scaffold facilitates their solubility in aqueous
media and improves their anti-cancer activities. The complexes are capable of
hydrolysis to form an aqua-adduct, which was reversed on the addition of
sodium chloride. Interestingly, osmium complexes were more active than their
ruthenium counterparts, which could be a result of their higher chemical
inertness preventing deactivating side reactions.
Figure 1.21. General structure of chlorido Os(II) and Ru(II) arene complexes containing
quinoxalinone bidentate ligands.
Pharmacophoric
feature
Leaving
group
M = Ru or Os
X = O, NH or S
R1 = H, CH3 or Cl
R2 = H, CH3 or Cl
R3 = H, CH3 or Cl
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In contrast, Meggers group have produced Ru(II) complexes that are based on
the structure of a naturally occurring kinase inhibitor, staurosporine.22 The metal
acts as a scaffold for a bidentate ligand, forming a structurally rigid and stable
complex mimicking staurosporine's shape and size (see Figure 1.22). The
complexes are unreactive with an inert metal centre and possess a purely
structural function. They are potent inhibitors of GSK-3β (glycogen synthase 
kinase), capable of blocking its ATP-active site.79,80 Moreover, an osmium
analogue was synthesised and compared to its ruthenium counterpart.81 It was
found to have very similar or slightly better biological activity in terms of anti-
proliferative activity against 1205Lu melanoma cells and ability to inhibit GSK-
3β. 
Figure 1.22. The molecular structure of (A) staurosporine, and (B) the general structure of
Ru(II) GSK-3β inhibitors synthesised by the Meggers’ group. 
R1 = H or OH
R2 = H or F
R3 = H or X
(A) (B)
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1.3.4.4.2. 'Click' carbene complexes
One class of complexes that has been relatively neglected in the field of anti-
cancer research is that of N-heterocyclic carbenes (NHCs), which interestingly
have been very successful in catalytic applications.82 The Dyson group has
successfully produced biologically active 'click' 1,2,3-triazolylidene NHC
complexes. Analogous to their RAPTA/OsAPTA complexes, the PTA ligand is
replaced with an NHC ligand that can incorporate various substituents to tailor
lipophilicity (see Figure 1.23).83
Figure 1.23. General structure of Ru(II) and Os(II) arene dichlorido complexes incorporating
monodentate 'click' 1,2,3-triazolylidene NHCs.
Hydrolysis of these complexes (involving the displacement of one or both of the
chloride ligands with water) occurs very rapidly compared to RAPTA-C and is
suppressed in the presence of NaCl. The complexes showed selectivity towards
A2780 and A2780cis cells over normal human embryonic kidney cells (HEK),
M = Ru or Os
R = ethyl, n-hexyl, n-dodecyl, benzyl,
2,3,4,6-tetra-O-β-ᴅ-glucopyranosyl, 
or 2,6-diisopropylphenyl
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with some showing IC50 values in the nano-molar range. Improved activity over
RAPTA/OsAPTA type complexes may be in part explained by the fast
hydrolysis process, as a relationship between fast hydrolysis (activation) and
cytotoxicity has been demonstrated before.24 No obvious trends were observed
when switching the metal centre from Ru(II) to Os(II), however increasing the
lipophilicity by varying the substituent (R) did produce an improvement in
activity.
1.3.4.4.3. Complexes with glucose-derived ligands
Similarly to 'click' carbene complexes, the Dyson group has reported complexes
analogous to RAPTA/OsAPTA complexes where the PTA ligand is replaced
with a glucose-derived ligand (see Figure 1.24).84 The motivation was to exploit
the altered metabolism of cancer cells, their increased glucose uptake in
comparison with normal cells. The rate of hydrolysis of osmium complexes was
very slow in comparison to their ruthenium analogues. In this instance, the
ruthenium analogues were generally 2x more cytotoxic towards selected cancer
cell lines than their osmium counterparts, which could be explained by their lack
of reactivity with 5'-GMP compared to ruthenium analogues, and lack of ease of
hydrolysis.
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Figure 1.24. Molecular structures of Ru(II) and Os(II) arene dichlorido complexes bearing
glucose-derived monodentate ligands.
1.3.4.4.4. Os(VI) nitrido complexes
In the first of its kind, Tai-Chu Lau’s group reported the synthesis of novel
osmium(VI) nitrido octahedral anti-cancer complexes with azole ligands.85 The
Os≡N triple bond helps to stabilise the high oxidation state of Os(VI). The 
complexes are capable of forming 3 geometric isomers (see Figure 1.25). Many
of the complexes have good cellular uptake into HeLa cervical cancer cell lines
and a correlation between cellular uptake and cancer cell cytoxicity was
observed, with IC50 values ranging between 9 - 82 µM over 4 different cancer
cell lines. Cell cycle analysis showed S-phase arrest with the entry of cells from
the G1-phase. Further in vitro DNA damage studies show that DNA is likely the
primary target of these complexes.
M = Ru or Os
R = C(CH3)2 or C6H10
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Figure 1.25. General structure of Os(VI) nitridohazole complexes. (A) Trans-isomer. (B) Cis-
isomer with facial Cl ligands. (C) Cis-isomer with meridional Cl ligands.
1.4. Project aims
The general aim of this project was to synthesise and characterise novel
osmium anti-cancer complexes with bidentate ligands containing an azo-bond.
Then to undertake biological studies to determine their anti-cancer activities,
structure-activity relationships, and further understand their mechanisms of
activity. The more specific aims of this project are outlined below.
L =
(A) (B) (C)
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In terms of azo-ligand complexes, the Sadler group has previously explored
only Os(II) and Ru(II) arene AZPY complexes in depth, with the exception of
some Ru(II) arene phenylazopyrazole (AZPYZ) complexes that were featured in
one publication.54 There is an interest in exploring complexes of alternative azo-
ligands to expand on our library of complexes, and gain a greater understanding
of the properties of novel anti-cancer complexes. In Chapter 3, a new class of
complexes is synthesised and their unique chemical properties are explored.
The synthesis and exploration of Os(II) arene complexes with bidentate
phenylazobenzothiazole (AZBTZ) ligands are described.
Chapter 4 describes the synthesis of further novel Os(II) arene AZPY anti-
cancer complexes. This is undertaken utilising the structure-activity
relationships that have already been established in Section 1.3.4.3. One of the
key challenges is to improve drug solubility in aqueous media, which is an
inherent problem for this class of complexes. The attachment of water-
solubilising glycol substituents to the AZPY ligands of complexes is explored.
The trends in anti-proliferative activity, lipophilicity, cellular uptake and water
solubility of new complexes are investigated, as well as the effect that key
complexes have on the cell cycle and intracellular ROS levels of cancer cells.
The aim in Chapter 5 is to label key Os(II) arene AZPY complexes with I-131
for the purpose of exploring intracellular activity. The most active species of this
class contain a monodentate iodido ligand, which is replaced herein with the
radioactive isotope, I-131. The subsequent radiotracers are used to study the
stability of complexes in cell culture media, human blood serum and in the
presence of MCF-7 cancer cells. These studies were designed to determine
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whether the monodentate iodide ligand remains bound to the complex. It is easy
to distinguish between complex-bound I-131 and free iodide-131 using radio-
HPLC, and other gamma-ray detection techniques are utilised to determine the
cellular accumulation of I-131.
Currently, little is known about the mechanism(s) by which Os(II) arene AZPY
complexes increase ROS levels inside cancer cells. In Chapter 6, the
mechanisms by which Os(II) arene AZPY complexes increase intracellular ROS
levels are explored. Studies are carried out on FY026, [Os(ɳ6-p-cym)(AZPY-
NMe2)I]PF6, and the new AZPY complexes synthesised in Chapter 4 to probe
their intracellular interactions with biological targets: GSH, N-acetyl-L-cysteine
(NAC), H2O2 and NADH.
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2.1. Materials and synthesis
2.1.1. Materials
2.1.1.1. Chemicals
OsCl3.3H2O was purchased from either Sigma Aldrich or Heraeus (South
Africa), K2[OsVIO2(OH)4] from Alfa Aesar, and α-terpinene and biphenyl from 
Sigma Aldrich. Ammonium hexafluorophosphate, ammonium triflate and
potassium iodate (counter ions for complexes) were all purchased from Sigma
Aldrich. Magnesium sulphate (drying agent) and silica gel (particle size 40-63 Å)
were purchased from Sigma Aldrich, and phosphorus pentoxide (vacuum
desiccant) was purchased from VWR. Dry ethanol was produced by distilling
absolute ethanol over Mg/I under a N2 atmosphere. Synthesis grade deionised
water was obtained from a Millipore Elix 5 purification system. Analysis grade
doubly deionised water (18 MΩ cm-1) was obtained from either a Millipore
Simplicity UV, or an USF Elga UHQ PS purification system. The osmium ICP
standard was 1000±10 μg/mL in 15% HCl (v/v) and purchased from Inorganic 
Ventures. All other solvents and reagents for synthesis and analysis were
purchased from commercial suppliers and used as received.
Stock phosphate buffer solutions (600 mM) were prepared by dissolving
monosodium phosphate monohydrate (1.56 g, 11.305 mmol) and disodium
phosphate heptahydrate (13.1 g, 48.868 mmol) (both purchased from Fisher
Scientific) together in doubly deionised water (100 mL). The pH of the
phosphate buffer solution was measured using the pH bench top meter (Section
2.2.7.1) and adjusted to pH 7.4(±0.1) using aqueous sodium hydroxide.
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Phosphate-buffered D2O solutions were prepared in a similar manner, adjusting
the pH* to 7.4(±0.1) using sodium hydroxide in D2O without correcting for the
effect of deuterium on the glass electrode.
2.1.1.2. Cell culture
DMEM and RPMI-1640 cell culture media, penicillin/streptomycin mixture, foetal
bovine serum, L-gutamine, phosphate buffered saline solution (PBS), AccuMax
cell dissociation solution, trypsin and trypsin/EDTA were all purchased from
PAA Laboratories GmbH. Cell culture media (500 mL) were supplemented with
foetal bovine serum (50 mL), penicillin/streptomycin mixture (5 mL) and L-
glutamine (5 mL). All cancer cell lines were purchased from the European
Collection of Cell Cultures and Public Health England.
2.1.2. Synthesis of Os(II) dimers
Osmium dimers are vital precursors for the synthesis of osmium(II) arene
‘piano-stool’ complexes. A total of six dimers were synthesised; [Os(η6-p-
cym)Cl2]2, [Os(η6-p-cym)Br2]2, [Os(η6-p-cym)I2]2, [Os(η6-bip)Cl2]2, [Os(η6-
bip)Br2]2, [Os(η6-bip)I2]2. Reported traditional synthetic methods were utilised1-3
and implemented to improve product yields. Also, new synthetic strategies
involving microwave synthesis were developed.4 The two principal synthetic
routes for generating dimers from inorganic osmium compounds are
summarised in Scheme 2.1.
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remove a light brown precipitate. The filtrate was concentrated under reduced
pressure and placed in the freezer overnight. An orange precipitate formed,
which was collected via vacuum filtration and washed with ice-cold EtOH (2 x 5
mL) and Et2O (2 x 5 mL). The product was dried overnight in a vacuum
desiccator. Yield: 3.92 g, (70%).
Method 2. OsCl3.3H2O (1.00 g, 2.85 mmol) and α-terpinene (1.84 g, 13.51 
mmol) were dissolved in MeOH (10 mL) in a microwave reaction vessel. The
mixture was irradiated with microwave radiation for 5 min at 150 °C. The
mixture was placed in the freezer overnight, and the resulting orange precipitate
was collected via vacuum filtration and washed with ice-cold EtOH (2 x 5 mL)
and Et2O (2 x 5 mL). The product was dried overnight in a vacuum desiccator.
Yield: 1.02 g, (90%). 1H NMR (400 MHz, (CD3)2SO): δ 6.07 (d, 4H, J = 6.0 Hz), 
5.99 (d, 4H, J = 6.0 Hz), 2.74 (sept., 2H, J = 6.9 Hz), 2.13 (s, 6H), 1.19 (12H, d,
J = 7.0 Hz).
2.1.2.2. Synthesis of [Os(η6-p-cym)Br2]22
Method 1. [Os(η6-p-cym)Cl2]2 (200.0 mg, 0.25 mmol) and LiBr (10.98 g, 0.13
mol) were mixed in deionised water (50 mL). The solution was heated to 100 °C
for 18 h and a brown precipitate was observed. The reaction mixture was
cooled to room temperature then placed in the fridge for 2 h. The precipitate
was filtered and washed with water (2 x 5 mL), ice-cold EtOH (2 x 5 mL) and
Et2O (2 x 5 mL). The product was dried overnight in a vacuum desiccator. Yield:
159.6 mg, (65%).
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Method 2. K2[OsVIO2(OH)4] (1.07 g, 2.90 mmol) was dissolved in absolute EtOH
(20 mL) and 48% aqueous hydrobromic acid (10 mL) was added. The mixture
was heated under reflux for 18 h under a N2 atmosphere. α-Terpinene (5.52 g, 
40.52 mmol) was added and the mixture was heated under reflux for a further
18 h under N2. Deionised water (20 mL) was added and the product was
extracted with DCM (3 x 20 mL). The combined DCM extracts were
concentrated to 5-10 mL under reduced pressure and diethyl ether (5 mL) was
added. The mixture was placed in the freezer overnight yielding brown
crystalline needles, which were collected via vacuum filtration and washed with
ice-cold EtOH (2 x 5 mL) and Et2O (2 x 5 mL). The product was dried overnight
in a vacuum desiccator. Yield: 0.57 g, (41%). 1H NMR (400 MHz, (CD3)2SO): δ 
6.10 (d, 4H, J = 6.0 Hz), 6.03 (d, 4H, J = 6.0 Hz), 2.82 (sept., 2H, J = 6.9 Hz),
2.22 (s, 6H), 1.20 (d, 12H, J = 7.0 Hz).
2.1.2.3. Synthesis of [Os(η6-p-cym)I2]23
Method 1. A solution of LiI (55.64 g, 0.42 mol) in deionised water (100 mL) was
prepared and N2 was bubbled through for 20 min to remove molecular oxygen.
[Os(η6-p-cym)Cl2]2 (657.4 mg, 0.83 mmol) was added and the solution was
heated at 80 °C for 18 h under a N2 atmosphere and a brown precipitate was
observed. The reaction mixture was cooled to room temperature and the
precipitate was collected via vacuum filtration, re-dissolved in DCM (20 mL) and
filtered again to remove a black precipitate. The filtrate was concentrated to 5-
10 mL under reduced pressure and placed in the freezer overnight, yielding a
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red-brown precipitate. The product was collected via vacuum filtration, washed
with ice-cold EtOH (2 x 5 mL) and Et2O (2 x 5 mL), and dried overnight in a
vacuum desiccator. Yield: 585.8 mg, (61%).
Method 2. [Os(η6-p-cym)Cl2]2 (602.9 mg, 0.76 mmol) was dissolved in MeOH (5
mL) in a microwave reaction vessel. A solution of KI (12.66 g, 76.27 mmol) in
deionised water (10 mL) was added and the mixture was irradiated with
microwave radiation for 5 min at 150 °C. The mixture was cooled in the fridge
overnight, and the resulting red precipitate was collected via vacuum filtration
and washed with water (2 x 5 mL), ice-cold EtOH (2 x 5 mL) and Et2O (2 x 5
mL). The product was dried overnight in a vacuum desiccator. Yield: 707.5 mg,
(80%). 1H NMR (400 MHz, (CD3)2SO): δ 6.09 (d, 4H, J = 6.1 Hz), 6.04 (d, 4H, J 
= 6.1 Hz), 3.00 (sept., 2H, J = 6.9 Hz), 2.39 (s, 6H), 1.21 (12H, d, J = 6.9 Hz).
2.1.2.4. Synthesis of 1-phenyl-cyclohexa-2,5-diene7
All glassware was oven dried and purged with N2 prior to use and the synthesis
was carried out under anhydrous conditions. Biphenyl (15.43 g, 100.06 mmol)
was dissolved in anhydrous THF (150 mL) in a 1L 3-necked flask. Liquid NH3
(~200 mL) was condensed into a 2L 3-necked flask submerged in an
acetone/dry ice bath (-78 °C). The biphenyl solution was transferred into the
liquid NH3 via a cannula and stirred with a mechanical stirrer. Lithium (1.85 g,
0.27 mol) was added to the stirring mixture, which turned blue, green, and
finally red. The mixture was left to stir for a further 30 min. NH4Cl (20.0 g, 0.37
mol) was added and the mixture was left to stir overnight at ambient
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temperature. Deionised water (500 mL) was added and the mixture was
adjusted to pH 1 with 6 M HCl. The crude product was extracted with Et2O (3 x
300 mL), dried over MgSO4, filtered, and the solvent was removed under
reduced pressure. The product was purified by vacuum distillation (45 °C, 0.1
mbar). Yield: 12.8 g, (82%). 1H NMR (400 MHz, CDCl3): δ 7.23-7.22 (m, 2H), 
7.14-7.13 (m, 3H), 5.75-5.74 (m, 2H), 5.66-5.65 (m, 2H), 3.88-3.87 (m, 1H),
2.68-2.67 (m, 2H).
2.1.2.5. Synthesis of [Os(η6-bip)Cl2]26
Method 1. OsCl3.3H2O (1.00 g, 2.85 mmol) was dissolved in dry freshly distilled
EtOH (50 mL) and 1-phenyl-cyclohexa-2,5-diene (1.78 g, 11.41 mmol) was
added drop-wise. The mixture was heated under reflux under a N2 atmosphere
for 72 hours. The resulting mixture contained a light brown precipitate, which
was cooled down to room temperature. The precipitate was collected via
vacuum filtration and washed with ice-cold EtOH (2 x 5 mL) and Et2O (2 x 5
mL). The product was dried overnight in a vacuum desiccator. Yield: 1.02 g,
(86%).
Method 2. OsCl3.3H2O (1.00 g, 2.85 mmol) and 1-phenyl-cyclohexa-2,5-diene
(1.58 g, 10.11 mmol) were dissolved in MeOH (5 mL) in a microwave reaction
vessel, and the mixture was irradiated with microwave radiation for 10 min at
120 °C. After cooling to room temperature, an orange precipitate was collected
via vacuum filtration and washed with ice-cold ethanol (2 x 5 mL) and Et2O (2 x
5 mL). The product was dried overnight in a vacuum desiccator. Yield: 1.13 g,
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(95%). 1H NMR (400 MHz, (CD3)2SO): δ 7.71 (dd, 4H, J = 8.1, 1.4 Hz), 7.49-
7.44 (m, 6H), 6.68 (d, 4H, 5.6 Hz), 6.38-6.31 (m, 6H).
2.1.2.6. Synthesis of [Os(η6-bip)I2]23
[Os(η6-bip)Cl2]2 (500.0 mg, 0.60 mmol) was dissolved in MeOH (5 mL) in a
microwave reaction vessel. A solution of KI (9.99 g, 60.18 mmol) in deionised
water (10 mL) was added and the mixture was irradiated with microwave
radiation for 3 min at 100 °C. The mixture was cooled in the fridge overnight,
and a dark brown precipitate was collected via vacuum filtration and washed
with water (2 x 5 mL), ice-cold EtOH (2 x 5 mL) and Et2O (2 x 5 mL). The
product was dried overnight in a vacuum desiccator. Yield: 520.4 mg, (72%). 1H
NMR (400 MHz, (CD3)2SO): δ 7.72 (dd, 4H, J = 8.1, 1.6 Hz), 7.50-7.41 (m, 6H), 
6.82 (d, 4H, J = 6.0 Hz), 6.57-6.55 (m, 2H), 6.34-6.32 (m, 4H).
2.2. Instrumentation
2.2.1. NMR spectroscopy
1H and 13C NMR spectra were acquired in 5 mm NMR tubes at 298 K on either
Bruker DPX-300 or 400, AV-400, or DRX-500 spectrometers. Data processing
was carried out using TOPSPIN version 2.1 (Bruker U.K. Ltd). 1H NMR
chemical shifts were internally referenced to TMS via their residual solvent
peaks: acetonitrile (δ = 1.94 ppm), acetone (δ = 2.05 ppm), methanol (δ = 3.31 
ppm), water (δ = 4.79 ppm), chloroform (δ = 7.26 ppm), DMSO (δ = 2.50 ppm).8
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Likewise for 13C NMR chemical shifts: acetonitrile (δ = 118.26 ppm), acetone (δ 
= 206.26 ppm), methanol (δ = 49.00 ppm).8 1D 1H NMR spectra were recorded
using standard pulse sequences and 1D 13C NMR spectra were recorded using
a JMOD pulse sequence. Typically, 1H data were acquired with 16 transients
into 32 k data points over a spectral width of 14 ppm, and 13C data with 256
transients into 64 k data points over a spectral width of 260 ppm.
2.2.2. Electrospray ionisation mass spectrometry (ESI-MS)
Positive and negative ion electrospray mass spectra were obtained using the
Agilent 6130B single Quad (ESI) mass spectrometer. Samples of complexes
were typically prepared in methanol, deionised water or acetonitrile and run in
positive ion mode (500-1000 m/z) and negative ion mode (50-500 m/z).
Likewise, samples submitted for high-resolution mass spectroscopy were
carried out using a Bruker MaXis UHR-ESI-TOF by Phil Aston.
2.2.3. Elemental analysis
All purified complexes and ligands were analysed via elemental analysis.
Analyses (carbon, hydrogen and nitrogen) were performed by Warwick
Analytical Service using an Exeter Analytical elemental analyser (CE440).
2.2.4. UV-Vis spectroscopy
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UV-Vis spectroscopy was used routinely as a means of characterising
complexes and following chemical reactions. A Varian Cary 300 Bio or Varian
Cary 300 Scan instrument was used with 1 cm path length quartz cuvettes, and
a Varian Cary temperature controller. Unless otherwise stated, spectra were
recorded at 25 °C between 800-200 nm at a scan rate of 600 nm/min with 1 nm
intervals. Varian Cary WinUV software was used to record the spectra, using
either Scan version 4.10(464), Scanning Kinetics version 4.10(461), or Kinetics
version 4.10(461) mode, depending on the type of experiment. Commercially
available solvents were used and any aqueous solutions were made using
doubly deionised water. All spectra were processed using MS Excel 2010.
2.2.5. Microwave reactor
Microwave assistance was utilised for the synthesis of some Os(II) arene
dimers. Microwave synthesis enables increased solvent molecular vibrations
and for reactions to take place at higher temperatures than traditional heating
apparatus. A CEM Discover-SP microwave reactor was used with the following
settings: maximum power = 150 W, maximum pressure = 250 PSI. Reaction
times and temperatures varied and are stated in the synthesis experimental
(Section 2.1.2).
2.2.6. Automated reverse-phase column chromatography
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Sometimes Os(II) arene complexes required an alternative purification method
when recrystallization methods were not viable. Complexes were purified using
a Biotage Isolera one instrument with a Biotage KP-C18-HS 12g SNAP
cartridge. The mobile phase consisted of; (A) H2O + 0.1 %TFA, and (B) MeCN
+ 0.1 % TFA. The complex (≤100 mg) was dissolved in DCM, loaded onto 
ISOLUTE HM-N granules and installed onto the top of the column. The
following solvent gradient was used with a 12 mL/min flow rate.
Start
(%B)
End
(%B)
Column
volumes
0 0 1
0 10 1
10 80 20-30
80 80 6
80 10 1
The collected fractions were analysed by MS and the chosen fractions were
combined. MeCN was removed under reduced pressure and the product was
extracted with DCM (10-20 mL). The product was re-dissolved in EtOH and
recombined with its original counter ion by adding the appropriate salt (e.g.
ammonium hexafluorophosphate), then recrystallised in EtOH.
2.2.7. pH measurements
2.2.7.1. pH bench top meter
A Martini instruments Mi 150 pH/Temperature bench meter with a Mettler-
Toledo U402-M3-S7/200 chloride pH probe was used. The instrumentation was
calibrated with three Mettler-Toledo buffer solutions; pH 4.01±0.02, 7.00 ±0.02,
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and 10.00±0.02. The probe was washed between measuring samples with
deionised water, and stored in 1 M KCl when not in use. All pH meter readings
were recorded at room temperature.
2.2.7.2. Portable pH meter device
A portable pH meter was specifically used for pH measurements when
measuring the pKa of a complex by 1H NMR. A HACH H138 minilab instrument
was used and calibrated using 3 buffer solutions that were supplied with the
instrument; pH 4.01±0.02, 7.00±0.02, and 10.01±0.02. The probe was washed
with deionised water between measuring samples. All pH meter readings were
recorded at room temperature.
2.2.8. X-ray crystallography
All diffraction data were collected by Dr. Guy Clarkson using an Oxford
Diffraction Gemini four-circle system with a Ruby CCD area detector. All
structures were refined by full-matrix least squares against F2 using SHELXL-
97, and were solved by direct methods using SHELXS(TREF) with additional
light atoms found by Fourier methods.9 Hydrogen atoms were added at
calculated positions and refined using a riding model. Anisotropic displacement
parameters were used for all non-H atoms. H-atoms were given an isotropic
displacement parameter equal to 1.2 (or 1.5 for methyl and NH H-atoms) times
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the equivalent isotropic displacement parameter of the atom to which they are
attached. The data were processed using Mercury 3.3.software.
2.2.9. High performance liquid chromatography (HPLC)
The HPLC analysis of complexes was carried out on an Agilent Technologies
1200 series HPLC instrument with a VWD and 100 µL loop, and an Agilent
ZORBAX Eclipse Plus C18 250 x 4.6 mm column with a pore size of 5 µm was
used. The mobile phase consisted of; (A) HPLC grade H2O + 0.1 %TFA, and
(B) HPLC grade MeCN + 0.1 % TFA. The following solvent gradient was used
with a flow rate of 1 mL/min.
Time
(min) % (B)
0 10
30 80
40 80
41 10
45 10
Samples were typically prepared at 100 μM in H2O (10% MeCN) using HPLC
grade solvents and were filtered through Iso-DiscTM filters (PTFE-4-4 4 mm x
0.45 μm). Sample volumes of 50μM were injected into the HPLC instrument and 
analysed at a detection wavelength of 254 nm with reference wavelengths set
to 360 nm and 510 nm. Some samples also required a detection wavelength of
610 nm with a reference wavelength setting of 360 nm. The chromatograms
were analysed using ChemStation software and any peaks greater than 10
mAU were integrated. Chromatograms were generated using MS Excel 2010.
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2.2.10. Liquid chromatography-mass spectrometry (LC-MS)
A Bruker Amazon X+ instrument coupled with an Agilent Technologies 1200
series HPLC instrument was used. The same HPLC column, method and
conditions were used as shown in Section 2.2.9. Sample injections were 20 μL 
and the mass spectrometer was operated in electrospray positive mode with a
scan range of 50-2000 m/z.
2.2.11. Electrochemistry10
Electrochemical measurements were carried out by Dr. Nicolas P. E. Barry and
Dr. Nichola Smith. All cyclic voltammogram (CV) experiments were carried out
using a CH Instrument model 600D Electrochemical Analyzer/Workstation
(Austin, TX). The electrochemical measurements were performed on
compounds in an acetonitrile solution (1 mg/mL) containing
tetrabutylammonium hexafluorophosphate (0.1 M) as supporting electrolyte.
The solutions were degassed under nitrogen and cyclic voltammograms were
typically scanned from -2.0 V to +2.0 V. In a typical experimental set up, a
three-electrode system was used: a glassy carbon electrode as the working
electrode, Ag/AgCl in 3.0 M KCl as the reference electrode (0.21 V versus
NHE), and platinum wire as the counter electrode. For each electrode, CV was
performed at a scan rate of 0.1 V/s.
2.2.12. Electron paramagnetic resonance (EPR)11
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All EPR experiments were conducted by Dr. Carlos Sanchez-Cano. EPR
spectra were recorded at room temperature on a Bruker EMX (X-band)
spectrometer fitted with a cylindrical Tm110 mode cavity (Bruker 4103TM).
Samples were contained in quartz capillary (I.D. 1.0 mm; O.D. 1.2 mm; Wilmad
Labglass) sealed with T-BluTac®, and placed inside larger quartz tubes (O.D.
2.0 mm) to achieve easy and accurate positioning of the sample inside the
resonator. Typical EPR spectrometer settings were; modulation amplitude 2.0
G, microwave power 0.63 mW, 1.0 x 105 receiver gain, conversion time 81.92
ms, time constant 81.92 ms, sweep width 200 G, and a repeated number of 10
X-scans with a resolution in Y of 5 or 9. Spin-trapping experiments of
complexes were performed in aqueous solutions with an excess of spin trap (1
mM complex, 6 mM DEPMPO, 10 mM hydrogen peroxide, in 75 mM phosphate
buffer, pH 7.4) in the presence or absence of ethanol. EPR spectra were
analysed and simulated using the EASYSPIN software.12
2.2.13. Ion-coupled plasma optical emission spectroscopy (ICP-OES)3,13
ICP-OES analysis of osmium solutions were carried out on a Perkin Elmer
(Optical Emission Spectrometer) Optima 5300 DV instrument. All samples and
standards were prepared fresh on the day in doubly deionised water with
distilled HNO3 (3.2%). The osmium standard was diluted to the following
concentrations for the calibration curve: 0, 25, 50, 100, 200, 400, 600, 800 and
1000 ppb. The samples were diluted by serial dilutions of typically 1 in 10 until
their concentrations fitted within the calibration range and the % total dissolved
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solids were below 0.2%. For samples in cell culture medium or containing
sodium chloride, the standards were prepared containing the same amount of
sodium chloride as the samples after dilution. Samples were made in triplicates
and the optical emissions at 228.226 and 225.585 nm were detected and
integrated.
2.2.14. Ion-coupled plasma mass spectrometry (ICP-MS)3,13
ICP-MS analysis of osmium solutions were carried out on an Agilent
Technologies 7500 series ICP-MS instrument. All samples and standards were
prepared fresh on the day in doubly deionised water with distilled HNO3 (3.2%).
The osmium standard was diluted to the following concentrations for the
calibration curve: 0, 0.1, 0.2, 0.5, 1, 2, 4, 8, 10, 20,40, 60, 80 and 100 ppb. The
samples were diluted by serial dilutions of typically 1 in 10 until their
concentrations fitted within the calibration range and the % total dissolved solids
were below 0.1%. For samples containing cell culture medium or sodium
chloride, the standards were prepared containing the same amount of sodium
chloride as the samples after dilution. Samples were made in triplicates and the
isotope detected was 189Os in no-gas mode.
2.3. Experimental methods
2.3.1. Cell culture
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Cell cultures were grown in T-75 or T-175 culture flasks as adherent
monolayers. The cells were passaged 2-3 times per week whenever confluence
reached 80-90%, using 0.25% trypsin for A2780 or 0.25% trypsin/EDTA for all
other cell lines. Cell cultures were stored in an incubator at 37 °C with a 5%
CO2 humidified atmosphere. Cells were used for experiments between 5-25
numbers of passages.
2.3.2. In vitro growth inhibition assay
IC50 values were determined by Dr. Isolda Romero-Canelón.13 Approximately
5000 A2780 human ovarian cancer cells were seeded per well in 96-well plates.
The cells were pre-incubated in drug-free media at 37 °C for 48 h before adding
different concentrations of the complexes to be tested. Cells were exposed to
complexes for 24 h at 37 °C. The supernatants were removed by suction and
each well was washed with PBS. The cells were allowed to recover for 72 h in a
drug-free medium at 37 °C. The SRB assay was used to determine cell viability.
Absorbance measurements of the solubilised dye (on a BioRad iMark
microplate reader using a 470 nm filter) allowed the determination of viable
treated cells compared to untreated controls. IC50 values (the concentration at
which 50% cell death occurs) were determined as triplicates of duplicates for
each complex. ICP-MS was used to determine the osmium concentrations of
the initial stock solutions of the complexes, and the IC50 value was corrected for
ICP factor.
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2.3.3. Determination of Partition coefficient (Log Po/w)
The partition coefficient was determined using a modified version of the shake-
flask method.14,15 A 300 mM solution of NaI was prepared in doubly distilled
water. Octanol-saturated water and water-saturated octanol were prepared by
stirring octanol (100 mL) and 300 mM NaI solution (100 mL) together for 24 h,
then separating the layers in a separating funnel. Complexes (0.5 – 3.0 mg)
were dissolved in octanol-saturated water solution (3 mL) with plenty of
stirring/shaking, then filtered. (NOTE: 300 mM NaI solution was used to supress
the hydrolysis of complexes containing monodentate iodide ligands. For
chlorido and bromido complexes, octanol-saturated water containing 300 mM
NaCl or NaBr was prepared and used instead in the same manner). Saturated
solutions of complexes in octanol-saturated water (1 mL) were combined with
water-saturated octanol (1 mL), and placed on a Vibrax VXB basic shaker for 24
h at a speed of 500 g/min. After partition, the aqueous layers were collected for
analysis, along with the aqueous solutions of complexes before partitioning. The
osmium concentrations of samples were determined by either ICP-MS or ICP-
OES, and the partition coefficient was calculated via the following equation; Log
Po/w = Log ([Os]octanol/[Os]water). Experiments were performed in duplicates of
triplicates in two independent experiments and at ambient temperature.
2.3.4. Cellular uptake
Cellular accumulation studies for osmium complexes were conducted by Dr.
Isolda Romero-Canelón in A2780 ovarian cancer cells.13 Approximately 4 x 106
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cells were seeded into P100 Petri dishes. After 24 h of pre-incubation time in
drug-free medium at 37°C in a 5% CO2 humidified atmosphere, the complexes
were added to give concentrations equal to IC50/3 and 24 h of incubated drug
exposure was allowed. Afterwards, the cells were treated with trypsin, counted,
and the cell pellets were collected. The experiment also included a set of control
samples with untreated cells. Cell pellets were digested overnight in 72%
distilled nitric acid at 80 °C in Wheaton V-vials. The resulting solutions were
diluted in a stabilisation solution of thiourea (10 mM) with ascorbic acid (0.1 g/L)
in doubly deionised water, diluting the nitric acid content to 3.6%. Ascorbic acid
acts as a reducing agent to reduce any OsO4 that may have been generated
during the digestion process, and thiourea acts as an osmium ‘chelator’.16
Osmium concentrations were determined by ICP-MS. Measurements were
carried out in triplicate for each complex and cellular accumulation was
calculated in units of ng Os /106 cells.
2.3.5. Cell cycle analysis
Cell cycle analyses were conducted by Dr. Isolda Romero-Canelón.15 Briefly,
1.5 x 106 A2780 cells per well were seeded in a 6-well plate. Cells were pre-
incubated in drug-free media at 37 °C for 24 h in a 5% CO2 humidified
atmosphere, then complexes were added to triplicates at 1x or 2x IC50
concentrations. This experiment included a set of control samples with
untreated cells. After 24 h of incubated drug exposure the supernatants were
removed by suction. The cells were washed with PBS and harvested using
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trypsin. Cells were fixed with 70% ethanol and stored at -20 °C. DNA staining
was achieved by re-suspending the cell pellets in PBS containing propidium
iodide (PI) and RNase. Cell pellets were re-suspended in PBS before being
analysed in a Becton Dickinson FACScan flow cytometer, using excitation of
DNA-bound PI at 536 nm with emission at 617 nm. Data were processed using
Flowjo software.
2.3.6. ROS experiments
Flow cytometry analysis of ROS/superoxide generation in A2780 cells caused
by exposure to osmium complexes, was carried out using the Total
ROS/Superoxide detection kit (Enzo-Life sciences) according to the supplier’s
instructions, by Dr. Isolda Romero-Canelón.17 Briefly, 1.5 x 106 cells per well
were seeded in a 6-well plate. Cells were pre-incubated in drug-free media at
37°C for 24 h in a 5% CO2 humidified atmosphere, then complexes were added
to triplicates at 1x and 2x IC50 concentrations. After 24 h of incubated drug
exposure, the supernatants were removed by suction and cells were washed
with PBS. Cells were harvested using trypsin and collected after centrifugation.
This experiment included pyocyanin as a positive control and untreated cells as
a negative control. Staining was achieved by re-suspending the cell pellets in
buffer containing the orange/green fluorescent reagents. Cells were analysed
on a Becton Dickinson FACScan Flow Cytometer using FL1 channel Ex/Em:
490/525 nm for the oxidative stress and FL2 channel Ex/Em: 550/620 nm for
superoxide detection. Compensation adjustments were carried out using
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pyocyanin-treated cells singly-stained with either fluorescent agent. Data were
processed using Flowjo software.
2.3.7. Induction of Apoptosis
Flow cytometry analyses of apoptotic populations of A2780 cells caused by
exposure to complexes were carried out using the Biovision Annexin V-FITC
Apoptosis detection kit, according the suppliers instructions. These were carried
out by Dr. Isolda Romero-Canelón.13,17 Briefly, 1.5 x 106 cells per well were
seeded in a 6-well plate. Cells were pre-incubated in drug-free media at 37°C
for 24 h in a 5% CO2 humidified atmosphere, then complexes were added to
triplicates at 1x and 2x IC50 concentrations. After 24 h of incubated drug
exposure, the supernatants were removed by suction and cells were washed
with PBS. Cells were harvested using trypsin and collected after centrifugation.
This experiment included a control with untreated cells. The cells were stained
with Annexin V-FITC and PI and analysed using a Becton Dickinson FACScan
flow cytometer, running Cell Quest software (20 000 events were collected from
each sample).
2.4. Radiolabelling studies at Kings College London18
2.4.1. Iodine-131
Radiolabelling studies of osmium complexes required the use of sodium iodide-
131. Iodine-131 is a ‘neutron rich’ 78-neutron nuclide that decays with a half-life
of 8.02 days into a stable xenon
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Biomedical Engineering in St Thomas’s Hospital. Work was carried out in
accordance with the Ionising Radiation Regulations 1999 (IRR99) and Local
Rules, which required prior health and safety training. All manual handling of
iodine-131 stock solutions, radio-chemical synthesis and reactions, were carried
out in a radioactive work station inside a fume-hood. A typical work station
consists of lead bricks walls and a 1-inch thick leaded glass safety screen as
shown in Figure 2.2. Dosimeter badges and finger rings were worn at all times
in the labs to monitor radioactive exposure. Radio-chemical syntheses were
carried out 2 mL plastic sealable tubes and placed on a mechanical
shaker/heater. All radioactive waste materials were monitored and disposed of
appropriately according to local rules. Samples containing iodine-131 were
stored in lead containers and samples in use were kept inside radioactivity work
stations where ever possible to minimise exposure.
Figure 2.2. A photograph of a radioactivity safety workstation
screen
Leaded glass78
Lead bricks
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2.4.3. Instrumentation
2.4.3.1. Radio-TLC20
TLC-sheets (12 x 100 mm, silica gel 60 F254, layer thickness 0.2 mm) were
used. Plates were spotted with 3 µL of reaction mixture at the baseline and
placed inside sealed plastic falcon tubes with eluent H2O:MeOH (1:1) (700 µL).
The solvent front was allowed to travel 90 mm from the baseline. Plates were
scanned on a LabLogic MINI-SCAN TLC scanner with a LabLogic B-FC-3200
gamma probe at a scan rate of 0.25 mm/s. TLC chromatograms were analysed
and integrated using Laura-TLC version 4.0.2.75 software.
2.4.3.2. Radio-HPLC18,21
An Agilent 1200 series instrument with a VWD (wavelength of detection 254
nm), a 200 µL loop, and an Agilent ZORBAX Eclipse Plus C18 250 x 4.6 mm
column with a pore size of 5 µm was used. The HPLC instrument was fitted with
either a raytest Gabi Star gamma detector with a raytest NaI-detector 1x1`` Std
gamma probe, or a LabLogic FLOW-COUNT gamma detector with a LabLogic
B-FC-3200 gamma probe. The HPLC instrument was specially equipped with
lead shielding. The mobile phase consisted of; (A) doubly deionised H2O +
0.1 % TFA, and (B) HPLC grade MeCN + 0.1 % TFA. The HPLC gradient used
was the same as shown in Section 2.2.9. Non-radioactive samples were filtered,
however, it was not possible to filter radioactive samples due to safety
concerns. Samples were injected into the loop at volumes of up to 200 μL. 
HPLC chromatograms were analysed and integrated using GINA Star version
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5.8, or Laura-HPLC version 4.0.2.75 software. All data were generated using
MS Excel 2010. Preparative radio-HPLC was also used under the same
conditions.
2.4.3.3. Gamma counter
Samples of low level radioactivity (>15 KBq) were analysed using a LKB Wallac
1282 Compugamma universal gamma counter with EdenTerm V1.21 software.
The data were processed using MS Excel 2010.
2.4.3.4. Electronic cell counting
Cell counting was carried out using an Invitrogen countess automated cell
counter with plastic disposable InvitrogenTM hemocytometers, after staining cells
with PI. The number of live cells and % cell viability were recorded.
2.4.4. Methods
2.4.4.1. Human blood serum stability assays
Stability assays were setup for both non-carrier added and carrier added
experiments (NOTE: Carrier added conditions are where the non-radiolabelled
complex is also added with the radio-tracer at a concentration comparable to
the IC50 value). Non-carrier added; human blood serum (900 µL) was combined
with radio-tracer complex (100 µL, ~500 KBq). Carrier added; human blood
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serum (900 µL) was combined with radio-tracer complex (50 µL, ~250 KBq),
and a solution of the non-radiolabelled carrier complex (50 µL, 5 μM), giving a 
carrier concentration of 0.25 µM. Samples were prepared in 2 mL plastic
sealable disposable tubes, incubated at 37 ºC with 300 rpm stirring for 24 h,
and analysed after 1 h and 24 h by radio-HPLC. The samples were firstly
treated with 1 part MeCN and centrifuged for 5 min (>10000 rpm) to precipitate
serum proteins before injection into the HPLC instrument.
2.4.4.2. Serum protein accumulation experiment
Samples were prepared in the same way as in Section 2.4.4.1 and incubated
for 24 h. One part MeCN was added to the samples before centrifuging for 5
min (>10000 rpm) to produce serum protein pellets. The supernatants were
collected into plastic test tubes, and the pellets were digested in 1 M NaOH and
collected into separate tubes. The fractions were analysed using the gamma
counter and the % iodine uptake into serum proteins was calculated.
2.4.4.3. In vitro stability assays
Approximately 1 x 106 MCF-7 cells were seeded per well in a 24-well plate. A
well was assigned for each time point measurement, then pre-incubated in drug
free media for 24 h in a 5% CO2 humidified atmosphere. The supernatants were
removed by suction and fresh media was added: non-carrier added
experiments; 900 µL of medium + 100 µL of radio-tracer complex (~500KBq),
carrier added
carrier complex
IC50/3. A second 24
control experiments
were incubated for 24 h and supernatants from wells were removed at different
time points: 2, 4, 8 and 24 h. Supernatants were combined with 1 part MeCN
and centrifuged for 5 min (>10000 rpm) to remove
cells, then
Figure 2.3.
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centrifuged at 10 ºC/1000 rpm for 3 min, and the supernatants were removed by
pipette and collected. The cells were then washed twice with refrigerated PBS
solution (1 mL) and the washings were combined with the supernatant fractions.
The cell pellets were digested in NaOH solution (1 M, 1 mL) at 37 °C for 30 min
and collected separately. The tubes were washed with twice with PBS solution
(1 mL) and residues were combined with digested cell fractions. Control
experiments were carried out in the same manner. The CPM of the supernatant
and digested cell fractions were measured using the gamma counter. The
number of cells in each digested cell sample was measured using a cell
calibration curve in Chapter 5, Section 5.2.3.2. The data were processed using
MS excel 2010 to obtain the % cell uptake of I-131 /106 cells.
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Chapter 3
Osmium(II) Arene Complexes of
Phenylazobenzothiazoles
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3.1. Introduction
Os(II) arene complexes with N,N- chelating phenylazopyridine (AZPY) ligands
have been previously reported by the Sadler group.1,2 Such complexes show
very promising anti-cancer properties with IC50 values against various cancer
cell lines in the nano-molar range, and novel mechanisms of action. Following
the success of these complexes, there is particular interest to explore Os(II)
complexes of alternative azo-ligands in order to expand our library and gain
more understanding of the properties of novel anti-cancer complexes. One
group of azo-ligands of potential interest are phenylazobenzothiazoles
(AZBTZs). Interestingly, AZBTZs have strong applications in the field of dyes
and pigments, owing to their intense red colourations.3 They can also be utilised
as probes for in vivo radio-imaging of neurofibrillary tangles in Alzheimer’s
disease brains, as they show promising selective binding towards β-amyloid 
peptides and hyper phosphorylated tau proteins associated with Alzheimer’s
disease.4
AZBTZs are analogous to AZPY ligands, whereby the pyridine is substituted by
a benzothiazole moiety (Figure 3.1). Benzothiazole is a bicyclic ring system
consisting of a benzene ring fused to a 5-membered 1,3-thiazole ring. Because
of their pronounced biological and pharmacological activities they are of great
interest for medicinal applications. Numerous benzothiazole compounds have
shown promising anticancer activity and have been reported frequently in the
Journal of Medicinal Chemistry,5-9 making benzothiazole a desirable functional
group to include in our study of osmium anti-cancer complexes. Furthermore,
there are also studies highlighting organometallic complexes bearing
benzothiazole groups with anti
capabilities.
Keppler et al
kinase inhibitor sites.
binding to a metal centre is
binding of AZBTZs in Os(II) arene complexes
Figure 3.1.
phenylazobenzothiazole ligand with a benzothiazole moiety.
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3.2.2. Synthesis
3.2.2.1. Synthesis of AZBTZ ligands
4-(2-Benzothiazolylazo)-N,N-dimethylaniline (L). 2-Aminobenzothiazole
(500.0 mg, 3.33 mmol) was mixed with glacial acetic acid (20 mL) and cooled to
0 °C in a water/ice bath. Sulphuric acid (>95%, 7 mL) was then added. A
solution of NaNO2 (252.7 mg, 3.66 mmol) in deionised water (10 mL) was
added drop-wise to the stirring mixture, and it instantaneously turned
yellow/orange. The mixture was stirred for 2 h at 0°C. An ice-cold solution of
N,N-dimethylaniline (425 µL, 3.33 mmol) in MeOH (34 mL) was added drop-
wise and the mixture turned dark purple. The mixture was stirred for a further 18
h, allowing it to warm to ambient temperature, then was combined with water
(200 mL) and DCM (100 mL), and the layers were separated. The aqueous
layer was washed with DCM (2 x 50 mL), and the combined DCM extracts were
washed with water (2 x 50 mL), dried over MgSO4, filtered, and the solvent was
removed under reduced pressure yielding a dark precipitate. The crude product
was re-crystallised from a minimum amount of chloroform, giving a dark green
precipitate. The product was collected by filtration, washed with ice-cold Et2O
(2x 5 mL), and dried overnight in a vacuum desiccator. Yield: 585.6 mg, (62%).
1H NMR (400 MHz, CDCl3): δ 8.07 (d, 1H, J = 7.8 Hz), 8.00 (d, 2H, J = 9.1 Hz), 
7.84 (d, 1H, J = 7.8 Hz), 7.47-7.46 (m, 1H), 7.38-7.37 (m, 1H), 6.77 (d, 2H, J =
9.4 Hz), 3.17 (s, 6H). ESI-MS calculated for C15H14N4S + H+: m/z 283.1. Found:
283.1. CHN analysis: Found: C, 63.22%; H, 4.92%; N, 19.67%. Calculated for
C15H14N4S: C, 63.81%; H, 5.00%; N, 19.84%.
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para-(2-Benzothiazolylazo)-3,5-dimethylaniline (L*). The synthesis follows
the same preparation as above, where 3,5-dimethylaniline (457 µL, 3.66 mmol)
was used instead of N,N-dimethylaniline. The crude product was purified via
flash column chromatography (SiO2, 1:2 acetone:n-hexane, Rf = 0.33). Due to
low solubility of the crude product in the mobile phase, it was only possible to
purify a portion of the crude product. The collected fractions containing product
were combined and the solvent was removed under reduced pressure to yield a
dark red precipitate, which was dried overnight in a vacuum desiccator. Yield:
53.2 mg. 1H NMR (400 MHz, CDCl3): δ 8.08 (d, 1H, J = 8.0 Hz), 7.81 (d, 1H, J = 
8.0 Hz), 7.46-7.45 (m, 1H), 7.37-7.36 (m, 1H), 6.43 (s, 2H), 4.33 (s. br, 2H),
2.64 (s, 6H). ESI-MS calculated for C15H14N4S + H+: m/z 283.1. Found:
282.8.CHN analysis: Found: C, 63.35%; H, 5.00%; N, 19.60%. Calculated for
C15H14N4S: C, 63.81%; H, 5.00%; N, 19.84%.
3.2.2.2. Synthesis of Os(II) arene AZBTZ complexes
[Os(η6-p-cym)(N,N-AZBTZ-NMe2)Cl]PF6 (1a). [Os(η6-p-cym)Cl2]2 (50.0 mg,
63.2 µmol) and 4-(2-benzothiazolylazo)-N,N-dimethylaniline (37.5 mg, 132.8
µmol) were dissolved in EtOH (20 mL). The mixture was stirred at 50 °C for 2 h
and the colour turned dark blue. The mixture was left to stir for 18 h at ambient
temperature and NH4PF6 (103.1 mg, 0.63 mmol) was added. The volume was
reduced under reduced pressure to ~2 mL, and the mixture was placed in the
freezer overnight. The resulting dark blue precipitate was collected by filtration.
The precipitate was dissolved in chloroform (10 mL), stirred for 1 h, and filtered.
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The filtrate was collected and the solvent was removed under reduced
pressure. The resulting dark blue precipitate was re-crystallised from a
minimum amount of EtOH. The product was collected by filtration and washed
with ice-cold EtOH (2 x 1 mL) and Et2O (2 x 5 mL). The product was dried
overnight in a vacuum desiccator. Yield: 44.9 mg, (45%). 1H NMR (400 MHz,
CD3OD): δ 8.28-8.27 (m, 2H), 8.15-8.14 (m, 2H), 7.83-7.82 (m, 1H), 7.75-7.74 
(m, 1H), 7.06-7.05 (m, 2H), 6.59-6.58 (m, 1H), 6.55-6.54 (m, 1H), 6.25-6.24 (m,
1H), 6.21-6.20 (m, 1H), 3.53 (s, 6H), 2.48 (s, 3H), 2.18 (sept., 1H, J = 6.9 Hz),
0.87 (d, 3H, J = 6.9 Hz), 0.76 (d, 3H, J = 6.9 Hz). ESI-MS calculated for
C25H28ClN4OsS+: m/z 643.1. Found: 643.0. CHN analysis: Found: C, 37.67%;
H, 3.42%; N, 6.91%. Calculated for C25H28ClF6N4OsPS: C, 38.14%; H, 3.59%;
N, 7.12%.
Os(η6-p-cym)(N,C-AZBTZ-NMe2)Cl (1b). [Os(η6-p-cym)Cl2]2 (50.0 mg, 63.2
µmol) and 4-(2-benzothiazolylazo)-N,N-dimethylaniline (37.5 mg, 132.8 µmol)
were dissolved in EtOH (20 mL). The mixture was stirred at 50 °C for 2 h and
the colour turned dark blue. The mixture was left to stir for 18 h at ambient
temperature, then the solvent was removed under reduced pressure. The
product was purified via flash column chromatography (SiO2, 50:1 DCM:MeOH,
Rf = 0.34). The collected fractions containing product were combined and the
solvent was removed under reduced pressure to give a dark purple precipitate.
The precipitate was recrystallized from a minimum amount of EtOH. The
product was collected by filtration and washed with ice-cold EtOH (2 x 1 mL)
and Et2O (2 x 5 mL), then dried in a vacuum desiccator overnight. Yield: 14.9
mg, (18%). 1H NMR (400 MHz, (CD3)2CO): δ 8.10 (m, 1H), 8.08 (d, 1H, J = 9.4 
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Hz), 7.96-7.95 (m, 1H), 7.60-7.59 (m, 2H), 7.47-7.46 (m, 1H), 6.94 (dd, 1H, J =
9.4, 2.7 Hz), 6.24-6.23 (m, 1H), 6.14-6.13 (m, 1H), 6.03-6.02 (m, 1H), 5.46-5.45
(m, 1H), 3.45 (s, 6H), 2.32 (sept., 1H, J = 6.9 Hz), 2.25 (s, 3H), 1.04 (d, 3H, J =
6.9 Hz), 0.79 (d, 3H, J = 6.9 Hz). ESI-MS calculated for C25H27ClN4OsS + H+:
m/z 643.1. Found: 643.0. CHN analysis: Found: C, 46.67%; H, 4.39%; N,
8.34%. Calculated for C25H27ClN4OsS: C, 46.83%; H, 4.24%; N, 8.74%.
[Os(η6-p-cym)(N,N-AZBTZ-NMe2)Br]PF6 (2a) and Os(η6-p-cym)(N,C-AZBTZ-
NMe2)Br (2b). [Os(η6-p-cym)Br2]2 (70.0 mg, 72.3 µmol) and 4-(2-
benzothiazolylazo)-N,N-dimethylaniline (40.8 mg, 144.6 µmol) were dissolved in
EtOH (20 mL). The mixture was stirred at 50 °C for 2 h and the colour turned
dark blue/purple. The mixture was left to stir for 18 h at ambient temperature
and NH4PF6 (103.1 mg, 0.63 mmol) was added. The solvent was removed
under reduced pressure and the dark blue residue was re-dissolved in
chloroform (20 mL) and stirred for 1 h. The mixture was filtered giving a
precipitate predominantly containing 2b, and filtrate predominantly containing
2a.
2a. The filtrate was concentrated under reduced pressure to ~1-2 mL, combined
with a small amount of Et2O (<1 mL), and placed in the freezer overnight. The
resulting dark blue precipitate was collected by filtration, washed with ice-cold
EtOH (1 mL) and Et2O (2 x 5 mL), and dried overnight in a vacuum desiccator.
Yield: 9.9 mg, (8%). 1H NMR (400 MHz, (CD3)2CO): δ 8.36 (d, 2H, J = 9.6 Hz), 
8.23-8.22 (m, 2H), 7.80-7.79 (m, 2H), 7.07 (d, 2H, J = 9.7 Hz), 6.80-6.79 (m,
1H), 6.75-6.74 (m, 1H), 6.46-6.45 (m, 1H), 6.41-6.40 (m, 1H), 3.58 (s, 6H), 2.66
(s, 3H), 2.26 (sept., 1H, J = 6.9 Hz), 0.94 (d, 3H, J = 6.9 Hz), 0.85 (d, 3H, J =
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6.9 Hz). ESI-MS calculated for C25H28BrN4OsS+: m/z 687.1. Found: 687.1. No
CHN analysis due to low yield and impure sample.
2b. The precipitate was dissolved in a minimum amount of MeOH and purified
via flash column chromatography (SiO2, MeOH, Rf = 0.74). The selected
fractions containing product were combined and the solvent was removed under
reduced pressure to give a dark purple solid, which was dried overnight in a
vacuum desiccator. Yield: 20.2 mg, (20%). 1H NMR (400 MHz, (CD3)2SO): δ 
7.98-7.91 (m, 1H), 7.96 (d, 1H, J = 9.3 Hz), 7.48-7.47 (m, 1H), 7.43 (d, 1H, J =
2.6 Hz), 7.35-7.34 (m, 1H), 6.85 (dd, 1H, J = 9.3, 2.6 Hz), 6.15-6.14 (m, 2H),
5.81-5.80 (m, 1H), 5.49-5.48 (m, 1H), 3.34 (s, 6H, hidden under water peak),
2.31 (sept., 1H, J = 6.9 Hz), 2.16 (s, 3H), 0.99 (d, 3H, J = 6.9 Hz), 0.70 (d, 3H, J
= 6.9 Hz). ESI-MS calculated for C25H27BrN4OsS + H+ and C25H27BrN4OsS +
Na+: m/z 687.1 and 709.1. Found: 687.0 and 708.9. CHN analysis: Found: C,
42.68%; H, 3.84%; N, 8.00 %. Calculated for C25H27BrN4OsS + ⅓CH2Cl2: C,
42.61%; H, 3.91%; N, 7.85%.
Os(η6-p-cym)(N,C-AZBTZ-NMe2)I (3b). [Os(η6-p-cym)I2]2 (50.0 mg, 43.2 µmol)
and 4-(2-benzothiazolylazo)-N,N-dimethylaniline (24.4 mg, 86.5 µmol) were
dissolved in EtOH (20 mL). The mixture was stirred at 50 °C for 2 h and the
colour turned dark blue/purple. The mixture was left to stir for 18 h at ambient
temperature, then the volume was reduced under reduced pressure to ~2 mL.
The mixture was placed in the freezer overnight resulting in a dark brown
precipitate, which was collected by filtration and washed with ice-cold EtOH (2 x
1 mL) and Et2O (2 x 5 mL). The product was dried overnight in a vacuum
desiccator. Yield: 48.6 mg, (77%). 1H NMR (700 MHz, CDCl3): δ 8.11 (d, 1H, J 
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= 9.2 Hz), 7.93 (d, 1H, J = 8.0 Hz), 7.76 (d, 1H, J = 7.9 Hz), 7.42-7.41 (m, 1H),
7.30-7.29 (m, 1H), 7.27 (d, 1H, J = 2.5 Hz), 6.71 (dd, 1H, J = 9.2, 2.5 Hz), 5.99-
5.98 (m, 1H), 5.87-5.86 (m, 1H), 5.67-5.66 (m, 1H), 5.36-5.35 (m, 1H), 3.32 (s,
6H), 2.58 (sept., 1H, J = 6.9 Hz), 2.41 (s, 3H), 1.13 (d, 3H, 6.9 Hz), 0.83 (d, 3H,
6.9 Hz). ESI-MS calculated for C25H27IN4OsS + H+ and C25H27IN4OsS + Na+:
m/z 735.1 and 757.1. Found: 735.0 and 756.9. CHN analysis: Found: C,
38.75%; H, 3.39%; N, 7.17%. Calculated for C25H27IN4OsS + ½CHCl3: C,
38.65%; H, 3.50%; N, 7.07%.
[Os(η6-p-cym)(N,N-AZBTZ*-NH2)Cl]PF6 (4). [Os(η6-p-cym)Cl2]2 (30.0 mg, 37.9
µmol) was stirred in EtOH (10 mL), and a solution of para-(2-
benzothiazolylazo)-3,5-dimethylaniline (22.5 mg, 79.7 µmol) in EtOH (5 mL)
was added drop-wise to the stirring mixture. The mixture was stirred for 2 h at
50 °C and the colour turned dark blue/purple. The mixture was left to stir for 18
h at ambient temperature, then NH4PF6 (61.8 mg, 0.38 mmol) was added. The
mixture was concentrated under reduced pressure and placed in the freezer
overnight. The resulting dark purple precipitate was collected by filtration and
washed with ice-cold EtOH (2 x 1 mL) and Et2O (2 x 5 mL). The product was
dried overnight in a vacuum desiccator. Yield: 41.0 mg (69%). 1H NMR (400
MHz, CDCl3): δ 8.22 (d, 1H, J = 8.3 Hz), 8.06-7.99 (m, 2H), 7.92-7.91 (m, 1H), 
6.90-6.89 (m, 1H), 6.60-6.59 (m, 1H), 6.48-6.47 (m, 1H), 6.05-6.04 (m, 1H),
5.90-5.89 (m, 1H), 5.65-5.64 (m, 1H), 4.20 (s. br, 2H), 2.49 (s, 3H), 2.34 (s, 3H),
2.28 (sept., 1H, J = 6.9 Hz), 1.92 (s, 3H), 1.11 (d, 3H, J = 6.9 Hz), 0.91 (d, 3H, J
= 6.9 Hz). ESI-MS calculated for C25H28ClN4OsS+: m/z 643.1. Found: 643.2.
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CHN analysis: Found: C, 38.14%; H, 3.59%; N, 7.12%. Calculated for
C25H28F6ClN4OsPS: C, 37.54%; H, 3.46%; N, 7.13%.
[Os(η6-p-cym)(N,N-AZBTZ*-NH2)I]PF6 (5). [Os(η6-p-cym)I2]2 (23.1 mg, 20.0
µmol) was stirred in EtOH (10 mL), and a solution of para-(2-
benzothiazolylazo)-3,5-dimethylaniline (11.3 mg, 39.9 µmol) in EtOH (5 mL)
was added drop-wise to the stirring mixture. The mixture was stirred for 2 h at
50 °C and the colour turned dark blue/purple. The mixture was left to stir for 18
h at ambient temperature, then NH4PF6 (32.6 mg, 0.20 mmol) was added. The
mixture was concentrated under reduced pressure and placed in the freezer
overnight. The resulting dark purple precipitate was collected by filtration and
washed with ice-cold EtOH (2 x 1 mL) and Et2O (2 x 5 mL). The product was
dried overnight in a vacuum desiccator. Yield: 20.4 mg, (58%). 1H NMR (400
MHz, CDCl3): δ 8.22 (d, 1H, J = 8.3 Hz), 8.02-7.96 (m, 2H), 7.89-7.88 (m, 1H), 
6.82-6.81 (m, 1H), 6.58-6.57 (m, 1H), 6.48-6.47 (m, 1H,), 6.08-6.07 (m, 1H),
5.94-5.93 (m, 1H), 5.74-5.73 (m, 1H), 4.13 (s. br, 2H), 2.69 (s, 3H), 2.62 (s, 3H),
2.53 (sept., 1H, J = 6.9 Hz), 1.86 (s, 3H), 1.05 (d, 3H, J = 6.9 Hz), 1.01 (d, 3H, J
= 6.9 Hz). ESI-MS calculated for C25H28IN4OsS+: m/z 735.1. Found: 735.0. CHN
analysis: Found: C, 31.26%; H, 2.93%; N, 6.14%. Calculated for
C25H28F6IN4OsPS + CHCl3: C, 31.29%; H, 2.93%; N, 5.61%.
3.2.3. Growing single crystals for X-ray crystallography
Single crystals 1a and 2b crystals were obtained by diffusion of n-hexane into
an acetone solution at ambient temperature. Crystals of 2a were obtained by
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slow evaporation of a MeOH solution at ambient temperature. Crystals of 3a
were obtained by slow evaporation of a chloroform solution at ambient
temperature.
3.2.4. 1D 1H sel-NOE NMR
A solution of complex 5 was prepared in CDCl3. A 1D 1H sel-NOE experiment
was conducted using a 600 mHz instrument, targeting the 1H resonance at 6.84
ppm. The 1H NMR spectrum was then superimposed to view the 1H resonances
that are in close proximity through space to the resonance at 6.84 ppm. (The
greater the intensity of the NOE peak, the closer the distance in space).
3.2.5. 1H NMR kinetic experiment
Solutions of complex 2b (1.13 mg, 1.648 μmol) in methanol-d4 (700 μL), and 
0.889 M HBr in methanol-d4 were prepared. HBr (9.27 μL, 5 mol. equiv.) was 
combined with the complex and the 1H NMR spectrum was collected every 30
min for 16 h at 25 °C on a 400 MHz NMR instrument.
3.2.6. Aqueous solution chemistry
Solutions of complexes 1a and 1b were prepared in H2O:MeOH (1:1, v/v) at
concentrations of 50 μM. The UV-Vis spectrum was measured at 25 °C every 1 
Chapter 3
97
h for 24 h. Also carried out was a 50 μM solution of complex 1a in H2O:MeOH
(1:1, v/v) with 100 mM NaCl.
3.2.7. Calculation of partial charges
The Mulliken partial charges of complex 2b were calculated by Dr. Nicolas P. E.
Barry from the optimised gas phase geometry, using Gaussian 03 program and
employing the DFT method and PBE1PBE functionals. A LanL2DZ basis set
and effective core potential was used for the osmium atom, and 6-31G**+ basis
set was used for all other atoms.
3.3. Results
3.3.1. Synthesis of AZBTZ ligands
The bidentate phenylazobenzothiazole ligand, AZBTZ-NMe2 (L), was
synthesised via a diazotisation coupling reaction3 (Scheme 3.1). Step (a):
nitrosation of the primary amine in 2-aminobenzothiazole occurs when the
nitrosonium cation is generated in situ from sodium nitrite and sulfuric acid,
leading to the formation of a reactive diazonium salt intermediate. Step (b): on
addition of N,N-dimethylaniline, the electrophilic diazonium salt reacts at the
para- position of the aniline ring to form the highly coloured ligand, L. Reactivity
at the ortho- position of the ring is blocked by the presence of tertiary amine
methyl groups. Similarly, a second ligand, AZBTZ*-NH2 (L*), was synthesised
via the same reaction. Step (c): when 3,5-dimethylaniline is added to the
Chapter 3
98
diazonium salt, there are no methyl groups situated on the amine group to
prevent electrophilic addition occurring at the ortho-position. An ortho-
substituated impurity was found at 18% by 1H NMR and the product was
purified by SiO2 column chromatography. Full mechanistic details of the
diazotisation coupling reaction are shown in Scheme 3.2.
Scheme 3.1. Diazotisation coupling reactions used for the synthesis of L and L*. (a) Glacial
acetic acid:water:concentrated H2SO4 (6:3:2), NaNO2, 0°C. (b) N,N-Dimethylaniline, MeOH,
0 °C. (c) 3,5-Dimethylaniline, MeOH, 0 °C.
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Scheme 3.2. Reaction mechanism for the synthesis of ligand L. Showing (A) in situ generation
of the nitrosonium cation from sodium nitrite under strong acid conditions, (B) formation of the
diazonium salt reactive intermediate, and (C) addition of N,N-dimethylaniline, yielding L.
3.3.2. Synthesis of Os(II) arene AZBTZ complexes
Os(II) arene AZBTZ complexes were synthesised by stirring 2 mol. equiv. of L
with an Os(II) p-cym dimer; [Os(η6-p-cym)X2]2 (where X = Cl, Br or I), in EtOH at
ambient temperature. All three dimers react with L to form both a positively
charged N,N-coordinated complex, A, and a neutral cyclo-metalated N,C-
coordinated complex, B, in varying ratios (Scheme 3.3). These were observed
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possible for charged complexes 1a and 2a due to their high affinities for SiO2.
Unfortunately a pure bulk sample of 2a was not obtained after re-crystallisation,
but a pure single crystal suitable for an X-ray crystallography study was grown
in MeOH.
Complex X R1 R2 R3 Complex X
**1a Cl H H Me *1b Cl
**2a Br H H Me **2b Br
3a I H H Me **3b I
*4 Cl Me Me H
*5 I Me Me H
* product has been isolated
** product has been isolated and X-ray structure determined
Figure 3.3. Complexes formed from ligands L and L*. Complexes 1 - 3 were formed using L,
and 4 and 5 using L*. Complexes 1a, 2a, 3a, 4 and 5 are N,N-coordinated species. Complexes
1b, 2b and 3b are N,C-coordinated osmacycles.
The reaction conditions were altered to see if the formation of a N,N-
coordinated species can be favoured over N,C-coordination; when the reaction
between [Os(η6-p-cym)I2]2 was carried out with L in the aprotic and weakly
coordinating solvent DCM, formation of the N,N-coordinated species (3a) was
still disfavoured. Furthermore, carrying out the reaction between [Os(η6-p-
cym)Br2]2 and L in the presence of HBr did not prevent deprotonation of the
(A) (B)
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phenyl ring, hence prevent formation of the N,C-coordinated species. Even
when the reaction was carried out with 50 mol. equiv. HBr per 1 mol. equiv. of
L. Ligand L* has methyl groups situated at the R1 and R2 positions on the
aniline ring (Figure 3.3), hence preventing cyclo-metalation and the formation of
a N,C-coordinated species from occurring. When [Os(η6-p-cym)I2]2 was reacted
with 2 mol. equiv. of L*, the reaction took notably longer for the initial colour
change but was successful in yielding complex 5. Complex 4 was also
synthesised via the same reaction using [Os(η6-p-cym)Cl2]2. The molecular
structures of all the complexes synthesised in this chapter are shown in the
Appendices, Section 8.1.
3.3.3. Characterisation of complexes
The 1H NMR spectrum of the aromatic region of 1a is shown in Figure 3.4.
There are 12 aromatic protons and characterisation was confirmed by 2D
COSY 1H NMR. In contrast, the 1H NMR spectrum of complex 3b reveals a
species containing 11 rather than 12 aromatic protons (Figure 3.5). It was
confirmed that the missing proton is from the 3-position of the aniline ring, which
is bonded to osmium giving a neutral osmacycle structure. This structure is
characterised by the doublet of doublets, proton e (J = 9.2, 2.5 Hz), which has
short range coupling to proton f (3J = 9.2 Hz) and long range coupling to proton
g (4J =2.5 Hz).
Figure 3.4.
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The 1H NMR spectrum of complex 5 consists of 10 aromatic protons, four of
which correspond to the p-cym ligand. It was noted that the chemical shift of
one of these multiplets is abnormally more de-shielded than the others; three
protons reside between 6.09 – 5.72 ppm, whilst one resides at 6.82 ppm. A 1H
sel-NOE experiment was conducted, where a 1D NOE is used to irradiate a
specific resonance (at 6.82 ppm) and show other resonances in close proximity
through space. Figure 3.6 shows the spectrum obtained for the 1H sel-NOE with
the 1H NMR spectrum aligned above, and an assignment of the neighbouring
protons. The de-shielded arene proton (a) is neighbouring another aromatic p-
cym proton (c), a methyl group on the arene (d), and interestingly, it is in close
proximity to the proton at the 8-position on the benzothiazole group (b). In
comparison, the chlorido complex (4) also shows the same trend with a de-
shielded p-cym proton residing at 6.90 ppm.
Figure 3.6
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+ H+ and M + Na+). For example, complex 2a; C25H28BrN4OsS+: m/z 687.1, and
complex 2b; C25H27BrN4OsS + H+: m/z 687.1, and C25H27BrN4OsS + Na+:708.9.
3.3.4. X-ray crystal structures
The molecular structures of complexes 1a, 2a, 2b, and 3b were determined by
single crystal X-ray diffraction (Figure 3.7). The crystallographic data are shown
in Table 3.1 and selected bond lengths, bond angles, torsion angles, and atom
to atom distances are summarised in Table 3.2. The complexes adopt the
familiar pseudo-octahedral three-legged piano-stool geometry that is common
to all Os(II) η6-arene structures, where the Os(II) centre is π-bonded to the 
arene ligand. The Os(II) centre is also coordinated to a monodentate halide
ligand and the bidentate ligand, L, via either N,N or N,C atoms, which constitute
the three legs of the piano stool. All complexes exhibit a five-membered chelate
ring with L; N1-C9-N10-N11-Os1 for 1a and 2a, and N10-N11-C12-C17-Os1 for
2b and 3b. They all crystallise as racemates, owing to the presence of a chiral
Os(II) centre. Complexes 1a and 2a have PF6- counter-ions in their X-ray crystal
structures, whereas complexes 2b and 3b incorporate molecules of acetone
and chloroform in their crystal lattice, respectively, at a 2:1 ratio of complex:
solvent.
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Table 3.1. Crystallographic data for complexes 1a, 2a, 2b and 3b
1a 2a 2b·0.5C3H6O 3b·0.5CHCl3
Formula C25H28ClF6N4OsPS C25H28BrF6N4OsPS C25H27BrN4OsS·0.5C3H6O C25H27IN4OsS·0.5CHCl3
Molar mass /g mol-1 787.19 831.65 714.72 792.35
Density /mg m-3 1.869 2.011 1.876 2.021
Crystal system Monoclinic Monoclinic Monoclinic Monoclinic
Crystal dimensions /mm 0.20 x 0.16 x 0.10 0.20 x 0.16 x 0.12 0.55 x 0.30 x 0.15 0.40 x 0.10 x 0.01
Space group C2/c P2(1)/c P2(1)/c P2(1)/c
Crystal character purple block blue block black block brown plate
a/Å 15.13119(10) 14.5035(3) 8.6795(3) 8.7369(5)
b/Å 14.67057(10) 8.02511(14) 26.5519(10) 26.6425(12)
c/Å 25.80898(15) 24.5348(5) 11.6929(5) 11.8741(8)
α/deg 90 90 90 90
β/deg 102.3937(6) 105.828(2) 110.116(4) 109.544(7)
γ/deg 90 90 90 90
T/K 100(2) 150(2) 150(2) 100(2)
Z 8 4 4 4
R [F> 4σ(F)] 0.0260 0.0292 0.0560 0.0701
Rw 0.0665 0.0685 0.1010 0.1782
GOF 1.106 1.066 1.255 1.087
Δρ max and min /eÅ-3 1.397 & -0.862 3.098 & -0.989 2.967 & -3.209 3.646 & -2.888
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Table 3.2. Selected bond lengths (Å), atom to atom distances (Å), and bond/torsion angles (°),
observed in the X-ray crystal structures of complexes 1, 2a, 2b·0.5C3H6O and 3b·0.5CHCl3. X =
Cl, Br or I.
Bond length (Å) 1a 2a 2b·0.5C3H6O 3b·0.5CHCl3
Os1-X1 2.3785(6) 2.5243(3) 2.5530(8) 2.7115(9)
Os1-N1 2.072(2) 2.055(2) N/A N/A
Os1-N10 N/A N/A 2.073(5) 2.081(9)
Os1-N11 2.079(3) 2.089(2) N/A N/A
Os1-C17 N/A N/A 2.020(7) 2.038(10)
N10-N11 1.334(4) 1.336(3) 1.325(8) 1.304(13)
Os1-Arene
Centroid
1.705 1.705 1.723 1.725
Atom to atom
distance (Å)
1a 2a 2b·0.5C3H6O 3b·0.5CHCl3
H3···24 2.041 2.379 N/A N/A
H13···H22 2.144 2.238 N/A N/A
H16···24 N/A N/A 2.441 2.290
S1···S1 N/A N/A 3.229 3.252
Bond angle (°) 1a 2a 2b·0.5C3H6O 3b·0.5CHCl3
θX1-Os1-N1 84.55(7) 85.72(7) N/A N/A
θN1-Os1-N11 75.01(10) 74.66(9) N/A N/A
θN11-Os1-X1 85.56(7) 85.87(7) N/A N/A
θX1-Os1-N10 N/A N/A 84.86(16) 85.8(3)
θN10-Os1-C17 N/A N/A 75.8(2) 75.9(4)
θC17-Os1-X1 N/A N/A 86.2(2) 85.4(3)
Torsion angle (°) 1a 2a 2b·0.5C3H6O 3b·0.5CHCl3
θN1-C9-N10-N11 -1.63 0.66 N/A N/A
θN10-N11-C12-C17 -17.00 14.16 1.08 -5.57
θS8-C9-N10-N11 N/A N/A 0.42 0.03
Figure 3.7
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3.3.5. Aqueous solubility and stability
All complexes isolated in this chapter are too insoluble in water and cell culture
media for
stabilities of
period by UV
Figure 3.9.
complex 1a
Changes in the UV
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biological studies
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-Vis spectroscopy at 25 °C (Figure 3.9).
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the absorption peaks
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observed over 24 h
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Chapter 3
112
. (B) 50 μM 
, and a
.
Chapter 3
113
Repeating the experiment in the presence of 100 mM NaCl inhibited any
changes to the spectra over 24 h. In contrast, no decomposition of 1b was
observed over a 24 h period in MeOH:H2O (1:1, v/v). Two stable maxima were
observed at 447 and 562 nm.
3.3.6. Acid stability and regio-specific aniline ring deuteration of 2b
When complex 2b was stirred with 100 mol. equiv. HBr in MeOH, no conversion
to the N,N-coordinated species, 2a, was observed by 1H NMR. It was only after
heating under reflux for two days that a new set of small aliphatic p-cym proton
peaks started to emerge in the 1H NMR spectrum. TLC analysis in MeOH
revealed a small blue spot residing close to the base-line, likely indicating the
presence of a charged N,N-coordinated species. Further experiments showed
that carrying out reactions between [Os(η6-p-cym)Br2]2 and L in the presence of
HBr did not influence the ratio of products 2a and 2b, as observed by 1H NMR.
The ratio of 2a:2b formed remained unchanged even when the reaction was
carried out in the presence of 100 mol. equiv. HBr.
Complex 2b was combined with 3 mol. equiv. HBr in methanol-d4 and studied
by 1H NMR. The aromatic hydrogen which lies next to the Os-C bond (Ha, 7.58
ppm) disappears over time, showing almost complete disappearance after 15 h.
The disappearance of this peak in the 1H NMR spectrum also coincides with a
loss of long-range proton coupling to Hb (4J = 2.5 Hz, 7.26 ppm, see Figure
3.10).
Figure 3.10.
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showing the
, which
+,
25 °C, where a spectrum was collected every 30 min
disappearance of H
version 2.1
of the phenyl ring with a rate constant of
(Figure 3.12).
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Figure 3.12
2b at 25 °C.
3.3.7. Mulliken par
The Mulliken partial charge
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regio-specific deuteration occurs) is significantly more negatively charged than
the other carbon atoms making up the aniline ring. Furthermore, the aniline r
exhibits disrupted aromaticity with only two C=C bonds present; C1=C2 and
C4=C5, which have calculated bond lengths of 1.384 Å and 1.363 Å,
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structure, and
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Figure 3.13.
atoms.
3.4. Discussion
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deprotonation of the aniline ring at the ortho position. There are several
literature examples of ruthenium, rhodium, osmium and iridium metallocycles
formed via direct arylation of ligands such as 2-phenyl-substituated pyridines.13-
17 Metalation of the phenyl ring in these examples invariably occurs at the ortho
position and results in five-membered chelate rings. Older synthetic routes
utilise a trans-metalation pathway involving ortho-mercurated species,
eliminating the need for C-H activation.18-21 However, direct metalation of 2-
phenylpyridine (2-PhPy) is also possible in the presence of a suitable base such
as acetate and is controlled by the nitrogen-containing directing group
(pyridine), which initially binds to the metal centre. In the synthesis between
[Os(η6-p-cym)X2]2 (X = Cl, Br or I) and L, direction occurs via initial coordination
to the azo-bond nitrogen and C-H activation occurs spontaneously and
remarkably in the absence of an additional base. Cerón-Camacho et al, report
on the successful electrophilic cyclo-osmation of bidentate ligands; 2-PhPy and
N,N-dimethylbenzylamine.22 The latter of which was also achieved in the
absence of a base, and the ligand is believed to act as both a substrate and
base for its own C-H bond cleavage. Similarly to N,N-dimethylbenzylamine, L
possess a basic amine group which could be responsible for assisting C-H bond
cleavage at the ortho position of the aniline.
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Scheme 3.4. Two possible mechanisms for ortho C-H bond deprotonation. (A) SE3 mechanism.
(B) An alternative mechanism involving an agnostic ortho Os(C-H) bond.
The mechanism of C-H activation might be elucidated in more detail with
detailed computational and kinetic analyses, however a review of the literature
suggests a likely mechanism may involve base-assisted SE3 electrophilic cyclo-
metalation.23,24 Alternatively, a mechanism involving an agostic ortho Os(C-H)
bond cannot be ruled out either24,25 (Scheme 3.4). Both mechanisms require the
nucleophilic -NMe2 group on L playing a role as a proton acceptor during C-H
bond activation. Such mechanisms have been previously proposed for the
cyclo-metalation of 2-PhPy with ruthenium η6-arene complexes.
(B)
(A)
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3.4.2. Selectivity towards N,C-osmacycle formation over N,N-coordination
It was initially anticipated that ligand L may coordinate to the metal centre via
the S-atom of the benzothiazole group. However, to the best of our knowledge
there are no literature reports of benzothiazoles coordinating to metal centres
through the S-atom.26 The benzothiazole group of L favours N-binding in our
complexes as confirmed by X-ray crystal structures of complexes 1a and 2a.
N,C-coordination is the preferred geometry formed when X = Br or I, but for X =
Cl, N,N-coordination is preferred. From crystallographic observations, it is most
likely that the ratio of products formed is dependent on steric considerations.
Assessment of the crystal structures shows that N,N-coordinated species (1a
and 2a) exhibit more steric hindrance in the form of H···H clashes between p-
cym and L, than do N,C-coordinated species (2b and 3b). N,N-coordinated
species also show greater torsion angles in ligand L, than do N,C-coordinated
species where L is very much planar. The torsion of L in 1a and 2a appears to
show the aniline ring twisting to reduce clashing with the p-cym ligand. It is most
likely that when X = Br or I, N,N-coordination is more difficult due to the
increased halide size, hence producing greater steric crowding around the
metal centre, pushing the organic ligands closer together. Increased steric
crowding may entice coordination to occur via the cyclo-metalation route (Figure
3.14).
Figure 3.14.
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monodentate ligand is large.
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π*-orbitals. Both moieties, pyridine and benzothiazole, are weak
the reduced
preferential
Figure 3.15.
UV-Vis studies in aqueous media shows that the
undergoes a chemical change over a 24 h period, which is prevented in the
presence of NaCl (100 mM). This indicates that the chemical change involves
loss of the monodentate chloride ligand, and is likely a hydrolysis reaction. In
contrast,
h and exhibits a very stable Os
π-acceptor capability of benzothiazole may also ac
N,C-coordination, as well as steric factors.
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N,C-coordinated complex
FY026 and 3b
1b shows no sign of decompostion over 24
-Cl bond.
in their preferred coordination geometries.
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3.4.3. Hindered arene rotation of 5
The iodido complex, 5, was shown to possess a de-shielded aromatic hydrogen
belonging to the p-cym ligand. A 1H sel-NOE study confirmed that this proton is
pushed in close proximity to an aromatic proton belonging to L*. The steric
crowding is likely a result of N,N-coordination, which in this case is forced due
to blocking of the ortho positions on the aniline ring (preventing cyclo-
metalation). It was also found that the chlorido complex 4 exhibited the same
trend, with a de-shielded aromatic hydrogen on p-cym. N,N-coordinated
structures that were formed with ligand L (1a and 2a) do not exhibit the same
trend. It is therefore likely that hindered rotation may also play some role in the
de-shielding of the protons observed. The methyl groups at positions R1 and R2
in complexes 4 and 5 (Figure 3.3) may play a role in locking the p-cym ligand in
a fixed orientation, hence hindering its rotation. No X-ray crystal structure was
obtained for 4 or 5, and further temperature-controlled 1H NMR studies would
be required confirm the presence of hindered p-cym rotation.27
3.4.4. Regio-specific aniline ring deuteration of 2b
Remarkably, complex 2b undergoes deuteration of the aniline ring at the
position next to the Os-C bond (meta Ha), but only in the presence of acid (HBr).
On addition of 3 mol. equiv. of HBr the 1H NMR signal of Ha disappeared along
with its coupling to Hb, following first-order kinetics. The Mulliken partial charge
calculations showed that the same carbon where deuteration occurs carries a
greater negative partial charge (-0.461) than the other CH carbons making up
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the aniline ring (-0.264 and -0.275). This may account for the acidic nature of
Ha. Interestingly, its exchange with deuterium occurs under acidic conditions
suggesting an associative mechanism of exchange (see Scheme 3.5). To the
best of my knowledge, there are no literature examples of other complexes that
undergo 'self-deuteration' by aromatic hydrogen exchange under acidic
conditions. There are however examples of catalytic osmium complexes
capable of deuterating organic molecules that undergo temporary binding to the
osmium metal centre.28,29
Scheme 3.5. Proposed mechanism for the associative exchange of Ha with deuterium in
complex 2b under acidic conditions in methanol-d4.
3.5. Summary
This chapter has explored the novel synthesis of Os(II) p-cym
phenylazobenzothiazole complexes, which adopt two different coordination
geometries: N,N-coordination and N,C-coordination. Exploration of the
crystallographic data suggests that N,N-coordination geometry leads to steric
crowding around the metal centre, and so is formed as a minor product when
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the halide monodentate ligand is large (X = I or Br). N,C-coordination requires
C-H bond activation to form an osmacycle and occurs spontaneously in the
absence of a base, most likely owing to the presence of the basic -NMe2 group
assisting in aromatic deprotonation. The mechanism of cyclo-metalation is not
clear, but a SE3 mechanism is speculated. Furthermore, N,N-coordinated
species, 1a, was shown to be unstable in aqueous media over 24 h, but stable
over 24 h in the presence of 100 mM NaCl, indicating that the decomposition of
1a involves loss of the monodentate ligand and likely relates to hydrolysis. In
contrast, the N,C-coordinated analogue (2b) was stable over 24 h.
Complexes 4 and 5 were synthesised with intentional blocking of the C-H
activation sites with methyl groups to force formation of N,N-coordinated
geometries. This led to complexes with an unusually de-shielded aromatic p-
cym proton. Upon analysis by 1H sel-NOE the de-shielded proton in 5 was
found to be in close proximity to a proton on the benzothiazole group, thus
providing further evidence of steric crowding in N,N-coordinated species.
Unusual properties were also found for the N,C-coordinated complex, 2b. In the
presence of acid (HBr) in methanol-d4, the meta H (neighbouring the Os-C
bond) exchanges with deuterium and this was explored kinetically. Calculations
of the Mulliken partial charges showed that an increased negative partial charge
on the meta C may provide a reasonable explanation for this phenomenon.
The chemistry of novel complexes presented in this chapter has been explored
in some depth. Unfortunately, due to the complexes very poor solubility in
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aqueous media, it was not possible to progress with anti-cancer screening and
other biological evaluations.
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4.1. Introduction
The synthesis and chemistry of azobenzenes and pyridine-based azobenzenes
(see Figure 1.1) has been a matter of scientific interest for many years.
Traditionally, azobenzene was synthesised by an azo-coupling condensation
reaction between aniline and nitrosobenzene, which can be catalysed by acidic
or basic conditions.1-4 However, there are now multiple strategies for forming
azo-bonds between two aryl groups.5-7 Interestingly, azobenzenes and pyridine
based azobenzenes can be cleanly photo-isomerised from their trans to cis
configuration, and the reverse process can be induced either by visible light or
thermally. Such processes have proved useful in applications such as photo-
switchable ion-channel blockers, photo-control of the activity of enzymes,
switchable catalysts and liquid crystals.7,8
Figure 1.1. The structures of (A) azobenzene, (B) phenyazopyridine (AZPY), and (C)
azobispyridine (ABPY).
The first AZPY complexes of Ru(II) were synthesized in 1979 and were shown
to exhibit strong dπ-pπ interactions, which produced a stabilising effect towards  
Ru(II).9 The stabilising effects of AZPY ligands were later utilised by the Sadler
group in Ru(II) and Os(II) arene anti-cancer complexes (see Chapter 1,
(A) (B) (C)
Chapter 4
131
Sections 1.3.3.2 and 1.3.4.3) Interestingly, Os(II) arene complexes of ABPY10
and Ru(II) arene complexes of AZPY11 have unique redox properties. Using
cyclic voltammetry, two reduction potentials were observed that are attributed to
the reduction of the azo-bond.10 The azo-bond contains a low lying π*-orbital 
which can receive two electrons (see Scheme 4.1). This is described in greater
detail for Ru(II) arene AZPY complexes in Chapter 1, Section 1.3.3.2.
Scheme 4.1. Two successive one-electron reductions of the azo-bond.
Piano-stool Os(II) arene AZPY complexes with monodentate halide ligands
exhibit some of the most potent anti-proliferative activities of all osmium
complexes within the Sadler group. Their mechanism(s) of activation differ
greatly from earlier Os(II) arene complexes with σ-donor bidentate ligands, 
which rely primarily on monodentate ligand dissociation followed by DNA
binding.12 In contrast, the strong π-acceptor character of AZPYs produces 
different characteristics in their complexes, such as resistance towards
hydrolysis and mechanism(s) of action that involve raising intracellular levels of
ROS.13,14
1st reduction 2nd reduction
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The main aim of the work in this chapter was to synthesise new Os(II) arene
AZPY complexes, expand on our library of complexes, and improve on anti-
cancer activity and drug characteristics such as aqueous solubility, based on
the structure-activity relationships (SARs) that have already determined for
complexes of this class.15 Monodentate iodide ligands are known to improve
anti-cancer activity drastically over chloride ligands. Bip arene ligands enhance
activity over p-cym ligands, and substituents on the AZPY ligand positioned on
the pyridyl and phenyl moieties para to the azo-bond also maximise activity.
One of the key issues to resolve is poor drug solubility in aqueous media, which
is an inherent issue for Os(II) arene AZPY complexes. This could hinder the
administration of drugs to patients, hence their progress into clinical trials.
Tackling solubility issues needs to be overcome ideally without drastically
compromising anti-cancer activity. There are 3 main methods in which drug
solubility can be improved: (1) The addition of polar substituents on the AZPY
ligand. (2) Reducing crystal lattice energies of complexes by changing the
counter anion. (3) Disrupting molecular planarity/symmetry and crystal packing
by re-positioning substituents or changing substituents for bulkier groups. The
last approach has proved useful for increasing the solubility of small molecule
drugs, whilst maintaining their lipophilicity.16
Lipinski's 'rule of five' (Ro5) is a general rule of thumb, formulated by
Christopher A. Lipinski in 1997 to determine whether a drug candidate has
particular pharmacological properties that make it suitable for absorption,
distribution, metabolism and excretion within the human body.17 Ro5 predicts
that good absorption and permeation is more likely when the molecular
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structure has ≤5 H-bond donors, ≤10 H-bond acceptors, a molecular weight of 
≤500 g/mol, and a Log Po/w of ≤5. Ignoring counter-ions such as PF6, Os(II)
arene AZPY complexes comply with Ro5 specifications except for their high
molecular masses, which are typically higher than 500 g/mol due to the
presence of Os and I atoms. The reasons for lower drug absorption when the
molecular mass is ≥500 g/mol are not fully understood and it is purely 
observational. However, there are outliers such as vitamin B12 (1355.37 g/mol),
which like Os(II) arene AZPY drugs is also a metal complex.18 A variation to the
Ro5 states that the effective range of Log Po/w is -0.4 to 5.6 with an average
value of 2.52.19 Furthermore, an excessive number of H-bond donor or acceptor
groups can impair permeability across the cell membrane.
Herein, a novel synthesis is outlined for the attachment of alkoxy and water
solubilising glycolic side-chains to AZPY ligands. A new range of Os(II) arene
AZPY complexes were synthesized and the SARs were explored for anti-cancer
activity against A2780 cells, aqueous solubility in 100 mM NaCl(aq), HPLC
capacity factor, and cellular uptake. Furthermore, variation of the counter anion
was explored as a method of improving aqueous solubility, and the
monodentate ligand was varied with alternatives (Br-, N3- and SCN-) to
determine if anticancer activity can be improved upon. Figure 4.2 lists all of the
Os(II) arene AZPY complexes synthesised (6-35). Selected complexes were
further tested against other cell lines (MCF-7, SUNE1, OE19 and MRC-5), and
their ability to induce apoptosis, ROS elevation, and cell cycle arrest in A2780
cells was explored.
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Complex X R1 R2 Ar Y
AZPY
ligand
Max solubility
in 100 mMNaCl
(µM)
IC50 against
A2780 cells
(µM)
Capacity
factor (K)
Cell uptake in
A2780 cells
(ng Os /106)
6 I MeO H p-cym PF6- L1 9±2 n.d. n.d. n.d.
7 I MeO H p-cym CF3SO3- L1 405±19 0.5±0.1 2.61±0.09 8±2
8 Cl EtO H p-cym PF6- L2 118±7 15.1±0.5 1.94±0.06 11.0±0.8
9 Br EtO H p-cym PF6- L2 124±8 14.1±0.9 2.61±0.09 19±1
10 I EtO H p-cym PF6- L2 52±2 0.92±0.02 3.81±0.09 31±2
11 I EtO H p-cym CF3SO3- L2 185±9 0.9±0.2 4.0±0.1 30±2
12 I EtO H p-cym IO3- L2 341±3 1.6±0.3 n.d. n.d.
13 I EtO H bip CF3SO3- L2 26±2 0.51±0.02 3.7±0.1 21±1
14 I nPrO H p-cym PF6- L3 14.9±0.7 0.33±0.02 6.0±0.1 10±2
15 I iPrO H p-cym PF6- L4 75±2 0.30±0.09 5.4±0.1 n.d.
16 I nBuO H p-cym PF6- L5 1.7±0.3 10.2±0.7 9.4±0.2 n.d.
OsX
N N
N
R1
Ar YR2
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*Highlited green: Complexes with sub micro-molar IC50 values against A2780 cells.
Figure 4.2. List of all the Os(II) arene AZPY complexes synthesised, 6-35, using L1-L15, and their properties.
17 Cl HOCH2CH2O H p-cym PF6- L6 1686±63 >140 0.57±0.03 3.93±0.09
18 Br HOCH2CH2O H p-cym PF6- L6 640±4 >130 0.74±0.03 3.00±0.08
19 I HOCH2CH2O H p-cym PF6- L6 412±19 20.7±0.1 1.04±0.03 12±2
20 I HOCH2CH2O H bip PF6- L6 93±2 2.37±0.09 0.99±0.07 n.d.
21 I H(OCH2CH2)2O H p-cym PF6- L7 721±17 2.04±0.06 1.09±0.02 n.d.
22 I Me(OCH2CH2)2O H p-cym PF6- L10 239±5 1.80±0.09 2.63±0.03 n.d.
23 I Et(OCH2CH2)2O H p-cym PF6- L12 132±6 0.68±0.03 0.74±0.03 n.d.
24 I Et(OCH2CH2)2O H bip CF3SO3- L12 61±3 1.9±0.2 3.53±0.06 n.d.
25 I H(OCH2CH2)3O H p-cym PF6- L8 680±13 12±1 1.11±0.02 n.d.
26 I Me(OCH2CH2)3O H p-cym PF6- L11 359±31 2.1±0.2 2.52±0.04 n.d.
27 I Et(OCH2CH2)3O H p-cym PF6- L13 232±8 2.6±0.4 3.59±0.06 n.d.
28 I H(OCH2CH2)4O H p-cym PF6- L9 656±26 7.6±0.6 1.11±0.02 n.d.
29 Cl Br OH p-cym PF6- L14 n.d. 2.0±0.2 n.d. n.d.
30 Br Br OH p-cym PF6- L14 n.d. 1.2±0.1 n.d. n.d.
31 I Br OH p-cym PF6- L14 n.d. 0.54±0.02 n.d. n.d.
32 Cl F3C OH p-cym PF6- L15 n.d. 1.4±0.1 n.d. n.d.
33 Br F3C OH p-cym PF6- L15 n.d. 0.74±0.08 n.d. n.d.
34A S-SCN EtO H p-cym PF6- L2 n.d. >50 n.d. n.d.
34B N-SCN EtO H p-cym PF6- L2 n.d. 25-50 n.d. n.d.
35 N3 EtO H p-cym PF6- L2 n.d. 1.2±0.2 n.d. n.d.
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4.2. Experimental
4.2.1. Materials
Osmium dimers, [Os(η6-arene)X2]2, (where X= Cl, Br or I and arene = p-cym or
bip) were prepared as described in Chapter 2, Section 2.1.2. 2-Amino-5-
fluoropyridine, nitrosobenzene, 5-bromo-2-hydrazinopyridine, 2-hydrazinyl-5-
trifluoromethylpyridine, p-benzoquinone, benzene, and 70% perchloric acid
were purchased from Sigma Aldrich, and sodium hydroxide from Fisher
Scientific. The alcohols and glycols used to synthesise RO-AZPY ligands were
purchased from Sigma Aldrich, with the exception of ethylene glycol and
diethylene glycol, which were obtained from Alfa Aesar. Deionised water was
prepared as described in Chapter 2, Section 2.1.1.1. Deuterated NMR solvents
were purchased from Cambridge Isotope Laboratories Inc. and Sigma Aldrich.
Phosphate buffer solution was prepared as described in Chapter 2, Section
2.1.1.1.
4.2.2. Synthesis
2-(Phenylazo)-5-fluoropyridine (5-F-AZPY).15 2-Amino-5-fluoropyridine (1.00
g, 8.92 mmol) was stirred in a 1:4 mixture of benzene (5 mL) and water (20 mL).
Sodium hydroxide (4.28 g, 0.11 mol) was added and the mixture was left to stir
for 10 min at 50 ºC under N2. Nitrosobenzene (0.96 g, 8.96 mmol) was added to
the stirring mixture and an instant colour change to green was observed. The
mixture was heated at 100 ºC overnight under N2, and turned dark red-brown.
The layers were separated and the aqueous layer was washed with toluene (3 x
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50 mL). The combined organic extracts were washed with water (3 x 30 mL),
dried over MgSO4, and filtered. The solvent was removed under reduced
pressure to yield an oily red precipitate. The precipitate was then dissolved in a
minimum amount of DCM and purified via flash column chromatography (SiO2,
DCM, Rf = 0.52). The selected fractions were combined and the solvent was
removed under reduced pressure to yield an orange precipitate. The product
was dried overnight in a vacuum desiccator. Yield: 469.1 mg, (26%). 1H NMR
(400 MHz, CDCl3): δ 8.52 (d, 1H, J = 2.9 Hz), 7.98-7.96 (m, 2H), 7.83 (dd, 1H, J 
= 8.8, 4.3 Hz), 7.55-7.54 (m, 1H), 7.49-7.46 (m, 3H). ESI-MS calculated for
C11H8N3F + H+: m/z 202.1. Found: 202.1. CHN analysis: Found: C, 65.39%; H,
3.90%; N, 20.71%. Calculated for C11H8N3F: C, 65.66%; H, 4.01%; N, 20.88%.
4.2.2.1. General procedure for synthesis of RO-AZPY ligands
N
N
N
O
R
2-(Phenylazo)-5-fluoropyridine (100.00 mg, 0.50 mmol) was dissolved in ROH
(20 mL) and an aqueous potassium hydroxide solution (5 mol. equiv.) was
added. The mixture was either heated to reflux or heated at 120 °C (depending
on b.p. of ROH) for 18 h. The product was extracted with DCM (20 mL) and
washed with water (3 x 20 mL). The DCM extract was dried over MgSO4,
filtered, and the solvent was removed under reduced pressure. Some reaction
mixtures required vacuum distillation to remove excess ROH. Purification was
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usually carried out by either re-crystallisation or SiO2 column chromatography.
The product was dried overnight on a vacuum line.
5-MeO-AZPY (L1). (ROH = methanol). The crude product was purified via flash
column chromatography (SiO2, Et2O, Rf = 0.40). The selected fractions were
combined and the solvent was removed under reduced pressure to give a pale
orange precipitate. Yield: 62.1 mg, (59%). 1H NMR (400 MHz, CDCl3): δ 8.33 (d, 
1H, J = 3.0 Hz), 7.96-7.93 (m, 2H), 7.81 (d, 1H, J = 8.8 Hz), 7.47-7.40 (m, 3H),
7.30 (dd, 1H, J = 8.8, 3.0 Hz), 3.88 (s, 3H). ESI-MS calculated for C12H11N3O +
H+: m/z 214.1. Found: 214.0. CHN analysis: Found: C, 67.01%; H, 5.19%; N,
19.31%. Calculated for C12H11N3O: C, 67.59%; H, 5.20%; N, 19.71%.
5-EtO-AZPY (L2). (ROH = ethanol). The crude product was re-crystallised from
a minimum amount of hot Et2O. Orange crystals were collected via vacuum
filtration and washed with ice-cold Et2O. Yield: 78.1 mg, (69%). 1H NMR (400
MHz, CDCl3): δ 8.31 (d, 1H, J = 3.0 Hz), 7.95-7.92 (m, 2H), 7.79 (d, 1H, J = 8.8 
Hz), 7.47-7.39 (m, 3H), 7.27 (dd, 1H, J = 8.8, 3.0 Hz), 4.10 (q, 2H, J = 7.0 Hz),
1.40 (t, 3H, J = 7.0 Hz). ESI-MS calculated for C13H13N3O + H+: m/z 228.1.
Found: 228.0. CHN analysis: Found: C, 68.47%; H, 5.72%; N, 18.39%.
Calculated for C13H13N3O: C, 68.70%; H, 5.77%; N, 18.49%.
5-nPrO-AZPY (L3). (ROH = n-propanol). The crude product was purified via
flash column chromatography (SiO2, Et2O:n-hexane 1:1, Rf = 0.30). The
selected fractions were combined and the solvents were removed under
reduced pressure to give an orange precipitate. Yield: 102.1 mg, (85%). 1H
NMR (400 MHz, CDCl3): δ 8.30 (d, 1H, J = 3.0 Hz), 7.94-7.91 (m, 2H), 7.76 (d, 
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1H, J = 8.8 Hz), 7.44-7.38 (m, 3H), 7.24 (dd, 1H, J = 8.8, 3.0 Hz), 3.95 (t, 2H, J
= 6.5 Hz), 1.81-1.72 (m, 2H), 0.97 (t, 3H, J = 7.4 Hz). ESI-MS calculated for
C14H15N3O + H+: m/z 242.1. Found: 242.1. CHN analysis: Found: C, 69.50%; H,
6.24%; N, 17.25%. Calculated for C14H15N3O: C, 69.69%; H, 6.27%; N, 17.41%.
5-iPrO-AZPY (L4). (ROH = isopropanol). The crude product was purified via
flash column chromatography (SiO2, Et2O:n-hexane 1:1, Rf = 0.29). The
selected fractions were combined and the solvents were removed under
reduced pressure to give an orange viscous oil. Yield: 42.6 mg, (35%). 1H NMR
(400 MHz, CDCl3): δ 8.30 (d, 1H, J = 3.0 Hz), 7.96-7.93 (m, 2H), 7.79 (d, 1H, J 
= 8.8 Hz), 7.47-7.40 (m, 3H), 7.27 (dd, 1H, J = 8.8, 3.0 Hz), 4.63 (sept., 1H, J =
6.1 Hz), 1.35 (d, 6H, J = 6.1 Hz). ESI-MS calculated for C14H15N3O + H+: m/z
242.1. Found: 242.1.
5-nBuO-AZPY (L5). (ROH = n-butanol). Excess ROH was removed by vacuum
distillation. The crude product was dissolved in Et2O and filtered. The filtrate
was collected and the solvent removed under reduced pressure, resulting in an
orange precipitate. Yield: 102.4 mg, (81%). 1H NMR (400 MHz, CDCl3): δ 8.29 
(d, 1H, J = 2.9 Hz), 7.94-7.91 (m, 2H), 7.76 (d, 1H, J = 8.8 Hz), 7.45-7.37 (m,
3H), 7.23 (dd, 1H, J = 8.8, 3.0 Hz), 3.97 (t, 2H, J = 6.5 Hz), 1.71-1.70 (m, 2H),
1.41-1.40 (m, 2H), 0.89 (t, 3H, J = 7.4 Hz). ESI-MS calculated for C15H17N3O +
H+: m/z 256.1. Found: 256.1.
5-HOCH2CH2O-AZPY (L6). (ROH = ethylene glycol). The crude product was
dissolved in a minimum amount of hot DCM and the product was re-crystallised
upon adding Et2O. An orange precipitate was collected via vacuum filtration and
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washed with ice-cold Et2O. Yield: 64.7 mg, (54%). 1H NMR (400 MHz, CDCl3): δ 
8.45 (d, 1H, J = 2.9 Hz), 8.04-8.01 (m, 2H), 7.89 (d, 1H, J = 8.8 Hz), 7.55-7.48
(m, 3H), 7.43 (dd, 1H, J = 8.8, 3.0 Hz), 4.26-4.24 (m, 2H), 4.06-4.04 (m, 2H).
ESI-MS calculated for C13H13N3O2 +Na+: m/z 266.1. Found: 266.0. CHN
analysis: Found: C, 63.95%; H, 5.35%; N, 17.03%. Calculated for C13H13N3O2:
C, 64.19%; H, 5.39%; N, 17.27%.
5-HO(CH2CH2O)2-AZPY (L7). (ROH = diethylene glycol). The crude product
was re-crystallised from a minimum amount of hot DCM. An orange precipitate
was collected via vacuum filtration and washed with ice-cold Et2O. Yield: 51.3
mg, (36%). 1H NMR (400 MHz, CDCl3): δ 8.46 (d, 1H, J = 2.9 Hz), 8.04-8.01 (m, 
2H), 7.89 (d, 1H, J = 8.8 Hz), 7.55-7.48 (m, 3H), 7.43 (dd, 1H, J = 8.8, 3.0 Hz),
4.32-4.30 (m, 2H), 3.95-3.93 (m, 2H), 3.81-3.79 (m, 2H), 3.71-3.69 (m, 2H).
ESI-MS calculated for C15H17N3O3 + H+: m/z 288.1. Found: 288.1.
5-HO(CH2CH2O)3-AZPY (L8). (ROH = triethylene glycol). The crude product
was dissolved in Et2O and filtered. The filtrate was collected and the solvent
removed under reduced pressure, resulting in an orange viscous oil. Yield:
132.9 mg, (81%). 1H NMR (400 MHz, CDCl3): δ 8.32 (d, 1H, J = 2.9 Hz), 7.92-
7.88 (m, 2H), 7.74 (d, 1H, J = 8.8 Hz), 7.43-7.36 (m, 3H), 7.29 (dd, 1H, J = 8.8,
3.0 Hz), 4.16-4.14 (m, 2H), 3.79-3.77 (m, 2H), 3.65-3.61 (m, 4H), 3.58-3.56 (m,
2H), 3.51-3.49 (m, 2H). ESI-MS calculated for C17H21N3O4 + H+: m/z 332.2.
Found: 332.1.
5-HO(CH2CH2O)4-AZPY (L9). (ROH = tetraethylene glycol). The crude product
was dissolved in Et2O and filtered. The filtrate was collected and the solvent
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removed under reduced pressure, resulting in an orange viscous oil. Yield:
151.3 mg, (81%). 1H NMR (400 MHz, CDCl3): δ 8.35 (d, 1H, J = 3.0 Hz), 7.95-
7.92 (m, 2H), 7.79 (d, 1H, J = 8.8 Hz), 7.44-7.39 (m, 3H), 7.33 (dd, 1H, J = 8.8,
3.0 Hz), 4.22-4.20 (m, 2H), 3.84-3.82 (m, 2H), 3.68-3.58 (m, 11H), 3.53-3.51
(m, 2H). ESI-MS calculated for C19H25N3O5 + Na+: m/z 398.2. Found: 398.2.
5-MeO(CH2CH2O)2-AZPY (L10). (ROH = diethylene glycol monomethyl ether).
The crude product was dissolved in MeOH and decanted, removing a white oily
substance. Excess ROH was removed by vacuum distillation and the product
was dried, resulting in an orange viscous oil. Yield: 148.0 mg, (99%). 1H NMR
(400 MHz, CDCl3): δ 8.41 (d, 1H, J = 3.0 Hz), 8.01-7.98 (m, 2H), 7.85 (d, 1H, J 
= 8.8 Hz), 7.52-7.46 (m, 3H), 7.38 (dd, 1H, J = 8.8, 3.0 Hz), 4.28-4.25 (m, 2H),
3.90-3.88 (m, 2H), 3.72-3.70 (m, 2H), 3.57-3.55 (m, 2H), 3.37 (s, 3H). ESI-MS
calculated for C16H19N3O3 + Na+: m/z 324.1. Found: 324.1.
5-MeO(CH2CH2O)3-AZPY (L11). (ROH = triethylene glycol monomethyl ether).
Excess ROH was removed by vacuum distillation. The crude product was
dissolved in Et2O and filtered. The filtrate was collected and the solvent
removed under reduced pressure, resulting in an orange viscous oil. Yield:
154.0 mg, (90%). 1H NMR (400 MHz, CDCl3): δ 8.38 (d, 1H, J = 2.9 Hz), 7.98-
7.96 (m, 2H), 7.82 (d, 1H, J = 8.8 Hz), 7.50-7.44 (m, 3H), 7.35 (dd, 1H, J = 8.8,
2.9 Hz), 4.23-4.21 (m, 2H), 3.87-3.85 (m, 2H), 3.71-3.69 (m, 2H), 3.65-3.60 (m,
4H), 3.51-3.49 (m, 2H), 3.33 (s, 3H). ESI-MS calculated for C18H23N3O4 + H+:
m/z 368.1. Found: 368.1.
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5-EtO(CH2CH2O)2-AZPY (L12). (ROH = diethylene glycol monoethyl ether).
Excess ROH was removed by vacuum distillation. The crude product was
dissolved in Et2O and filtered. The filtrate was collected and the solvent
removed under reduced pressure, resulting in an orange viscous oil. Yield:
135.1 mg, (86%). 1H NMR (400 MHz, CDCl3): δ 8.33 (d, 1H, J = 3.0 Hz), 7.93-
7.90 (m, 2H), 7.76 (d, 1H, J = 8.8 Hz), 7.44-7.36 (m, 3H), 7.29 (dd, 1H, J = 8.8,
3.0 Hz), 4.18-4.16 (m, 2H), 3.82-3.80 (m, 2H), 3.64-3.62 (m, 2H), 3.53-3.51 (m,
2H), 3.43 (q, 2H, J = 7.0 Hz), 1.12 (t, 3H, J = 7.0 Hz). ESI-MS calculated for
C17H22N3O3 + H+: m/z 316.2. Found: 316.1.
5-EtO(CH2CH2O)3-AZPY (L13). (ROH = triethylene glycol monoethyl ether).
Excess ROH was removed by vacuum distillation. The crude product was
dissolved in Et2O and filtered. The filtrate was collected and the solvent
removed under reduced pressure, resulting in an orange viscous oil. Yield:
170.8 mg, (96%). 1H NMR (400 MHz, CDCl3): δ 8.33 (d, 1H, J = 2.9 Hz), 7.94-
7.91 (m, 2H), 7.77 (d, 1H, J = Hz), 7.46-7.39 (m, 3H), 7.30 (dd, 1H, J = 8.8, 2.9
Hz), 4.18-4.15 (m, 2H), 3.82-3.79 (m, 2H), 3.67-3.48 (m, 6H), 3.42 (q, 2H, J =
7.0 Hz), 1.11 (t, 3H, J = 7.0 Hz). ESI-MS calculated for C19H25N3O4 + H+: m/z
382.2. Found: 382.1.
5-bromo-2-(4-hydroxyphenylazo)pyridine (Br-AZPY-OH) (L14). p-
Benzoquinone (316.0 mg, 2.93 mmol) was dissolved in deionised water (50 mL)
and perchloric acid (70% v/v, 2.6 mL) was added. A solution of 5-bromo-2-
hydrazinopyridine (500.0 mg, 2.66 mmol) in MeOH (10 mL) was added drop-
wise to the stirring mixture. The mixture turned red-brown and was stirred for 18
h at ambient temperature. The pH was neutralised with the drop-wise addition
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of aqueous sodium hydroxide (6 M). The product was extracted with ethyl
acetate (3 x 50 mL) and washed with water (3 x 50 mL). The mixture was
concentrated under reduced pressure and placed in the freezer overnight. The
resulting brown precipitate was collected via vacuum filtration and washed with
ice-cold EtOH (2 x 1 mL) and Et2O (2 x 5 mL). Yield: 495.5 mg (67%). 1H NMR
(400 MHz, CD3OD): δ 8.73 (d, 1H, J = 2.4 Hz), 8.19 (dd, 1H, J = 8.6, 2.4 Hz), 
7.93-7.92 (m, 2H), 7.76 (d, 1H, J = 8.6 Hz), 6.96-6.94 (m, 2H). ESI-MS
calculated for C11H8BrN3O + H+: m/z 278.0. Found: 277.9. CHN analysis:
Found: C, 47.28%; H, 2.80%; N, 14.82%. Calculated for C11H8BrN3O: C,
47.51%; H, 2.90%; N, 15.11%.
5-trifluoromethyl-2-(4-hydroxyphenylazo)pyridine (F3C-AZPY-OH) (L15). p-
Benzoquinone (343.0 mg, 3.2 mmol) was dissolved in deionised water (50 mL)
and perchloric acid (70% v/v, 2.6 mL) was added. A solution of 2-hydrazinyl-5-
trifluoromethylpyridine (511.3 mg, 22.9 mmol) in MeOH (10 mL) was added
drop-wise to the stirring mixture. The mixture turned dark red and was stirred for
18 h at ambient temperature. The pH was neutralised with the drop-wise
addition of aqueous sodium hydroxide (6 M). The product was extracted with
ethyl acetate (3 x 50 mL) and washed with water (3 x 50 mL). The mixture was
concentrated under reduced pressure and placed in the freezer overnight. The
resulting brown precipitate was collected via vacuum filtration and washed with
ice-cold EtOH (2 x 1 mL) and Et2O (2 x 5 mL). Yield: 266.2 mg (34%). 1H NMR
(400 MHz, CD3OD): δ 8.97-8.96 (m, 1H), 8.33 (dd, 1H, J = 8.6, 2.3 Hz), 7.99-
7.94 (m, 3H), 6.98-6.96 (m, 2H). ESI-MS calculated for C12H8F3N3O + Na+: m/z
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290.1. Found: 290.0. CHN analysis: Found: C, 53.14%; H, 2.88%; N, 15.19%.
Calculated for C12H8F3N3O: C, 53.94%; H, 3.02%; N, 15.73%.
4.2.2.2. General procedure for synthesis of Os(II) arene AZPY complexes
[Os(η6-arene)X2]2 (where X = Cl, Br or I, and arene = p-cym or bip) was
dissolved in EtOH (10 mL), and a solution of the AZPY ligand (2.1 mol. equiv.)
in EtOH (5 mL) was added drop-wise. The mixture was stirred for 18 h at
ambient temperature, then filtered through glass microfibre to remove a black
precipitate and NH4PF6, NH4CF3SO3 or KIO3 (10 mol. equiv.) were added.
Complexes were isolated using either method 1 or 2. Method 1 involves
obtaining the product via re-crystallisation. Some complexes were difficult to re-
crystallise and hence method 2 was employed.
Method 1. The mixture was concentrated under reduced pressure to ~3 mL and
placed in the freezer overnight. A dark crystalline precipitate formed, which was
collected via vacuum filtration, and washed with ice-cold EtOH (2 x 1 mL) and
Et2O (2 x 5 mL), and dried overnight in a vacuum desiccator.
Method 2. The mixture was concentrated under reduced pressure to ~3 mL, a
small amount of n-hexane was added (~1 mL), and the mixture was placed in
the freezer overnight forming a dark residue. The solvents were decanted out
and the resulting residue was washed with Et2O (3 x 5 mL). The brown residue
was dissolved in DCM (3 mL) and transferred into a pre-weighed vial, and dried
overnight on a vacuum line.
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[Os(η6-p-cym)(5-MeO-AZPY)I]PF6 (6). [Os(η6-p-cym)I2]2 (50.0 mg, 43.2 µmol),
5-MeO-AZPY (19.4 mg, 90.8 µmol), NH4PF6 (70.5 mg, 0.43 mmol), and
Isolation method 1. Yield: 54.6 mg (78%). 1H NMR (400 MHz, (CD3)2CO): δ 
9.23 (d, 1H, J = 2.7 Hz), 8.95 (d, 1H, J = 9.1 Hz), 8.13-8.10 (m, 2H), 8.08 (dd,
1H, J = 9.1, 2.7 Hz), 7.78-7.74 (m, 1H), 7.72-7.67 (m, 2H), 6.73-6.72 (m, 1H),
6.41-6.40 (m, 1H), 6.29-6.28 (m, 1H), 6.21-6.20 (m, 1H), 4.23 (s, 3H), 2.76 (s,
3H), 2.59 (sept., 1H, J = 6.9 Hz), 0.98 (d, 3H, J = 6.9 Hz), 0.97 (d, 3H, J = 6.9
Hz). ESI-MS calculated for C22H25IN3OOs+: m/z 666.1. Found: 666.1. CHN
analysis: Found: C, 32.15%; H, 3.12%; N, 5.22%. Calculated for
C22H25F6IN3OOsP: C, 32.64%; H, 3.11%; N, 5.19%.
[Os(η6-p-cym)(5-MeO-AZPY)I]CF3SO3 (7). [Os(η6-p-cym)I2]2 (50.0 mg, 43.2
µmol), 5-MeO-AZPY (19.4 mg, 90.8 µmol), NH4CF3SO3 (72.3 mg, 0.43 mmol),
and Isolation method 1. Yield: 57.1 mg (81%). 1H NMR (400 MHz, CD3OD): δ 
9.09 (d, 1H, J = 2.7 Hz), 8.86 (d, 1H, J = 9.1 Hz), 8.03-8.02 (m, 2H), 7.97 (dd,
1H, J = 9.1, 2.7 Hz), 7.74-7.70 (m, 1H), 7.67-7.64 (m, 2H), 6.49-6.48 (m, 1H),
6.18-6.17 (m, 1H), 6.05-6.04 (m, 1H), 5.98-5.97 (m, 1H), 4.18 (s, 3H), 2.71 (s,
3H), 2.46 (sept., 1H, J = 6.9 Hz), 0.93 (d, 3H, J = 6.9 Hz), 0.92 (d, 3H, J = 6.9
Hz). ESI-MS calculated for C22H25IN3OOs+: m/z 666.1. Found: 665.9. CHN
analysis: Found: C, 33.24%; H, 3.09%; N, 5.27%. Calculated for
C23H25F3IN3O4OsS: C, 33.95%; H, 3.10%; N, 5.16%.
[Os(η6-p-cym)(5-EtO-AZPY)Cl]PF6 (8). [Os(η6-p-cym)Cl2]2 (50.0 mg, 63.2
µmol), 5-EtO-AZPY (30.2 mg, 132.8 µmol), NH4PF6 (103.0 mg, 0.63 mmol), and
Isolation method 1. Yield: 81.4 mg (88%). 1H NMR (400 MHz, (CD3)2CO): δ 
9.91 (d, 1H, J = 2.7 Hz), 8.90 (d, 1H, J = 9.1 Hz), 8.10-8.06 (m, 3H), 7.77-7.70
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(m, 3H), 6.76-6.75 (m, 1H), 6.39-6.38 (m, 1H), 6.22-6.21 (m, 2H), 4.59-4.47 (m,
2H), 2.47 (sept., 1H, J = 6.9 Hz), 2.43 (s, 3H), 1.53 (t, 3H, J = 7.0 Hz), 0.95 (d,
3H, J = 7.0 Hz), 0.92 (d, 3H, J = 7.0 Hz). ESI-MS calculated for
C23H27ClN3OOs+: m/z 588.2. Found: 588.0. CHN analysis: Found: C, 37.43%;
H, 3.55%; N, 5.69%. Calculated for C23H27ClF6N3OOsP: C, 37.73%; H, 3.72%;
N, 5.74%.
[Os(η6-p-cym)(5-EtO-AZPY)Br]PF6 (9). [Os(η6-p-cym)Br2]2 (50.0 mg, 51.6
µmol), 5-EtO-AZPY (24.6 mg, 108.4 µmol), NH4PF6 (84.2 mg, 0.52 mmol), and
Isolation method 1. Yield: 61.8 mg (77%). 1H NMR (400 MHz, (CD3)2CO): δ 
9.20 (d, 1H, J = 2.7 Hz), 8.91 (d, 1H, J = 9.1 Hz), 8.10-8.06 (m, 3H), 7.76-7.70
(m, 3H), 6.75-6.74 (m, 1H), 6.41-6.40 (m, 1H), 6.25-6.21 (m, 2H), 4.59-4.47 (m,
2H), 2.56 (s, 3H), 2.51 (sept., 1H, J = 6.9 Hz), 1.53 (t, 3H, J = 7.0 Hz), 0.97 (d,
3H, J = 7.0 Hz), 0.94 (d, 3H, J = 7.0 Hz). ESI-MS calculated for
C23H27BrN3OOs+: m/z 632.1. Found: 631.9. CHN analysis: Found: C, 35.25%;
H, 3.32%; N, 5.34%. Calculated for C23H27BrF6N3OOsP: C, 35.57%; H, 3.50%;
N, 5.41%.
[Os(η6-p-cym)(5-EtO-AZPY)I]PF6 (10). [Os(η6-p-cym)I2]2 (100.0 mg, 86.5
µmol), 5-EtO-AZPY (41.3 mg, 181.6 µmol), NH4PF6 (140.9 mg, 0.86 mmol), and
isolation method 1. Yield: 119.6 mg (84%). 1H NMR (400 MHz, CD3OD): δ 9.07 
(d, 1H, J = 2.6 Hz), 8.84 (d, 1H, J = 9.1 Hz), 8.04-8.01 (m, 2H), 7.94 (dd, 1H, J =
9.1, 2.6 Hz), 7.73-7.63 (m, 3H), 6.47-6.46 (m, 1H), 6.16-6.15 (m, 1H), 6.03-6.02
(m, 1H), 5.96-5.95 (m, 1H), 4.50-4.38 (m, 2H), 2.70 (s, 3H), 2.45 (sept., 1H, J =
6.9 Hz), 1.55 (t, 3H, J = 7.0 Hz), 0.94-0.92 (2x d, 6H, J = 6.9 Hz). ESI-MS
calculated for C23H27IN3OOs+: m/z 680.1. Found: 679.9. CHN analysis: Found:
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C, 33.30%; H, 3.26%; N, 4.98%. Calculated for C23H27F6IN3OOsP: C, 33.54%;
H, 3.30%; N, 5.10%.
[Os(η6-p-cym)(5-EtO-AZPY)I]CF3SO3 (11). [Os(η6-p-cym)I2]2 (50.0 mg, 43.2
µmol), 5-EtO-AZPY (20.6 mg, 90.8 µmol), NH4CF3SO3 (72.3 mg, 0.43 mmol),
and isolation method 1. Yield: 66.8 mg (93%). 1H NMR (400 MHz, CD3OD): δ 
9.07 (d, 1H, J = 2.6 Hz), 8.84 (d, 1H, J = 9.1 Hz), 8.05-8.01 (m, 2H), 7.94 (dd,
1H, J = 9.1, 2.6 Hz), 7.74-7.69 (m, 1H), 7.68-7.63 (m, 2H), 6.47-6.46 (m, 1H),
6.17-6.16 (m, 1H), 6.03-6.02 (m, 1H), 5.96-5.95 (m, 1H), 4.51-4.38 (m, 2H),
2.71 (s, 3H), 2.45 (sept., 1H, J = 6.9 Hz), 1.55 (t, 3H, J = 7.0 Hz), 0.94-0.92 (2x
d, 6H, J = 6.9 Hz). ESI-MS calculated for C23H27IN3OOs+: m/z 680.1. Found:
680.0. CHN analysis: Found: C, 34.74%; H, 3.26%; N, 5.01%. Calculated for
C24H27F3IN3O4OsS: C, 34.83%; H, 3.29%; N, 5.08%.
[Os(η6-p-cym)(5-EtO-AZPY)I]IO3 (12). [Os(η6-p-cym)I2]2 (50.0 mg, 43.2 µmol),
5-EtO-AZPY (20.6 mg, 90.8 µmol), KIO3 (92.5 mg, 0.43 mmol), and isolation
method 1. Yield: 39.2 mg (53%). 1H NMR (400 MHz, CD3OD): δ 9.07 (d, 1H, J = 
2.6 Hz), 8.84 (d, 1H, J = 9.1 Hz), 8.04-8.02 (m, 2H), 7.94 (dd, 1H, J = 9.1, 2.6
Hz), 7.72-7.71 (m, 1H), 7.65-7.64 (m, 2H), 6.48-6.47 (m, 1H), 6.17-6.16 (m, 1H),
6.04-6.03 (m, 1H), 5.96-5.95 (m, 1H), 4.51-4.38 (m, 2H), 2.71 (s, 3H), 2.46
(sept., 1H, J = 6.9 Hz), 1.55 (t, 3H, J = 7.0 Hz), 0.94 (d, 6H, J = 6.9 Hz), 0.93 (d,
6H, J = 6.9 Hz). ESI-MS calculated for C23H27IN3OOs+: m/z 680.1. Found:
680.0. CHN analysis: Found: C, 33.40%; H, 3.33%; N, 4.98%. Calculated for
C23H27I2N3O4Os + C2H6O: C, 33.38%; H, 3.70%; N, 4.67%.
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[Os(η6-bip)(5-EtO-AZPY)I]CF3SO3 (13). [Os(η6-bip)I2]2 (50.0 mg, 41.8 µmol), 5-
EtO-AZPY (19.9 mg, 87.8 µmol), NH4CF3SO3 (69.8 mg, 0.42 mmol), and
isolation method 1. Yield: 59.2 mg (84%). 1H NMR (400 MHz, CD3OD): δ 8.77 
(d, 1H, J = 9.1 Hz), 8.61 (d, 1H, J = 2.6 Hz), 7.89-7.87 (m, 2H), 7.83 (dd, 1H, J =
9.1, 2.6 Hz), 7.63-7.62 (m, 1H), 7.53-7.48 (m, 3H), 7.42-7.36 (m, 4H), 6.92-6.91
(m, 1H), 6.71-6.70 (m, 1H), 6.56-6.55 (m, 1H), 6.42-6.35 (m, 2H), 4.21-4.07 (m,
2H), 1.44 (t, 3H, J = 7.0 Hz). ESI-MS calculated for C25H23IN3OOs+: m/z 700.1.
Found: 700.0. CHN analysis: Found: C, 36.85%; H, 2.84%; N, 4.84%.
Calculated for C26H23F3IN3O4OsS: C, 36.84%; H, 2.74%; N, 4.96%.
[Os(η6-p-cym)(5-nPrO-AZPY)I]PF6 (14). [Os(η6-p-cym)I2]2 (50.0 mg, 43.2
µmol), 5-nPrO-AZPY (21.9 mg, 90.8 µmol), NH4PF6 (70.5 mg, 0.43 mmol), and
isolation method 2. Yield: 69.3 mg (73%). 1H NMR (400 MHz, CD3OD): δ 9.08 
(d, 1H, J = 2.6 Hz), 8.84 (d, 1H, J = 9.1 Hz), 8.05-8.02 (m, 2H), 7.95 (dd, 1H, J =
9.1, 2.6 Hz), 7.73-7.63 (m, 3H), 6.48-6.47 (m, 1H), 6.18-6.17 (m, 1H), 6.04-6.03
(m, 1H), 5.96-5.95 (m, 1H), 4.40-4.29 (m, 2H), 2.71 (s, 3H), 2.45 (sept., 1H, J =
7.0 Hz), 2.00-1.92 (m, 2H), 1.15 (t, 3H, J = 7.5 Hz), 0.94-0.91 (2x d, 6H, J = 7.0
Hz). ESI-MS calculated for C24H29IN3OOs+: m/z 694.1. Found: 694.1. CHN
analysis: Found: C, 34.32%; H, 3.40%; N, 4.98%. Calculated for
C24H29F6IN3OOsP: C, 34.41%; H, 3.49%; N, 5.02%.
[Os(η6-p-cym)(5-iPrO-AZPY)I]PF6(15). [Os(η6-p-cym)I2]2 (50.0 mg, 43.2 µmol),
5-iPrO-AZPY (21.9 mg, 90.8 µmol), NH4PF6 (70.5 mg, 0.43 mmol), and isolation
method 2. Yield: 58.9 mg (81%). 1H NMR (400 MHz, CD3OD): δ 9.04 (d, 1H, J = 
2.6 Hz), 8.83 (d, 1H, J = 9.1 Hz), 8.04-8.01 (m, 2H), 7.95 (dd, 1H, J = 9.1, 2.6
Hz), 7.73-7.63 (m, 3H), 6.46-6.45 (m, 1H), 6.15-6.14 (m, 1H), 6.04-6.03 (m, 1H),
Chapter 4
149
5.96-5.95 (m, 1H), 5.07 (sept., 1H, J = 6.0 Hz), 2.68 (s, 3H), 2.46 (sept., 1H, J =
6.9 Hz), 1.49 (t, 6H, J = 6.3 Hz), 0.95 (d, 3H, J = 6.9 Hz), 0.94 (d, 3H, J = 6.9
Hz). ESI-MS calculated for C24H29IN3OOs+: m/z 694.1. Found: 694.1.
[Os(η6-p-cym)(5-nBuO-AZPY)I]PF6(16). [Os(η6-p-cym)I2]2 (50.0 mg, 43.2
µmol), 5-nBuO-AZPY (23.2 mg, 90.8 µmol), NH4PF6 (70.5 mg, 0.43 mmol), and
isolation method 2. Yield: 69.0 mg (94%). 1H NMR (400 MHz, (CD3)2CO): δ 9.25 
(d, 1H, J = 2.7 Hz), 8.94 (d, 1H, J = 9.1 Hz), 8.13-8.10 (m, 2H), 8.07 (dd, 1H, J =
9.1, 2.7 Hz), 7.78-7.67 (m, 3H), 6.73-6.72 (m, 1H), 6.42-6.41 (m, 1H), 6.28-6.27
(m, 1H), 6.20-6.19 (m, 1H), 4.52-4.41 (m, 2H), 2.77 (s, 3H), 2.58 (sept., 1H, J =
6.9 Hz), 1.94-1.87 (m, 2H), 1.61-1.51 (m, 2H), 1.01 (t, 3H, J = 7.4 Hz), 0.98 (d,
3H, J = 6.9 Hz), 0.96 (d, 3H, J = 6.9 Hz). ESI-MS calculated for C25H31IN3OOs+:
m/z 708.1. Found: 708.1.
[Os(η6-p-cym)(5-HOCH2CH2O-AZPY)Cl]PF6 (17). [Os(η6-p-cym)Cl2]2 (50.0 mg,
63.2 µmol), 5-HOCH2CH2O-AZPY (32.3 mg, 132.8 µmol), NH4PF6 (103.0 mg,
0.63 mmol), and isolation method 2. Yield: 78.5 mg (83%). 1H NMR (400 MHz,
CD3OD): δ 9.05 (d, 1H, J = 2.7 Hz), 8.77 (d, 1H, J = 9.1 Hz), 8.00-7.97 (m, 3H), 
7.71-7.66 (m, 3H), 6.49-6.48 (m, 1H), 6.13-6.12 (m, 1H), 5.98-5.97 (m, 2H),
4.55-4.42 (m, 2H), 4.01 (t, 2H, J = 4.5 Hz), 2.36 (s, 3H), 2.34 (sept., 1H, J = 6.9
Hz), 0.91 (d, 3H, J = 6.9 Hz), 0.88 (d, 3H, J = 6.9 Hz). ESI-MS calculated for
C23H27ClN3O2Os+: m/z 604.1. Found: 604.0. CHN analysis: Found: C, 36.95%;
H, 3.54%; N, 5.41%. Calculated for C23H27ClF6N3O2OsP: C, 36.93%; H, 3.64%;
N, 5.62%.
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[Os(η6-p-cym)(5-HOCH2CH2O-AZPY)Br]PF6 (18). [Os(η6-p-cym)Br2]2 (50.0
mg, 51.6 µmol), 5-HOCH2CH2O-AZPY (26.4 mg, 108.4 µmol), NH4PF6 (84.2
mg, 0.52 mmol), and isolation method 1. Yield: 70.1 mg (86%). 1H NMR (400
MHz, CD3OD): δ 9.04 (d, 1H, J = 2.6 Hz), 8.78 (d, 1H, J = 9.1 Hz), 8.03-7.99 
(m, 2H), 7.96 (dd, 1H, J = 9.1, 2.7 Hz), 7.72-7.65 (m, 3H), 6.46-6.45 (m, 1H),
6.00-5.99 (m, 1H), 6.13-6.12 (m, 1H), 5.97-5.96 (m, 1H), 4.54-4.41 (m, 2H),
4.01 (t, 2H, J = 4.5 Hz), 2.46 (s, 3H), 2.39 (sept., 1H, J = 6.9 Hz), 0.93 (d, 3H, J
= 6.9 Hz), 0.90 (d, 3H, J = 6.9 Hz). ESI-MS calculated for C23H27BrN3O2Os+:
m/z 648.1. Found: 647.9. CHN analysis: Found: C, 34.51%; H, 3.33%; N,
5.19%. Calculated for C23H27ClF6N3O2OsP: C, 34.85%; H, 3.43%; N, 5.30%.
[Os(η6-p-cym)(5-HOCH2CH2O-AZPY)I]PF6 (19). [Os(η6-p-cym)I2]2 (100.0 mg,
86.5 µmol), 5-HOCH2CH2O-AZPY (44.2 mg, 181.6 µmol), NH4PF6 (140.9 mg,
0.87 mmol), and isolation method 1. Yield: 128.6 mg (89%). 1H NMR (400 MHz,
CD3OD): δ 9.03 (d, 1H, J = 2.6 Hz), 8.78 (d, 1H, J = 9.1 Hz), 8.04-8.00 (m, 2H), 
7.92 (dd, 1H, J = 9.1, 2.7 Hz), 7.71-7.62 (m, 3H), 6.45-6.44 (m, 1H), 6.12-6.11
(m, 1H), 6.03-6.02 (m, 1H), 5.94-5.93 (m, 1H), 4.53-4.39 (m, 2H), 4.00 (t, 2H, J
= 4.4 Hz), 2.64 (s, 3H), 2.46 (sept., 1H, J = 6.9 Hz), 0.95-0.91 (2x d, 6H, J = 6.9
Hz). ESI-MS calculated for C23H27IN3O2Os+: m/z 696.1. Found: 695.9. CHN
analysis: Found: C, 32.19%; H, 3.19%; N, 4.82%. Calculated for
C23H27F6IN3O2OsP: C, 32.90%; H, 3.24%; N, 5.00%.
[Os(η6-bip)(5-HOCH2CH2O-AZPY)I]PF6 (20). [Os(η6-bip)I2]2 (39.8 mg, 33.3
µmol), 5-HOCH2CH2O-AZPY (17.0 mg, 69.9 µmol), NH4PF6 (54.2 mg, 0.33
mmol), and isolation method 1. Yield: 30.7 mg (54%). 1H NMR (400 MHz,
(CD3)2CO): δ 8.94 (d, 1H, J = 2.3 Hz), 8.87 (d, 1H, J = 9.1 Hz), 8.00 (dd, 1H, J = 
Chapter 4
151
9.1, 2.3 Hz), 7.90-7.88 (m, 2H), 7.66-7.64 (m, 1H), 7.54-7.41 (m, 7H), 7.08-7.07
(m, 1H), 6.94-6.93 (m, 1H), 6.78-6.77 (m, 1H), 6.71-6.70 (m, 1H), 6.63-6.62 (m,
1H), 4.31-4.30 (m, 2H), 3.95-3.94 (m, 2H). ESI-MS calculated for
C25H23IN3O2Os+: m/z 716.1. Found: 716.1. CHN analysis: Found: C, 34.71%; H,
2.61%; N, 4.86%. Calculated for C25H23F6IN3O2OsP: C, 34.93%; H, 2.70%; N,
4.89%.
[Os(η6-p-cym)(5-HO{CH2CH2O}2-AZPY)I]PF6 (21). [Os(η6-p-cym)I2]2 (50.0 mg,
43.2 µmol), 5-HO(CH2CH2O)2-AZPY (26.1 mg, 90.8 µmol), NH4PF6 (70.5 mg,
0.43 mmol), and isolation method 2. Yield: 70.3 mg (92%). 1H NMR (400 MHz,
CD3OD): δ 9.13 (d, 1H, J = 2.6 Hz), 8.84 (d, 1H, J = 9.1 Hz), 8.05-8.02 (m, 2H), 
7.99 (dd, 1H, J = 9.1, 2.7 Hz), 7.74-7.63 (m, 3H), 6.49-6.48 (m, 1H), 6.18-6.17
(m, 1H), 6.04-6.03 (m, 1H), 5.96-5.95 (m, 1H), 4.60-4.51 (m, 2H), 3.97 (t, 2H, J
= 4.4 Hz), 3.74-3.71 (m, 2H), 3.68-3.65 (m, 2H), 2.71 (s, 3H), 2.45 (sept., 1H, J
= 6.9 Hz), 0.94-0.91 (2x d, 6H, J = 6.9 Hz). ESI-MS calculated for
C25H31IN3O3Os+: m/z 740.1. Found: 740.1. CHN analysis: Found: C, 34.09%; H,
3.42%; N, 4.80%. Calculated for C25H31F6IN3O3OsP: C, 33.98%; H, 3.54%; N,
4.76%.
[Os(η6-p-cym)(5-MeO{CH2CH2O}2-AZPY)I]PF6 (22). [Os(η6-p-cym)I2]2 (75.0
mg, 64.8 µmol), 5-MeO(CH2CH2O)2-AZPY (41.0 mg, 136.2 µmol), NH4PF6
(105.7 mg, 0.65 mmol), and isolation method 2. The product was purified using
the Biotage Isolera instrument (Chapter 2, Section 2.2.6). Yield: 99.4 mg
(85%). 1H NMR (400 MHz, CD3OD): δ 9.11 (d, 1H, J = 2.6 Hz), 8.83 (d, 1H, J = 
9.1 Hz), 8.04-8.02 (m, 2H), 7.98 (dd, 1H, J = 9.1, 2.6 Hz), 7.74-7.63 (m, 3H),
6.48-6.47 (m, 1H), 6.17-6.16 (m, 1H), 6.04-6.03 (m, 1H), 5.96-5.95 (m, 1H),
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4.59-4.50 (m, 2H), 3.96 (t, 2H, J = 4.3 Hz), 3.74-3.72 (m, 2H), 3.60-3.57 (m,
2H), 3.37 (s, 3H), 2.71 (s, 3H), 2.46 (sept., 1H, J = 6.9 Hz), 0.95-0.92 (2x d, 6H,
J = 6.9 Hz). ESI-MS calculated for C26H33IN3O3Os+: m/z 754.1. Found: 754.1.
CHN analysis: Found: C, 34.78%; H, 3.61%; N, 4.53%. Calculated for
C26H33F6IN3O3OsP: C, 34.79%; H, 3.71%; N, 4.68%.
[Os(η6-p-cym)(5-EtO{CH2CH2O}2-AZPY)I]PF6 (23). [Os(η6-p-cym)I2]2 (100.0
mg, 86.5 µmol), 5-EtO(CH2CH2O)2-AZPY (57.3 mg, 181.6 µmol), NH4PF6
(140.9 mg, 0.87 mmol), and isolation method 2. Yield: 150.5 mg (96%). 1H NMR
(400 MHz, CD3OD): δ 9.12 (d, 1H, J = 2.6 Hz), 8.83 (d, 1H, J = 9.1 Hz), 8.05-
8.02 (m, 2H), 7.98 (dd, 1H, J = 9.1, 2.6 Hz), 7.74-7.70. (m, 1H), 7.78-7.63 (m,
2H), 6.48-6.47 (m, 1H), 6.17-6.16 (m, 1H), 6.04-6.03 (m, 1H), 5.96-5.95 (m,
1H), 4.60-4.50 (m, 2H), 3.97 (t, 2H, J = 4.4 Hz), 3.74-3.72 (m, 2H), 3.64-3.61
(m, 2H), 3.54 (q, 2H, J = 7.0 Hz), 2.71 (s, 3H), 2.46 (sept., 1H, J = 6.9 Hz), 1.19
(t, 3H, J = 7.0 Hz), 0.95-0.92 (2x d, 6H, J = 6.9 Hz). ESI-MS calculated for
C27H35IN3O3Os+: m/z 768.1. Found: 768.0. CHN analysis: Found: C, 34.90%; H,
3.68%; N, 4.49%. Calculated for C27H35F6IN3O3OsP: C, 35.57%; H, 3.87%; N,
4.61%.
[Os(η6-bip)(5-EtO{CH2CH2O}2-AZPY)I]CF3SO3 (24). [Os(η6-p-cym)I2]2 (50.0
mg, 41.8 µmol), 5-EtO(CH2CH2O)2-AZPY (27.7 mg, 87.8 µmol), NH4CF3SO3
(69.8 mg, 0.42 mmol), and isolation method 2. The product was purified using
the Biotage Isolera instrument (Chapter 2, Section 2.2.6). Yield: 68.1 mg
(87%). 1H NMR (400 MHz, CD3OD): δ 8.77 (d, 1H, J = 9.1 Hz), 8.71 (d, 1H, J = 
2.3 Hz), 7.90-7.85 (m, 3H), 7.62-7.61 (m, 1H), 7.52-7.48 (m, 3H), 7.41-7.36 (m,
4H), 6.92-6.91 (m, 1H), 6.73-6.71 (m, 1H), 6.59-6.58 (m, 1H), 6.44-6.39 (m,
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2H), 4.31-4.21 (m, 2H), 3.87 (t, 2H, J = 4.2 Hz), 3.71-3.69 (m, 2H), 3.63-3.61
(m, 2H), 3.55 (q, 2H, J = 7.0 Hz), 1.20 (t, 3H, J = 7.0 Hz). ESI-MS calculated for
C29H31IN3O3Os+: m/z 788.1. Found: 788.1. CHN analysis: Found: C, 37.85%; H,
3.20%; N, 4.81%. Calculated for C30H31F3IN3O6OsS: C, 38.51%; H, 3.34%; N,
4.49%.
[Os(η6-p-cym)(5-HO{CH2CH2O}3-AZPY)I]PF6 (25). [Os(η6-p-cym)I2]2 (50.0 mg,
43.2 µmol), 5-HO(CH2CH2O)3-AZPY (30.1 mg, 90.8 µmol), NH4PF6 (70.5 mg,
0.43 mmol), and isolation method 2. Yield: 79.3 mg (99%). 1H NMR (400 MHz,
CD3CN): δ 8.95 (d, 1H, J = 2.6 Hz), 8.75 (d, 1H, J = 9.1 Hz), 8.00-7.97 (m, 2H), 
7.86 (dd, 1H, J = 9.1, 2.7 Hz), 7.74-7.63 (m, 3H), 6.33-6.32 (m, 1H), 6.06-6.05
(m, 1H), 5.96-5.95 (m, 1H), 5.86-5.85 (m, 1H), 4.49-4.48 (m, 2H), 3.91-3.90 (m,
2H), 3.70-3.67 (m, 2H), 3.64-3.59 (m, 4H), 3.52-3.50 (m, 2H), 2.66 (s, 3H), 2.42
(sept., 1H, J = 6.9 Hz), 0.88 (d, 3H, J = 6.9 Hz), 0.87 (d, 3H, J = 6.9 Hz). ESI-
MS calculated for C27H35IN3O4Os+: m/z 784.1. Found: 784.1. CHN analysis:
Found: C, 33.87%; H, 3.65%; N, 4.68%. Calculated for C27H35F6IN3O4OsP +
½CH2Cl2: C, 34.05%; H, 3.74%; N, 4.33%.
[Os(η6-p-cym)(5-MeO{CH2CH2O}3-AZPY)I]PF6 (26). [Os(η6-p-cym)I2]2 (50.0
mg, 43.2 µmol), 5-MeO(CH2CH2O)3-AZPY (31.4 mg, 90.8 µmol), NH4PF6 (70.5
mg, 0.43 mmol), and isolation method 2. The product was purified using the
Biotage Isolera instrument (Chapter 2, Section 2.2.6). Yield: 76.4 mg (94%). 1H
NMR (400 MHz, CD3OD): δ 9.12 (d, 1H, J = 2.5 Hz), 8.84 (d, 1H, J = 9.1 Hz), 
8.04-8.03 (m, 2H), 7.99 (dd, 1H, J = 9.1, 2.5 Hz), 7.71-7.70 (m, 1H), 7.67-7.63
(m, 2H), 6.48-6.47 (m, 1H), 6.18-6.17 (m, 1H), 6.04-6.03 (m, 1H), 5.96-5.95 (m,
1H), 4.60-4.50 (m, 2H), 3.97 (t, 2H, J = 4.3 Hz), 3.74-3.73 (m, 2H), 3.68-3.62
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(m, 4H), 3.55-3.53 (m, 2H), 3.35 (s, 3H), 2.71 (s, 3H), 2.46 (sept., 1H, J = 6.9
Hz), 0.95-0.92 (2x d, 6H, J = 6.9 Hz). 13C NMR ((CD3)2CO): δ 161.95 (C),
159.46 (C), 158.81 (C), 143.97 (CH), 134.21 (CH), 130.31 (CH), 129.93 (CH),
126.99 (CH), 126.52 (CH), 105.99 (C), 104.96 (C), 85.13 (CH), 83.41 (CH),
81.03 (CH), 72.77 (CH2), 71.53 (CH2), 71.34 (CH2), 71.16 (CH2), 71.11 (CH2),
70.09 (CH2), 58.91 (CH3), 32.59 (CH), 22.44 (CH3), 22.34 (CH3), 21.35 (CH3).
ESI-MS calculated for C28H37IN3O4Os+: m/z 798.1. Found: 798.0.
[Os(η6-p-cym)(5-EtO{CH2CH2O}3-AZPY)I]PF6 (27). [Os(η6-p-cym)I2]2 (50.0 mg,
43.2 µmol), 5-EtO(CH2CH2O)3-AZPY (32.6 mg, 90.8 µmol), NH4PF6 (70.5 mg,
0.43 mmol), and isolation method 2. The product was purified using the Biotage
(Chapter 2, Section 2.2.6). Yield: 77.2 mg (93%). 1H NMR (400 MHz,
(CD3)2CO): δ 9.26 (d, 1H, J = 2.6 Hz), 8.94 (d, 1H, J = 9.1 Hz), 8.13-8.09 (m, 
3H), 7.78-7.74 (m, 1H), 7.72-7.67 (m, 2H), 6.76-6.75 (m, 1H), 6.46-6.45 (m,
1H), 6.30-6.29 (m, 1H), 6.20-6.19 (m, 1H), 4.66-4.56 (m, 2H), 3.97 (t, 2H, J =
4.4 Hz), 3.71-3.69 (m, 2H), 3.66-3.63 (m, 2H), 3.61-3.58 (m, 2H), 3.55-3.52 (m,
2H), 3.47 (q, 2H, J = 7.0 Hz), 2.79 (s, 3H), 2.58 (sept., 1H, J = 6.9 Hz), 1.13 (t,
3H, J = 7.0 Hz), 0.98 (d, 3H, J = 6.9 Hz), 0.96 (d, 3H, J = 6.9Hz). ESI-MS
calculated for C29H39IN3O4Os+: m/z 812.2. Found: 812.1.CHN analysis: Found:
C, 35.30%; H, 4.00%; N, 4.36%. Calculated for C29H39F6IN3O4OsP + ½CH2Cl2:
C, 35.50%; H, 4.04%; N, 4.21%.
[Os(η6-p-cym)(5-HO{CH2CH2O}4-AZPY)I]PF6 (28). [Os(η6-p-cym)I2]2 (50.0 mg,
43.2 µmol), 5-HO(CH2CH2O)4-AZPY (34.1 mg, 90.8 µmol), NH4PF6 (70.5 mg,
0.43 mmol), and isolation method 2. Yield: 82.8 mg (98%). 1H NMR (400 MHz,
CD3OD): δ 9.12 (d, 1H, J = 2.6 Hz), 8.84 (d, 1H, J = 9.1 Hz), 8.04-8.02 (m, 2H), 
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7.99 (dd, 1H, J = 9.1, 2.6 Hz), 7.74-7.64 (m, 3H), 6.48-6.47 (m, 1H), 6.18-6.17
(m, 1H), 6.04-6.03 (m, 1H), 5.96-5.65 (m, 1H), 4.60-4.51 (m, 2H), 3.97 (t, 2H, J
= 4.4 Hz), 3.76-3.73 (m, 2H), 3.70-3.63 (m, 8H), 3.58-3.55 (m, 2H), 2.71 (s,
3H), 2.46 (sept., 1H, J = 6.9 Hz), 0.94 (d, 3H, J = 6.9 Hz), 0.93 (d, 3H, J = 6.9
Hz). ESI-MS calculated for C29H39IN3O5Os+: m/z 828.2. Found: 828.1. CHN
analysis: Found: C, 34.54%; H, 4.00%; N, 4.62%. Calculated for
C29H39F6IN3O5OsP + 2H2O: C, 34.56%; H, 4.30%; N, 4.17%.
[Os(η6-p-cym)(5-Br-AZPY-OH)Cl]PF6 (29). [Os(η6-p-cym)Cl2]2 (50.0 mg, 63.2
µmol), 5-Br-AZPY-OH (36.9 mg, 132.8 µmol), NH4PF6 (103.1 mg, 0.63 mmol),
and isolation method 1. Yield: 89.6 mg (91%). 1H NMR (400 MHz, (CD3)2CO): δ 
9.66 (d, 1H, J = 2.1 Hz), 8.75 (d, 1H, J = 8.7 Hz), 8.56 (dd, 1H, J = 8.7, 2.1 Hz),
8.15-8.11 (m, 2H), 7.15-7.11 (m, 2H), 6.82-6.81 (m, 1H), 6.53-6.52 (m, 1H),
6.40-6.35 (m, 2H), 2.47 (sept., 1H, J = 6.9 Hz), 2.43 (s, 3H), 0.97 (d, 3H, J = 6.9
Hz), 0.91 (d, 3H, J = 6.9 Hz). ESI-MS calculated for C21H22BrClN3OOs+: m/z
638.0. Found: 637.9. CHN analysis: Found: C, 31.87%; H, 2.70%; N, 5.16%.
Calculated for C21H22BrClF6N3OOsP: C, 32.21%; H, 2.83%; N, 5.37%.
[Os(η6-p-cym)(5-Br-AZPY-OH)Br]PF6 (30). [Os(η6-p-cym)Br2]2 (50.0 mg, 51.6
µmol), 5-Br-AZPY-OH (30.2 mg, 108.4 µmol), NH4PF6 (84.2 mg, 0.52 mmol),
and isolation method 1. Yield: 78.1 mg (91%). 1H NMR (400 MHz, (CD3)2CO): δ 
9.66 (d, 1H, J = 2.1 Hz), 8.78 (d, 1H, J = 8.7 Hz), 8.53 (dd, 1H, J = 8.7, 2.1 Hz),
8.16-8.12 (m, 2H), 7.15-7.11 (m, 2H), 6.82-6.81 (m, 1H), 6.55-6.54 (m, 1H),
6.42-6.39 (m, 2H), 2.56 (s, 3H), 2.51 (sept., 1H, J = 6.9 Hz), 0.99 (d, 3H, J = 6.9
Hz), 0.92 (d, 3H, J = 6.9 Hz). ESI-MS calculated for C21H22Br2N3OOs+: m/z
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682.0. Found: 681.9. CHN analysis: Found: C, 30.19%; H, 2.60%; N, 4.98%.
Calculated for C21H22Br2F6N3OOsP: C, 30.48%; H, 2.68%; N, 5.08%.
[Os(η6-p-cym)(5-Br-AZPY-OH)I]PF6 (31). [Os(η6-p-cym)I2]2 (100.0 mg, 86.5
µmol), 5-Br-AZPY-OH (50.5 mg, 181.6 µmol), NH4PF6 (140.9 mg, 0.87 mmol),
and isolation method 1. Yield: 76.7 mg (51%). 1H NMR (400 MHz, CD3OD): δ 
9.10-9.09 (m, 1H), 8.12-8.08 (m, 2H), 8.02-8.01 (m, 2H), 6.43-6.39 (m, 2H),
7.15-7.11 (m, 2H), 6.20-6.19 (m, 1H), 6.07-6.06 (m, 1H), 6.03-6.02 (m, 1H),
5.97-5.96 (m, 1H), 2.73 (s, 3H), 2.39 (sept., 1H, J = 6.9 Hz), 0.97 (d, 3H, J = 6.9
Hz), 0.89 (d, 3H, J = 6.9 Hz). ESI-MS calculated for C21H22BrIN3OOs+: m/z
730.0. Found: 729.8. CHN analysis: Found: C, 28.62%; H, 2.63%; N, 4.73%.
Calculated for C21H22BrF6IN3OOsP: C, 28.85%; H, 2.54%; N, 4.81%.
[Os(η6-p-cym)(5-F3C-AZPY-OH)Cl]PF6 (32). [Os(η6-p-cym)Cl2]2 (40.0 mg, 50.6
µmol), 5-F3C-AZPY-OH (28.4 mg, 106.2 µmol), NH4PF6 (82.5 mg, 0.51 mmol),
and isolation method 1. Yield: 69.2 mg (89%). 1H NMR (400 MHz, (CD3)2CO): δ 
9.78-9.77 (m, 1H), 9.03 (d, 1H, J = 8.5 Hz), 8.68 (dd, 1H, J = 8.5, 2.0 Hz), 8.21-
8.17 (m, 2H), 7.18-7.14 (m, 2H), 6.88-6.87 (m, 1H), 6.62-6.61 (m, 1H), 6.48-
6.47 (m, 1H), 6.44-6.43 (m, 1H), 2.48 (sept., 1H, J = 6.9 Hz), 2.42 (s, 3H), 0.97
(d, 3H, J = 6.9 Hz), 0.91 (d, 3H, J = 6.9 Hz). ESI-MS calculated for
C22H22ClF3N3OOs+: m/z 628.1. Found: 628.0. CHN analysis: Found: C, 34.71%;
H, 3.18%; N, 5.17%. Calculated for C22H22ClF9N3OOsP: C, 34.22%; H, 2.87%;
N, 5.44%.
[Os(η6-p-cym)(5-F3C-AZPY-OH)Br]PF6 (33). [Os(η6-p-cym)Br2]2 (50.0 mg, 51.6
µmol), 5-F3C-AZPY-OH (29.0 mg, 108.4 µmol), NH4PF6 (84.2 mg, 0.52 mmol),
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and isolation method 1. The product was purified using the Biotage Isolera
instrument (Chapter 2, Section 2.2.6). Yield: 70.9 mg (84%). 1H NMR (400 MHz,
(CD3)2CO): δ 9.78-9.77 (m, 1H), 9.06 (d, 1H, J = 8.6 Hz), 8.66 (dd, 1H, J = 8.6, 
1.9 Hz), 8.22-8.18 (m, 2H), 7.19-7.15 (m, 2H), 6.89-6.88 (m, 1H), 6.64-6.63 (m,
1H), 6.49-6.48 (m, 2H), 2.56 (s, 3H), 2.53 (sept., 1H, J = 6.9 Hz), 0.99 (d, 3H, J
= 6.9 Hz), 0.92 (d, 3H, J = 6.9 Hz). ESI-MS calculated for C22H22BrF3N3OOs+:
m/z 672.1. Found: 672.0. CHN analysis: Found: C, 32.30%; H, 2.62%; N,
5.06%. Calculated for C22H22BrF9N3OOsP: C, 32.36%; H, 2.72%; N, 5.15%.
[Os(η6-p-cym)(5-EtO-AZPY)(S-SCN)]PF6 (34A) and [Os(η6-p-cym)(5-EtO-
AZPY)(N-SCN)]PF6 (34B). [Os(η6-p-cym)Cl2]2 (50.0 mg, 63.2 µmol) was
dissolved in EtOH (10 mL) and a solution of 5-EtO-AZPY (30.2 mg, 132.8 µmol)
in EtOH (5 mL) was added drop-wise. The mixture was stirred for 18 h at
ambient temperature then filtered through glass micro-fibre to remove a black
precipitate. The solvent was removed under reduced pressure and a solution of
KSCN (6.15 g, 63.24 mmol) in MeOH:H2O (1:1 v/v, 12 mL) was added to the
brown residue. The mixture was heated to reflux for 18 h. The product was
extracted with DCM (2 x 10 mL), washed with water (2 x 10 mL), dried over
MgSO4, and filtered. The solvent was removed under reduced pressure and the
product was re-dissolved in a minimum amount of hot EtOH, and NH4PF6
(103.1 mg, 0.63 mmol) was added. Isolation method 2 was used. Yield: 60.6 mg
(64%). 1H NMR (400 MHz, (CD3)2CO): Major isomer; δ 9.05 (d, 1H, J = 2.6 Hz), 
8.89 (d, 1H, J = 9.1 Hz), 8.06-8.00 (m, 3H), 7.74-7.72 (m, 3H), 6.88-6.87 (m,
1H), 6.53-6.52 (m, 1H), 6.38-6.37 (m, 1H), 6.33-6.32 (m, 1H), 4.68-4.51 (m,
2H), 2.54 (sept., 1H, J = 6.9 Hz), 2.49 (s, 3H), 1.53 (t, 3H, J = 7.0 Hz), 1.01 (d,
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3H, J = 6.9 Hz), 0.96 (d, 3H, J = 6.9 Hz). Minor isomer; δ 9.35 (d, 1H, J = 2.6 
Hz), 8.94 (d, 1H, J = 9.1 Hz), 8.15 (dd, 1H, J = 9.1, 2.6 Hz), 8.11-8.08 (m, 2H),
7.79-7.77 (m, 3H), 6.91-6.90 (m, 1H), 6.57-6.56 (m, 1H), 6.74-6.73 (m, 1H),
6.42-6.41 (m, 1H), 4.68-4.61 (m, 2H), 2.46 (s, 3H), 1.55 (t, 3H, J = 7.0 Hz), 1.00
(d, 3H, J = 6.9 Hz), 0.97 (d, 3H, J = 6.9 Hz). ESI-MS calculated for
C24H27N4OOsS+: m/z 611.2. Found: 611.1.
[Os(η6-p-cym)(5-EtO-AZPY)N3]PF6 (35). [Os(η6-p-cym)Cl2]2 (50.0 mg, 63.2
µmol) was dissolved in a solution of MeOH:H2O (2:1 v/v, 10 mL) and a solution
of AgNO3 (20.10 mg/mL, 4 mol. equiv.) in water was added. A white precipitate
immediately formed and the solute turned yellow. The precipitate was removed
by filtration and 5-EtO-AZPY (30.2 mg, 132.8 µmol), then NaN3 (41.1 mg, 0.63
mmol) were added. The mixture was heated to 50 °C for 2 h. Isolation method 1
was used. Yield: 34.8 mg (37%). The product was impure and a portion was
purified by preparative HPLC. 1H NMR (400 MHz, CD3OD): δ 9.08 (d, 1H, J = 
2.5 Hz), 8.83 (d, 1H, J = 9.1 Hz), 8.01 (dd, 1H, J = 9.1, 2.5 Hz), 7.95-7.93 (m,
2H), 7.73-7.71 (m, 3H), 6.56-6.55 (m, 1H), 6.16-6.15 (m, 1H), 6.01-5.98 (m,
2H), 4.56-4.43 (m, 2H), 2.35 (s, 3H), 2.30 (sept., 1H, J = 6.9 Hz), 1.57 (t, 3H, J
= 7.0 Hz), 0.88 (d, 3H, J = 6.9 Hz), 0.84 (d, 3H, J = 6.9 Hz). 13C NMR
((CD3)2CO): δ161.89 (C), 160.67 (C), 157.96 (C), 142.67 (CH), 134.16 (CH),
130.66 (CH), 130.19 (CH), 126.69 (CH), 125.61 (CH), 110.30 (C), 105.80 (C),
85.87 (CH), 85.40 (CH), 80.71 (CH), 79.96 (CH), 67.6 (CH2), 32.30 (CH), 22.94
(CH3), 22.80 (CH3), 18.64 (CH3), 14.82 (CH3). ESI-MS calculated for
C23H27N6OOs+: m/z 595.2. Found: 595.1.
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4.2.3. Growing single crystals for X-ray crystallography
Single crystals of 6, 10, 32, 33 and FY026 were obtained by cooling MeOH or
EtOH solutions of approximately 1-2 mg/mL in a freezer at -20 °C. Crystals of
13A were obtained by slow evaporation of a MeOH solution at ambient
temperature.20
4.2.4. Measuring the pKa of 31
A solution of 31 (100 µM) in water was prepared and divided into 34x 1mL
aliquots in glass vials. The pH of the aliquots were individually adjusted by the
addition of 1-10 μL of either KOH or HClO4 (0.01, 0.1, 1, 2, 3, 4, 6, 8 or 10 M),
and measured over a range of 1.9 - 12.8 using a pH bench top meter. Changes
in the UV-Vis absorption spectra were then recorded at different pH values
using disposable polystyrene semi-micro 1.6 mL cuvettes, ensuring no further
contact with glass after the pH measurements (contact with glass affects pH).
The change in intensity of the absorption at 588 nm with pH was fitted to the
Henderson-Hasselbalch equation using Origin 8.5.
4.2.5. Aqueous stability testing
The stability after 24 h in D2O was determined by 1H NMR for all complexes. A
more detailed assessment was conducted by HPLC for complexes 8, 9 and 10,
which explored stability after 37°C incubation with different concentrations of
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NaCl in phosphate buffer solution. No precautions were made to protect
samples from light or air.
4.2.5.1. 1H NMR spectroscopy
Saturated solutions of complexes were prepared by dissolving 1-2 mg in
DMSO-d6 (50 µL) followed by drop-wise addition of D2O (950 µL), accompanied
with vigorous stirring and shaking. The solutions were then filtered and
transferred into NMR tubes. 1H NMR spectra were collected straight after
sample preparation (10-20 min) and after 24 h, leaving the sample at ambient
temperature. Spectra were collected on a 400 or 500 MHz instrument.
4.2.5.2. HPLC
Solutions of complexes 8, 9 and 10 (100 µM) were prepared with phosphate
buffer (9.5 mM, pH 7.4), 5% DMSO, and NaCl at concentrations of either 23 or
103 mM. Samples were incubated for 0, 2, 12 and 24 h at 37 °C and placed in a
freezer at -20 °C for storage, before running HPLC analysis (see Chapter 2,
Section 2.2.9 for HPLC conditions).
4.2.6. Aqueous solubility testing
Saturated solutions of complexes were prepared in triplicates by combining 1-3
mg of complex with 100 mM NaCl solution (1 mL) and shaking samples for 24 h
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on a mechanical shaker. If all the solids fully dissolve then more were added to
ensure a saturated solution. The solutions were filtered using Iso-DiscTM filters
(PTFE-4-4 4 mm x 0.45 μm) and the concentrations of osmium were 
determined using either ICP-OES or ICP-MS (see Chapter 2, Sections 2.2.13
and 2.2.14). The experiments were repeated to obtain duplicates of triplicates.
4.2.7. Measuring HPLC capacity factors
The isocratic HPLC analysis of complexes and uracil was carried out using the
same instrument and column described in Chapter 2, Section 2.2.9. The mobile
phase consisted of H2O:MeCN (1:1, v/v) with 50 mM NaCl with no solvent
gradient (HPLC grade materials used). The temperature of the column was kept
constant at 25 °C. Samples of the complexes and uracil (500 µM) were
prepared in H2O:MeCN (1:1, v/v) and were analysed in triplicates on three
separate days (50 µL injection volume). The capacity factors were calculated
using the following equations, where tR is the retention time of the retained
complex, t0 is the retention time of an unretained compound (uracil), RF is the
retention factor, and K is the capacity factor.21-23
RF = (tR - t0) (1)
K = RF/t0 (2)
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4.2.8. Preparative HPLC
Preparative HPLC was used to purify 34 and 35 using the same instrument,
mobile phase, solvent gradient and wavelengths of detection described in
Chapter 2, Section 2.2.9, with a flow rate of 2 mL/min. An Agilent ZORBAX
Eclipse XDB-C18 250 x 9.4 mm column with a pore size of 5 µm was used with
a 1mL loop. Samples were prepared in MeCN:H2O (1:9, v/v) at concentrations
of 500 µM and filtered through Iso-DiscTM filters (PTFE-4-4 4 mm x 0.45 μm).
Aliquots of 0.45-0.50 mL were injected at a time and fractions were collected
from the waste line. Selected fractions were combined and MeCN was removed
under reduced pressure. The sample was then freeze dried to remove the
residual water and TFA. Complex 35 was re-dissolved in EtOH and recombined
with excess ammonium hexafluorophosphate (100 mg). The solvent was then
removed under reduced pressure and the resulting precipitate was re-dissolved
in DCM, filtered into a pre-weighed vial, and dried under vacuum.
4.2.9. Stability testing of the structural isotopes of 34
After the isotopes of 34 were separated by preparative HPLC and freeze dried,
the samples were re-dissolved in DMSO (50 µL) and PBS solution (950 µL),
filtered through Iso-DiscTM filters (PTFE-4-4 4 mm x 0.45 μm), and incubated at
37 °C for 24 h. The samples were then analysed using HPLC as described in
Chapter 2, Section 2.2.9.
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4.3. Results
4.3.1. Synthesis of AZPY ligands
Two different types of AZPY ligand were synthesised. Ligands with alkoxy or
glycolic side chains situated on the pyridine moiety, para to the azo-bond (RO-
AZPY, see Scheme 4.2). Ligands with two substituents: an electron-withdrawing
substituent on the pyridine ring and an electron-donating OH group on the
phenyl ring, both situated para to the azo-bond (R-AZPY-OH, see Scheme 4.4).
4.3.1.1. RO-AZPY ligands
Phenylazopyridine (AZPY) ligands functionalised with alkoxy or glycolic side
chains were synthesised via a two-step process detailed in Scheme 4.2. Step 1
is a condensation reaction that generates an azo-bond when 2-amino-5-
fluoropyridine is reacted with nitrosobenzene in the presence of a base, forming
5-F-AZPY. This reaction is well understood for the synthesis of azobenzene.3,4
Step 2 is an aromatic nucleophilic substitution reaction, whereby the reagent
also behaves as a solvent matrix for the reaction to take place. The mechanism
occurs via an addition-elimination process (Scheme 4.3), where the nucleophile
(RO-) is generated in situ under basic conditions and attacks the electropositive
fluorinated carbon.24 The π* orbital of the azo-bond provides a platform for 
electrons to occupy temporarily, making the addition process accessible.
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Scheme 4.2. Two-step synthesis of AZPY ligands with para alkoxy/glycol substituents (RO-
AZPYs).
Scheme 4.3. Reaction mechanism for the nucleophilic addition-elimination of 5-F-AZPY, where
the addition of nucleophile RO- leads to the elimination of F-.24
N NH2
F N
O
N
F
N
N
N
O
N
NR
+
Water:Benzene (4:1),
NaOH (12 mol. equiv.)
reflux, 18 h
ROH, KOH(aq) (5 mol. equiv.),
reflux or 120 oC, 18 h
R = Alkyl or glycol chain
Step 1
Step 2
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A total of 13 ligands were synthesised utilising a variety of alcohols and glycols
with different chain lengths. Table 4.1 summarises all the ligands that were
synthesised and the solvent/reagent (ROH) used to make them.
Table 4.1. List of all RO-AZPY ligands synthesized.
Ligand ROH Structure
L1
5-MeO-AZPY Methanol
L2
5-EtO-AZPY Ethanol
L3
5-nPrO-AZPY n-propanol
L4
5-iPrO-AZPY Isopropanol
L5
5-nBuO-AZPY n-butanol
L6
5-HOCH2CH2O-AZPY
ethylene
glycol
L7
5-HO(CH2CH2O)2-AZPY
diethylene
glycol
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L8
5-HO(CH2CH2O)3-AZPY
triethylene
glycol
L9
5-HO(CH2CH2O)4-AZPY
tetraethylene
glycol
L10
5-MeO(CH2CH2O)2-AZPY
diethylene
glycol
monomethyl
ether
L11
5-MeO(CH2CH2O)3-AZPY
triethylene
glycol
monomethyl
ether
L12
5-EtO(CH2CH2O)2-AZPY
diethylene
glycol
monoethyl
ether
L13
5-EtO(CH2CH2O)3-AZPY
triethylene
glycol
monoethyl
ether
4.3.1.2. R-AZPY-OH ligands
The synthesis of AZPY ligands baring two substituents para to the azo-bond
posed a significant challenge. There are many reported azo-coupling reactions
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in the literature.1-6 However, azo-couplings are sensitive to the presence of
multiple electron donating/withdrawing substituents, hindering formation of the
azo-bond. The synthesis of such ligands was attempted using a variety of
different strategies and only one methodology proved to be successful
producing significant yields (Scheme 4.4).7 Two ligands were synthesised using
this protocol, L14 and L15.
Scheme 4.4. One step synthesis of R-AZPY-OH ligands with a para electron withdrawing
substituent on the pyridine ring and para hydroxyl substituent on the phenyl ring.
4.3.2. Synthesis of Os(II) arene AZPY complexes
Shown in Scheme 4.5 is the general synthesis protocol of Os(II) arene AZPY
complexes baring halido monodentate ligands (6-33). The reaction involved
stirring [Os(ɳ6-p-cym)X2]2 (where X = Cl, Br or I) in ethanolic solution with 2.1
mol. equiv. of an AZPY ligand (L1-L15). The reactions occurred readily at
ambient temperature, forming a cationic complex of +1 charge. Reactions
involving [Os(ɳ6-bip)I2]2, required further heating at reflux for 1 h. The second
step of the synthesis involved exchanging the I- counter-ion for an anion of
choice (PF6-, CF3SO3- or IO3-) by adding 10 mol. equiv. of either NH4PF6,
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NH4CF3SO3 or KIO3. When ESI-MS analysis of the complexes was acquired in
positive mode, a m/z peak was observed that corresponds to the positively
charged complex without its counter-ion (M - Y). When run in negative mode a
m/z peak corresponding to the anion was observed (145.0 and 149.0 for PF6-
and CF3SO3- respectively). IO3- was not observed by ESI-mass spectrometry.
Scheme 4.5. General scheme for the synthesis of Os(II) arene AZPY complexes bearing
monodentate halide ligands.
The synthesis of complexes bearing pseudo-halide ligands required different
strategies. For thiocyanato complex (34), the first step involved reacting the
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chloride dimer, [Os(ɳ6-p-cym)Cl2]2, with 2.1 mol.equiv. of 5-EtO-AZPY to form a
chlorido Os(II) arene AZPY complex in situ. The complex was then heated for
18 h under reflux with 500 mol. equiv. of KSCN and the chloride ligand was
displaced by the pseudo-halide anion (see Scheme 4.6, A). The reaction formed
a mixture of two different structural isomers (see Section 4.3.11). The chloride
dimer was selected because chloride is more labile and easier displace than
bromide or iodide. Finally, the counter anion was changed to PF6- by adding
NH4PF6 (10 mol. equiv.) to an ethanolic solution of the complex. Drying the
mixtures and filtering them after re-dissolving in DCM was a process used to
remove excess salts, as DCM does not solubilise KSCN or NH4PF6.
)(A)(B169
Scheme 4.6. Protocols for the synthesis of Os(II) p-cym 5-EtO-AZPY complexes bearing; (A) a
SCN- monodentate ligand, and (B) a N3- monodentate ligand.
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Because of the dangers associated with azides, the method was altered to
prevent using excessive amounts NaN3 when synthesising 35. [Os(ɳ6-p-
cym)Cl2]2 was reacted with AgNO3 (4 mol. equiv.) to remove the chloride
ligands and the resulting aqua-species was reacted with 2.1 mol. equiv. 5-EtO-
AZPY and 10 mol. equiv. of NaN3 (see Scheme 4.6, B).
All complexes were characterised by 1H NMR, ESI-MS and CHN analysis.
Some complexes proved to be unsuitable for CHN analysis and were instead
characterised by 13C NMR. Their purities were analysed via HPLC and
complexes were only used for biological studies after ensuring a purity of >97%.
Impure complexes were purified by either re-crystallisation, preparative HPLC,
or automated reverse-phase column chromatography. The molecular structures
of all the complexes synthesised in this chapter are shown in the Appendices,
Section 8.2.
4.3.3. X-ray crystal structures
The molecular structures of complexes 6, 10, 13A, 32, 33 and FY026 were
determined by single crystal X-ray diffraction (Figure 4.3). Selected bond
lengths are summarised in Table 4.2 and the crystallographic data are shown in
Table 4.3. Complex 13A is analogous to 13 with a PF6- anion in place of
CF3SO3-. Complex FY026 is described in greater detail in Chapter 1, Section
1.3.4.3, and is studied in Chapters 5 and 6 herein.25 All the complexes adopt the
familiar pseudo-octahedral three-legged piano-stool geometry, where the Os(II)
centre is π-bonded to the arene ligand. The Os(II) centre is also coordinated to 
a halide ligand
the piano
metal centres and contain PF
Complexes
lattices. Complex
incorporate a MeOH molecule that is involved in hydrogen bonding between the
OH substituent of the AZPY ligand and the PF
Figure 4.3.
FY026. Ellipsoids are shown at the 50% probability level and all hydrogens, counter ions and
solvent molecules have been omitted for clarity.
and the bidentate
-stool. The complexes crystallise as racemates owing to their chiral
10, 32
10
ORTEP diagrams for complex
and 33 also incorporate solvent molecules in
incorporates half of a EtOH molecule, and
AZPY
6
- counter ions in their X
es
ligand, which constitute the three legs of
6
- anion
6, 10.0.5C2
-ray crystal structures.
(Figure 4.4
H6O, 32.CH
their crystal
32 and
).
4O, 33.CH4O,
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33 both
13A and
Figure 4.4.
33.CH4O, occurring between the OH substituent, a molecule of MeOH, and the PF
Table 4.2.
10.0.5C2H6
Bond
length (Å)
Os1-X1
Os1-N1/N10
Os1-N8/N7
N7-N8
Os1-Arene
Centroid
(A)
Hydrogen bonding interactions within the crystal structures of (A)
Selected bond lengths (Å)
O, 13A, 32.CH
6
2.7099(2)
2.060(3)
2.023(3)
1.286(4)
1.728
4O, 33.CH
10.0.5C
2.6974(2)
2.052(2)
2.022(2)
1.289(3)
1.712
observed in the
4O and FY026
2H6O
2.6918(3)
2.059(3)
2.029(4)
1.279(5)
X-ray crystal structures of complexes
. X = Cl, Br or I
13A 3
1.291(12)
1.704
(B)
(monodentate halide ligand)
2.CH4O
2.379(2)
2.051(8)
2.019(8)
1.711
32.CH
6
-
33.CH4O
2.4926(7)
2.051(5)
2.013(5)
1.300(8)
1.711
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4O, and (B)
anion.
6,
.
FY026
2.7124(2)
2.058(2)
2.041(2)
1.302(3)
1.714
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Table 4.3. Crystallographic data for complexes 6, 10, 13A, 32, 33 and FY026.
6 10.0.5C2H6O 13A 32.CH4O 33.CH4O FY026
Formula C22H25F6IN3OOsP C24H30F6IN3O1.5OsP C25H23F6IN3OOs P C23H26ClF9N3O2OsP C23H26BrF9N3O2OsP C23H28F6IN4OsP
Molar mass /g mol-1 809.52 846.58 843.53 804.09 848.55 822.56
Density /mg m-3 2.138 2.021 2.137 1.963 2.040 2.077
Crystal system Monoclinic Monoclinic Monoclinic Orthorhombic Orthorhombic Monoclinic
Crystal dimensions
/mm
0.4 x 0.3 x 0.2 0.52 x 0.38 x 0.28 0.20 x 0.08 x 0.02 0.4 x 0.1 x 0.08 0.2 x 0.2 x 0.1 0.6 x 0.18 x 0.1
Space group P2(1)/c P2(1)/c P2(1)/c Pna2(1) Pna2(1) P2(1)/c
Crystal character Brown block Brown block Brown block Brown block Brown block Purple block
a/Å 12.45801(8) 10.6922(3) 18.2542(6) 7.85520(7) 7.99294(7) 14.0452(3)
b/Å 13.88211(9) 12.2890(4) 7.2404(2) 20.50602(14) 20.44259(15) 10.7594(3)
c/Å 14.54312(11) 21.1818(6) 21.4614(6) 16.88981(11) 16.91178(14) 17.5925(4)
α/deg 90 90 90 90 90 90
β/deg 91.2934(6) 90.775(3) 112.418(4) 90 90 98.405(2)
γ/deg 90 90 90 90 90 90
T/K 150(2) 150(2) 150(2) 150(2) 150(2) 150(2)
Z 4 4 4 4 4 4
R [F> 4σ(F)] 0.0279 0.0311 0.0383 0.0435 0.0286 0.0306
Rw 0.0680 0.0600 0.0915 0.1120 0.0677 0.0554
GOF 1.105 1.052 1.079 1.072 1.077 1.084
Δρ max and min /eÅ-3 1.16 & -1.24 0.98 & -1.37 2.383 & -2.804 1.81 & -1.22 1.76 & -1.70 1.38 & -1.37
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4.3.4. pKa of complex 31
Complex 31 exhibits a Br-AZPY-OH ligand and the hydroxyl substituent on its
phenyl ring that is capable of deprotonation (Scheme 4.7). Utilising UV-Vis
spectroscopy, the intensity of the absorption at 588 nm was measured at
various pH values (see Figure 4.5) and the data were fitted to the Henderson-
Hasselbalch equation (Figure 4.6). The pKa was determined as 6.41±0.02 and
the error was obtained as a computer fitting error using Origin 8.5. When pH =
pKa the colour of the complex was brown. Interestingly, at high pH the complex
was a deep blue colour and when adjusted to a low pH the complex was orange
with a major absorption peak at 446 nm. Under physiological conditions (pH
7.4), the complex was blue and will predominantly exist in a zwitterionic form.
Figure 4.5. UV-Vis spectra of complex 31 (100 µM) in water at different pH levels. Absorption
bands at 588 nm (high pH) and 446 nm (low pH) were observed.
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Scheme 4.7. Protonation and deprotonation of 31 under acid and basic conditions, respectively.
Figure 4.6. Variation of the absorbance at 588 nm for 31 with pH. The red line represents a
computer fit to the Henderson-Hasselbalch equation.
4.3.5. Extent of hydrolysis of complexes in aqueous media
4.3.5.1. 1H NMR spectroscopy
The extent of hydrolysis after 24 h was determined for all complexes in D2O
(5% DMSO-d6) at ambient temperature via 1H NMR. Figure 4.7 shows the 1H
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NMR spectrum of 8 straight after sample preparation (10-20 min) and 24 h later
as an example. A new set of peaks that correspond to the aqua/hydroxido-
adduct was visible after sample preparation and increases in intensity after 24
h. The red box highlights a region corresponding to p-cym CH3 groups (2x 3H
doublets) and their integrals were used to calculate the %hydrolysis.
Interestingly, when the experiment was repeated in the presence of 100 mM
NaCl, hydrolysis was significantly suppressed with only 7% hydrolysis occurring
after 24 h.
The extent of hydrolysis of analogous complexes 8, 9 and 10 (with chlorido,
bromido and iodido ligands, respectively) was 23%, 7% and 0% after 24 h.
Likewise, analogous complexes 17, 18, and 19 baring chlorido, bromido and
iodido ligands show 20%, 15% and 0% hydrolysis, respectively. In general, the
susceptibility of a complex towards hydrolysis follows the order Cl>Br>I. The
extent of hydrolysis of all the other complexes was measured in the same
manner (the majority of which are iodido complexes) and are as follows after 24
h: Complexes 6-13, 20, 21, 23, 24, 29-35 were stable, complexes 14, 15, 25
and 28 showed <2% hydrolysis, and complexes 22, 26 and 27 showed 10-15%
hydrolysis. It is worth noting that this crude measurement may not give results
that are comparable with one another as the concentrations used in the
experiment were not fixed and resemble saturated solutions in D2O. Some
complexes have very poor solubility in D2O which may lead to greater extents of
hydrolysis. The pH of the solutions were not measured or controlled with a
buffer.
Figure 4.7.
immediately after sample preparation and 24 h later. (C) Expansion of the
showing the
showing the suppression of hydrolysis. Spectra were colle
(A)
(B)
(C)
(A) Reaction scheme for the hydrolysis of
p-cym CH3 groups. (D) The same expansion but in the presence of 100 mM NaCl,
8
cted on a 500 MHz instrument.
(D)
in D2O. (B) 1H NMR spectrum of
1H NMR spectrum
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4.3.5.2. HPLC
The extent of hydrolysis of 8, 9 and 10 was also determined by HPLC at a fixed
concentration (100 µM) after 0, 2, 12 and 24 h incubation at 37 °C. They were
solubilised in phosphate buffer (95 mol. equiv., pH 7.4) with 5% DMSO and
different concentrations of NaCl; 23 mM (intracellular conditions) and 103 mM
(extracellular conditions). The chromatograms are shown in Figure 4.8. Chlorido
and bromido complexes (8 and 9) show significant levels of hydrolysis after 24 h
incubation in 23 mM NaCl, with 85% and 84% of the aqua/hydroxido species
(10-OH) present, respectively. Incubation in 103 mM NaCl partially suppresses
the hydrolysis of 8 and 9 with 61% and 58% occurring, respectively. For the
bromido complex (9), formation of the chlorido species (8) was also observed in
the presence of NaCl, occurring at 8% and 27%, respectively for 23 mM and
103 mM NaCl. In contrast, the iodido complex (10) is much more resilient
towards hydrolysis, showing only 7% and 4% hydrolysis after 24 h incubation in
the presence of 23 mM and 103 mM NaCl, respectively. Formation of the
chlorido species (8) was also observed in small amounts when 10 was
incubated for 24 h (1% and 2% was observed for 23 mM and 103 mM NaCl,
respectively).
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Figure 4.8. HPLC traces for complexes 8, 9 and 10 (100 µM) after incubation in phosphate buffer solution (pH 7.4) and different concentrations of NaCl, for 0, 2, 12
and 24 h at 37 °C. (A) 8 in 23 mM NaCl. (B) 9 in 23 mM NaCl. (C) 10 in 23 mM NaCl. (D) 8 in 103 mM NaCl. (E) 9 in 103 mM NaCl. (F) 10 in 103 mM NaCl. Details
of the HPLC conditions are shown in Chapter 2, Section 2.2.9.
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4.3.6. Solubility of complexes in aqueous media
The thermodynamic solubility of complexes 6-28 at ambient temperature was
determined in 100 mM NaCl, resembling physiological extracellular conditions.
This series of complexes consists of those with RO-AZPY ligands containing
alkoxy and glycol side chains. Thermodynamic solubility requires an equilibrium
to be reached, whereby a maximum quantity of a substance is completely
dissolved at a given pressure and temperature and is thermodynamically valid
as long as a solid phase exists in equilibrium with the solution phase.17,26,27 The
trends in solubility are shown in Figures 4.9- 4.11.
Figure 4.9. Trends in solubility for complexes 17-19 and 8-10 in 100 mM NaCl.
In Figure 4.9, the solubility trends between 17-19 and 8-10 show that chlorido
and bromido complexes are considerably more soluble than their iodido
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analogues. The observed trend follows Cl>Br>I where chlorido complexes are
the most soluble with the exception of 8, which has around the same solubility
as bromido complex 9. Furthermore, the addition of a terminal OH group at the
end of the ethoxy substituent leads to a 14-fold, 5-fold and 8-fold increase in
solubility for the chlorido, bromido and iodido complexes respectively.
Figure 4.10. Trends in solubility for complexes 6, 7 and 10-16 in 100 mM NaCl.
Figure 4.10 shows the solubility trends for complexes bearing alkoxy side-
chains. The trends between 6 and 7, and 10-12 highlight that solubility can be
vastly improved by changing the counter anion from PF6- to either CF3SO3- or
IO3-, with the trend following the order IO3->CF3SO3->PF6-. Most notably,
changing the PF6- anion in 6 to CF3SO3- leads to 45-fold increase in solubility.
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The trend between 11 and 13 shows that changing the arene from p-cym to bip
leads to a 7-fold decrease in solubility. The solubility trend between 6, 10, and
14-16, where the R-substituent is varied follows a more complicated order:
iPr>Et>nPr>Me>nBu.
Figure 4.11. Trends in solubility for complexes 19-28 in 100 mM NaCl.
Figure 4.11 shows the solubility trends for complexes with glycolic side-chains.
The trend between 19, 21, 25 and 28 shows how glycol chain length impacts on
solubility when R= H. The poorest solubility was observed for 19, bearing the
monoethylene glycol substituent, and a notable solubility increase was
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observed when the chain length was varied in the order n= 2>3>4>1. Changing
the terminal R-substituent has an even greater impact on solubility as shown by
21-23 and 25-27, and follows the order H>>Me>Et. Furthermore, 20 and 24
show that changing the arene from p-cym to bip leads to a decrease in
solubility, despite containing a more solubilising counter anion.
The samples were further analysed by HPLC to determine whether they
remained stable in solution after the 24 h solubilisation process. The vast
majority of complexes remained >95% intact. However some complexes,
particularly those with very low aqueous solubility were less stable. Samples of
6, 14, 16 and 20 remained 88%, 95%, 85% and 91% intact, respectively after
solubilisation. There is potential for complexes to form aqua/hydroxido- species,
and chlorido-species in small amounts due to the presence of NaCl.
4.3.7. Anti-proliferative activity
The IC50 values of all the complexes were measured against A2780 cells by Dr.
Isolda Romero-Canelón using the protocol outlined in Chapter 2, Section 2.3.2.
The IC50 values of 8-10, 17-19 and 35 are shown in Figure 4.12. The trend
shows that placement of a terminal OH group at the end of the ethoxy
substituent is deactivating towards anti-cancer activity. Furthermore, complexes
with monodentate iodide ligands are considerably more active than their
chloride and bromide counter-parts. The pseudo-halide, N3, also provides
improved reactivity. The observed trend follows I>N3>>Br≥Cl. 
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Figure 4.12. Trends in IC50 values against A2780 cells for complexes 8-10, 17-19 and 35.
In Figure 4.13, the trend between 10-12 shows that changing the anion has no
impact on anti-cancer activity with the exception of 12 (IO3- counter-ion), which
is slightly less active than the others. The trend between 11 and 13 shows that
changing the arene from p-cym to bip increases activity. Furthermore, the trend
between 7, 10, 14, 15 and 16 where the R-substituent is varied follows the order
iPr>nPr>Me>Et>nBu.
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Figure 4.13. Trends in IC50 values against A2780 cells for complexes 7, 10-13 and 14-16.
In Figure 4.14, the trend between 19 and 20 (where R= H and n= 1) shows that
changing the arene from p-cym to bip results in a large increase in anti-cancer
activity. In contrast, the trend between complex 23 and 24 (R= H and n= 2)
shows that the same change actually leads to a small decrease in activity.
Changing the terminal group at the end of the glycol side chain from H to either
Me or Et leads to an increase in activity, as seen by the trends in 21-23 and 25-
27. Furthermore, the differences in activity between 19, 21, 25 and 28 where
the glycol chain length is varied (R= H) does not follow an obvious trend: n=
2>4>3>1. When R= Me or Et, increasing the glycol chain length from n= 2 to n=
3 produces a decrease in activity.
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Figure 4.14. Trends in IC50 values against A2780 cells for complexes 19-28.
The anti-cancer activity trends between 29-33 are shown in Figure 4.15. These
complexes exhibit R-AZPY-OH ligands. It is shown again that iodido complexes
are the most active complexes and the activity trend follows I>Br>Cl.
Furthermore, greater activity is observed when the R-substituent is CF3 over
analogous complexes containing a Br substituent.
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Figure 4.15. Trends in IC50 values against A2780 cells for complexes 29-33.
Table 4.4 shows the IC50 values of key complexes in various cancer cell lines:
A2780 ovarian cancer, MCF-7 breast cancer, SUNE1 nasopharyngeal cancer,
OP19 oesophageal cancer, and normal cell line: MRC-5 lung fibroblast cells.
Their selectivity factors (SFs) have been calculated for IC50-MRC-5/IC50-A2780.
With the exception of complex 23, all complexes that were tested against
SUNE1 cells show very potent sub micro-molar activity. Complexes 10, 13 and
23 exhibit exceptionally potent activity against OE19 cells. Particularly 13 which
has an IC50 value of 96 nM. Complex 15 exhibits the best activity against A2780
cells (the most widely used cell line in the Sadler group), and 13 exhibits the
best anti-cancer profile amongst all the tested cell lines, and has the highest SF.
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In contrast, 31, which exhibits potent activity against A2780 cells has very poor
selectivity towards A2780 cancer cells over MRC-5 normal cells.
Table 4.4. The IC50 values of key complexes 10, 13, 15, 22, 23 and 31, against various cancer
cell lines and normal MRC-5 cells. Selectivity factors are calculated as a ratio of IC50-MRC-
5/IC50-A2780. IC50 values are shown in µM.
A2780 MCF-7 SUNE1 OE19 MRC-5
Selectivity
Factor
10 0.92(±0.02) 1.2(±0.2) 0.86(±0.06) 0.20(±0.03) 2.2(±0.2) 2.4
13 0.51(±0.02) n.d. 0.31(±0.02) 0.096(±0.004) 6.1(±0.1) 12.0
15 0.30(±0.09) n.d. n.d. n.d. 1.99(±0.07) 6.6
22 1.80(±0.09) n.d. n.d. n.d. 7.4(±0.8) 4.1
23 0.68(±0.03) n.d. 1.7(±0.1) 0.42(±0.01) 3.6(±0.3) 5.3
31 0.54(±0.02) n.d. n.d. n.d. 0.62(±0.01) 1.1
4.3.8. Cellular accumulation
The cellular accumulation of complexes into A2780 cells was measured using
the protocol outlined in Chapter 2, Section 2.3.4 by Dr.Isolda Romero-Canelón,
and the amount of accumulated ng of Os /106 cells was determined using ICP-
MS. Figure 4.16 shows the cell uptake for complexes 7-11, 13, 14 and 17-19.
The trend between 8-10 and 17-19 shows that iodido complexes have greater
cellular uptake than their chlorido and bromido analogues, and it follows the
same order as anti-cancer activity (I>Br>Cl). It also shows that the presence of
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a terminal OH group leads to lowered cell uptake, likely owing to lowered
lipophilicity. The trends between 10, 11 and 13 shows that the anion has no
impact on cell uptake (similarly to anti-cancer activity), and switching the arene
from p-cym to bip leads to an unexpected decrease in cell uptake. When the R-
substituent is varied there is no obvious trend and cell uptake follows the order
Et>nPr>Me, as observed between 7, 10, 11 and 14.
Figure 4.16. Trends in cellular accumulation for complexes 7-11, 13, 14 and 17-19.
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The capacity factor (K) was determined for complexes 7-11 and 13-28 using an
isocratic HPLC method at 25 °C. The mobile phase was H2O:MeCN (1:1, v/v)
with 50 mM NaCl, and the stationary was a reverse-phase C18 column (250 x
4.6 mm column with a pore size of 5 µm). The capacity factor provides a
measure of affinity towards the stationary phase, hence provides a measure of
the relative lipophilicity of a complex. The greater the retention time (hence K),
the greater the lipophilicity of the complex. The trends in K are shown in Figures
4.17- 4.19.
Figure 4.17. Trends in capacity factor for complexes 17-19 and 8-10.
The capacity factors of 17-19 and 8-10 shown in Figure 4.17 show the opposite
trend to their water solubility. Generally, K is larger for iodido complexes than
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their chlorido and bromido analogues. The order follows I>Br>Cl, where iodido
complexes are the most lipophilic and chlorido complexes are the least.
Likewise, lower K-values were observed for complexes with a terminal OH
group at the end of the ethoxy substituent, indicating they are less lipophilic.
Figure 4.18 shows the trends in K for complexes with alkoxy side-chains. The
trend between 10 and 11 shows that varying the counter anion has little effect
on lipophilicity, and the trend between 11 and 13 shows that changing the arene
from p-cym to bip reduces lipophilicity. Moreover, the trend between 7, 10, and
14-16, where only the R-substituent is varied follows the order
nBu>nPr>iPr>Et>Me. Lipophilicity increases with alkyl chain length of the
substituent.
Figure 4.18. Trends in capacity factor for complexes 7 and 10-16.
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Figure 4.19 shows the trends in K for complexes bearing glycolic side-chains.
The trend between 19, 21, 25 and 28, where R= H shows that increasing the
glycol side-chain length does not have much impact on lipophilicity. When R=
Me or Et, increasing the glycol side-chain length slightly decreases the
lipophilicity of the complex, as shown by the trends between 22, 26, 23 and 27.
Changing the arene from p-cym to bip reduces the lipophilicity by a small
increment, which is shown by 19, 20, 23 and 24. Moreover, the clearest trend is
the effect of changing the terminal substituent, R. There are notable increases
in lipophilicity associated with varying R, occurring in the following order
H>Me>Et.
Figure 4.19. Trends in capacity factor for complexes 19-28.
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4.3.10. Octanol/water partition coefficients
The octanol/water partition coefficient (Po/w) of complexes were measured in
triplicate using a modified version of the shake-flask method,21,28 described in
Chapter 2, Section 2.3.3. The octanol-saturated water contained 300 mM of
NaX, where X = Cl, Br or I and was used to suppress the hydrolysis of chlorido,
bromido and iodido complexes, respectively. Due to the time consuming nature
of this method, Log Po/w was only determined for complexes 9, 17, 19, 20, 22,
23 and 25. It was not possible to measure the Log Po/w of complexes with very
poor aqueous solubility using the shake-flask method, due to Os concentrations
being below the limit of ICP-MS detection after partitioning.
A HPLC method for determining Log PHPLC was adopted.23 Using the K-values
determined previously, a calibration curve was produced by plotting Log Po/w vs.
Log K for complexes 9, 17, 19, 20, 22, 23 and 25 (see Figure 4.20). The linear
equation of the plot is: y = 2.4(±0.6)x + 1.2(±0.2). Using the measured K-values
of the complexes and the calibration curve, their Log PHPLC values were
determined. However, due to a relatively weak correlation in the calibration
curve (correlation coefficient = 0.743), the Log PHPLC values have large errors
ranging from ±0.2 to ±0.8, and could only be determined to one decimal place
(see Table 4.4). Furthermore, the Log K values of complexes 10, 11 and 14-16
fall outside the calibration range of the plot and their Log PHPLC values were
estimated by extrapolating the calibration curve.
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Table 4.4. List of Log K values of complexes 7-11 and 13-28, their determined Log PHPLC
values, and the Log Po/w values of 9, 17, 19, 20, 22, 23 and 25, which were measured using the
shake-flask method.
Complex Log (K) Log (Po/w) Log (PHPLC)
7 0.42(±0.02) 2.1(±0.5)
8 0.29(±0.01) 1.8(±0.4)
9 0.42(±0.01) 1.59(±0.03) 2.1(±0.5)
10* 0.58(±0.01) 2.5(±0.6)
11* 0.60(±0.01) 2.6(±0.6)
13 0.56(±0.01) 2.5(±0.6)
14* 0.779(±0.009) 3.0(±0.7)
15* 0.733(±0.008) 2.9(±0.7)
16* 0.972(±0.007) 3.5(±0.8)
17 -0.25(±0.02) 0.11(±0.02) 0.6(±0.4)
18 -0.13(±0.02) 0.8(±0.3)
19 0.02(±0.02) 1.87(±0.05) 1.2(±0.2)
20 0.00(±0.03) 1.10(±0.04) 1.1(±0.2)
21 0.038(±0.009) 1.2(±0.2)
22 0.420(±0.005) 2.29(±0.04) 2.1(±0.5)
23 0.574(±0.007) 2.6(±0.2) 2.5(±0.6)
24 0.548(±0.007) 2.4(±0.5)
25 0.044(±0.007) 1.41(±0.04) 1.3(±0.2)
26 0.402(±0.006) 2.1(±0.5)
27 0.555(±0.006) 2.5(±0.6)
28 0.045(±0.007) 1.3(±0.2)
*Complexes Log (K) value is outside the calibration range
Chapter 4
195
Figure 4.20. Plot of Log (Po/w) vs. Log (K) for complexes 9, 17, 19, 20, 22, 23 and 25.
4.3.11. Separation of structural isomers 34A and 34B
The synthesis of 34 with pseudo-halide monodentate ligand, SCN-, led to the
formation of two structural isomers; S-bound SCN- ([Os(η6-p-cym)(5-EtO-
AZPY)(S-SCN)]PF6, 34A) and N-bound SCN- ([Os(η6-p-cym)(5-EtO-AZPY)(N-
SCN)]PF6, 34B), see Figure 4.21. HPLC analysis of the product showed two
peaks in the chromatogram, corresponding to the two isomers with retention
times of 20.42 and 22.52 min (88.5% and 14.0%, respectively, see Figure 4.22).
Although no further analysis was carried out to characterise the isomers, it is
believed that the more hydrophilic peak (a) is the S-bound isomer. Sulfur has
preferential binding to osmium over nitrogen according to the Pearson acid-
base concept and peak (a) is the major peak. Furthermore, the S-bound isomer
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(which has the shorter retention time) has a H-bond acceptor group (-C≡N) 
pointing out into the solvent matrix (H2O/MeCN), which is likely to make it the
more hydrophilic of the two isomers, hence a shorter retention time.
Figure 4.21. Two structural isomers of complex 34. (A) with a S-bound SCN ligand (34A), and
(B) with a N-bound SCN ligand (34B).
Figure 4.22. HPLC chromatogram of 34 with two structural isomers (a) 88.5% and (b) 14.0%,
with retention times of 20.42 and 22.52 min, respectively. Details of the HPLC conditions are
shown in Chapter 2, Section 2.2.9.
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The isomers were separated and isolated by preparative HPLC and their
stabilities were tested in PBS solution over 24 h at 37 °C to determine whether
the isomers were inter-convertible. After incubation the samples were analysed
by HPLC. The chromatograms show that isomer (a) was the most stable with
98.7% purity after incubation. Isomer (b) on the other hand was only 84.4%
pure after incubation. No inter-conversion between isomers was observed (see
Figure 4.23).
Figure 4.23. Chromatograms showing the purity of isomers (a) and (b) after 24 h incubation in
PBS at 37 °C. (A) isomer (a), and (B) isomer (b). Details of the HPLC conditions are shown in
Chapter 2, Section 2.2.9.
The anti-proliferative activity of isomers (a) and (b) against A2780 cells was
measured. Interestingly, the structural arrangement of the SCN- ligand leads to
complexes with different anti-cancer activities. Isomer (b) was the most active
species, with an IC50 value between 25-50 µM, whereas isomer (a) was inactive
(IC50>50µM), see Figure 4.24.
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Figure 4.24. Cell viability studies of the structural isomers of complex 34, (a) and (b), against
A2780 cancer cells. The %cell survival was determined at different concentrations of the
isomers.
4.3.12. Cyclic voltammetry of 10
Cyclic voltammetry analysis was carried out by Dr. Nicolas P. E. Barry for key
active iodido complex 10. A 1 mg/mL solution of the complex in MeCN with
tetrabutylammonium hexafluorophosphate (0.1 M) as a supporting electrolyte
was prepared. The sample was scanned between -2.0 V to +2.0 V in both
directions. The cyclic voltammogram (CV) contains two reduction potentials at -
0.26 and -0.81 V, one of which (-0.26 V) falls within the biologically relevant
region (see Figure 4.25).29 These were assigned to reduction of the azo-bond,
which can accept two electrons into its π*-orbital. 
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Figure 4.25. Cyclic voltammogram of 10 (1 mg/mL) in MeCN with 0.1 M tetrabutylammonium
hexafluorophosphate. The red line represents the first segment where the voltage was scanned
from +2.0 to -2.0 V. The blue line represents the second segment where the voltage was
scanned back to +2.0 V. Identified are two reduction potentials at -0.26 and -0.81 V.
4.3.13. Cell cycle analysis
Changes in the cell cycle phase distribution of A2780 cells after incubation with
complexes 10, 13, 15, 19, 23 and 31 at 37 °C for 24 h, were monitored using
flow cytometry (see Chapter 2, Section 2.3.5). This work was undertaken by Dr.
Isolda Romero-Canelón. The histograms for the control experiment (no complex
added), and complex 10 at three different concentrations (1x, 2x and 3x IC50)
are shown in Figure 4.26. Cells that are in the G1-phase contain two sets of
DNA (2N). Those in the G2/M-phase contain four sets (4N), and any cells
inbetween are in the process of DNA replication (S-phase). The experiment
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Figure 4.27. Cell cycle distributions of A2780 cells after 24 h incubation at 37 °C with
complexes 10, 13, 15, 19, 23 and 31, at 1x and 2x IC50.
Figure 4.27 shows quantitatively the cell cycle distributions of A2780 cells after
24 h incubation with 10, 13, 15, 19, 23 and 31 at 1x and 2x IC50. Complex 19
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caused a slight elevation in the G1-phase population at 1x IC50, and doubling
the concentration led to an increase in the proportion sub-diploid cells, which
came primarily from the G1-phase. Complexes 13, 15, 23 and 31 all caused a
small increase in the population of cells in the G2/M-phase at both 1x and 2x
IC50.
4.3.14. Apoptotic behaviour
Complexes 10, 13, 19 and 31 were tested for their ability to induce apoptosis in
A2780 cells after 24 h incubation at 37 °C using flow cytometry, by Dr.Isolda
Romero-Canelón (see Chapter 2, Section 2.3.7). Apoptosis is a highly regulated
process of programmed cell death which is triggered when cells become
damaged or unhealthy. The early stages of apoptosis involve cell shrinkage and
blebbing of the cell membrane. Later stages involve breakdown of the cellular
components/DNA content and the formation of smaller apoptotic bodies, which
are removed from the body by macrophages (see Figure 4.28). The histograms
for the control experiment (no complex added), and complex 10 at three
different concentrations (1x, 2x and 3x IC50) are shown in Figure 4.28.
Increasing the concentration of 10 led to an increase in the population of cells in
Q2 (late stage apoptosis) and an even larger increase in the population of cells
in Q1 (non-viable cells). Figure 4.29 shows quantitatively the induction of
apoptosis caused after 24 h incubation with 10, 13, 19, and 31, at 1x and 2x
IC50. At 2x IC50, complexes raise the proportion of cells in late-stage apoptosis
in the order 31>10>19>13, with populations of 27.2%, 22.5%, 5.7% and 2.8%,
respectively. However, the proportion of non
40.9%, 17.6% and 5.8%, respectively.
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Figure 4.29. Proportions of healthy (Q4), early-apoptotic (Q3), late-apoptotic (Q2), and non-
viable (Q4) A2780 cells after 24 h incubation at 37 °C with complexes 10, 13, 19, and 31, at 1x
and 2x IC50.
4.3.15. Induction of ROS
Complexes 7, 10, 13, 15, 23 and 31 were tested for their ability to elevate ROS
levels in A2780 cells after 24 h incubation at 37 °C, by Dr. Isolda Romero-
Canelón using flow cytometry (see Chapter 2, Section 2.3.6). The protocol
utilises a total ROS/Superoxide detection kit capable of distinguishing O2·- from
other ROS.
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Figure 4.31. Proportions of A2780 cells that are healthy (Q4), with elevated ROS levels (Q3),
with elevated ROS and O2·- levels (Q2), and with elevated O2·- levels (Q4) after 24 h incubation
at 37 °C with complexes 10, 13, 19, and 31, at 1x and 2x IC50 concentrations.
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4.4. Discussion
4.4.1. Anti-proliferative activity and selectivity factors
A total of 31 new Os(II) arene AZPY complexes were synthesised using the
previously determined SARs as a guideline13,15 (Chapter 1, Section 1.3.4.3). Of
which, 9 complexes exhibited potent sub micro-molar activity against A2780
cells, and 6 key complexes were selected for testing against other cancer cell
lines (MCF-7, SUNE1, OE19) and a normal cell line (MRC-5). Complex 13,
[Os(ɳ6-bip)(5-EtO-AZPY)I]CF3SO3, exhibits the best activity profile with
extremely potent activity against the OE19 cell line (96±4 nM) and the highest
SF (IC50-MRC-5/IC50-A2780 = 12.0), which is comparable to that of cis-platin.29
However, none of the complexes herein exhibit activity against A2780 cells
greater than FY026, which also has a SF of 28.4.13,29 It might be possible to
improve on selectivity by synergistic treatment with L-BSO. This works by
lowering levels of the cells primary antioxidant (GSH), hence inhibiting the
normal cellular detoxification of ROS. Furthermore, a method for improving
cancer cell selectivity is outlined in Chapter 7, Section 7.7, where
pharmacophoric groups are introduced which target specific proteins associated
with cancerous cells.
According to the previously understood SARs,15 complex 31, [Os(ɳ6-p-cym)(5-
Br-AZPY-OH)I]PF6 was expected to have improved anti-cancer potency.
However, it is not as potent as FY026 and its selectivity is very poor (IC50-MRC-
5/IC50-A2780 = 1.1). Gaining better insight into the activity profiles the
complexes requires more extensive screening against a larger variety of cell
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lines, including platinum resistant lines (particularly A2780cis) to determine if
they overcome cis-platin resistance. They could also be tested further against a
variety of normal cell lines to gain a better understanding of their selectivity.
Despite its low SF, 31 is a highly novel complex with a colour dependence on
pH. Under basic conditions the OH group is deprotonated giving rise to a deep
blue colour, whereas acidic conditions gives rise to an orange colouration. The
MLCT band (Os 5d6→π*) of 31 shifts from 446 to 588 nm when the pH was
raised from 1.96 to 12.76. Likewise, Dougan et al found a similar occurrence for
chlorido Ru(II) arene AZPY-OH complexes.30 Deprotonation of the hydroxyl
substituent on the AZPY ligand (OH to O-) decreases the π-acidity of the azo-
bond, which in turn causes an increase in the energy of the Os(II) 5d6 orbitals.
This results in a smaller energy gap for MLCT (Os 5d6→π*, where π* is the 
anti-bonding orbital of the azo-bond in the AZPY ligand). The pKa of the OH
substituent was measured as 6.41 and under physiological conditions (pH 7.4) it
was blue, therefore predominantly existing in a deprotonated zwitterionic state.
It is believed that the negative charge is delocalised on the AZPY ligand,
whereas its positive charge is centred around Os(II).
4.4.2. Trends in anti-cancer activity, solubility and lipophilicity
Figure 4.32 highlights the general trends in anti-cancer activity against A2780
cells, aqueous solubility in 100 mM NaCl, and capacity factor (K) for two classes
of complex: (A) those with alkoxy substituents (6-16 and 35), and (B) those with
glycolic substituents (17-28).
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Figure 4.32. Trends in anti-cancer activity against A2780 cells, solubility in aqueous 100 mM NaCl solution, and capacity factor (relative lipophilicity) for:
(A) complexes with alkoxy side-chain substituents (6-16 and 35), and (B) complexes with glycolic side-chain substituents (17-28).
X: I > N3 >> Br > Cl
Y (R = Et): PF6- ≈ CF3SO3- ≥ IO3-
Ar: bip > p-cym
R: iPr ≈ nPr > Me > Et >> nBu
Trend in anti-cancer
activity
X: Br ≈ Cl > I
Y (R = Et): IO3- > CF3SO3- > PF6-
Ar: p-cym > bip
R (Y = PF6-): iPr > Et > nPr > Me > nBu
Trend in aqueous
solubility
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The findings herein re-confirm that iodido Os(II) arene AZPY complexes are
considerably more active than their chlorido and bromido analogues. In contrast
to previous chlorido Os(II) arene AZPY complexes synthesised by Ying et al
which were stable,13 8 (and bromido analogue 9) both readily hydrolyse when
incubated at 37 °C in phosphate buffer solution with 23 and 103 mM NaCl. The
iodido analogue, 10, was stable towards hydrolysis under the same conditions.
The stability of iodido complexes may account for their improved activity as they
are less likely deactivated by side reactions in extracellular conditions.
Furthermore, iodido complexes are more lipophilic than their chlorido and
bromido counter-parts, likely owing to a lesser polarised Os-I bond, which is
more covalent in character than Os-Cl and Os-Br bonds. Likewise, chlorido and
bromido complexes were considerably more water soluble, likely owing to a
more polarised Os-X bond.
Analogous iodido complexes, 10-12, share the same AZPY ligand (L2), but
contain different counter anions (PF6-, CF3SO3- and IO3-, respectively). The
trends show that varying the anion makes little difference to anti-cancer activity.
This is expected because they are interchangeable with other anions in
electrolytic solutions (e.g. cell culture medium containing 150 mM NaCl), and
they exhibit no structural anti-cancer properties independently. Likewise, there
is no difference in capacity factor between 10 and 11 because the anion is
exchangeable with Cl- in the mobile phase and the cationic fragments are
identical. Varying the anion does however have a huge impact on water
solubility without stifling activity, lipophilicity or cell uptake. Generally,
complexes containing PF6- anions have poorer solubility but are easier to
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crystallise during their synthesis. Changing the anion to IO3- or CF3SO3-
increases aqueous solubility by lowering the crystal lattice energy in their solid
states. This is the first time an extensive study into the aqueous solubility of
complexes has been explored in the Sadler group. To the best of my
knowledge, it is also the first time variation of the anion has been explored in
any depth for cationic anti-cancer complexes.
Changing the arene from p-cym to bip in most cases results in a sharp increase
in anti-cancer activity. It was previously speculated that complexes containing
bip arene ligands were more lipophilic, hence exhibit improved cell uptake
resulting in higher activity. However, the observed trends in K show that bip
complexes are no more lipophilic than their p-cym analogues, and in some
cases are slightly less lipophilic. Furthermore, the trend between 11 and 13
shows a decrease in cell uptake when p-cym is exchanged for bip. Perhaps the
improvement in activity can be explained by factors other than lipophilicity, such
as the potential for extended arenes to intercalate with DNA nucleobases.15
Complexes containing bip are also significantly less soluble than their p-cym
analogues. This may also be explained by increased crystal packing energies
due to the greater likely hood of π-π and/or CH-π interactions between aromatic 
groups in the solid state.16,31
For complexes with alkoxy side-chain substituents (Figure 4.32, A), the
differences in anti-cancer activity observed when the R-substituent is varied
follows a complicated trend that is not understood at this point. The trend in K,
however, follows a predictable trend where increasing the alkyl chain length of
R increases the lipophilicity. Likewise, solubility follows a general trend where
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increasing the alkyl chain length leads to decreases in solubility, which is likely
dictated by hydrophobicity (Et>nPr>nBu). However, 6 (R= Me) and 15 (R= iPr)
were exceptions to the trend. Complex 15 was the most soluble, likely owing to
the use of a branched alkyl group that destabilises crystal packing in the solid
state. Disrupting planarity/symmetry via the introduction of bulky substituents is
a known effective method for increasing the solubility of drug candidates.16
Complex 6 has much poorer solubility than anticipated and might be due to high
crystal lattice energy. The solubility of 6 was so poor that it was not possible to
determine its activity against A2780 cells. However, changing the anion to
CF3SO3- (7) created a 45-fold increase in solubility. The crystal packing
energies of complexes could be further investigated by a comparison of their
melting points.16
Complexes with glycolic side-chain substituents (Figure 4.32, B) have various
chain lengths (n) and a variety of terminal of groups (R= H, Me or Et). When R=
H, there was very little difference in K when the glycol chain length is varied.
Solubility follows the trend n= 2>3>4>1 and anti-cancer activity follows the trend
n= 2>4>3>1. These trends are not explainable at this point. Complex 21 (n = 2)
has the best attributes for this series with the highest solubility and anti-cancer
activity observed. When the terminal group, R, is replaced with a more lipophilic
group (Me or Et), as expected K increases, and the solubility decreases
dramatically due to increased hydrophobicity. The anti-cancer activity also
increases, which is likely due to higher lipophilicity resulting in greater cell
uptake. Interestingly, when R= Me or Et, increasing the glycol chain length from
n= 2 to n= 3 led to a slight decrease in K, which is perhaps a result of increasing
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the number of H-bond acceptor groups in the complex. This also led to a
decrease in anti-cancer activity, which is also likely a consequence of lower
lipophilicity.
4.4.3. Cell uptake and lipophilicity
Unfortunately, not all of the complexes in the series containing alkoxy/glycolic
side-chains were tested for cell uptake in A2780 cells. However, the trends that
are currently known are shown in Figure 4.33.
Figure 4.33. Trends in cellular accumulation in A2780 cells for: (A) complexes with alkoxy side-
chain substituents, and (B) complexes with a monoethylene glycol side-chain substituent.
The trends show that iodido complexes have considerably better uptake than
their chlorido and bromido counter-parts. This is likely related to the higher
X: I > Br > Cl
Y (R = Et): PF6- ≈ CF3SO3-
Ar: p-cym > bip
R: Et >> nPr > Me
X: I >> Cl > Br
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lipophilicity of iodido complexes involving passive cell uptake. Interestingly,
ruthenium complex, [Ru(ɳ6-p-cym)(IMPY-NMe2)I]+ (where IMPY is a
phenyliminopyridine ligand, analogous to AZPY), was found to accumulate into
A2780 cells via passive transport, whereas its chlorido analogue entered cells
primarily through active transport.32 Changing the anion had no effect on cell
uptake, which as explained previously in Section 4.4.1, is due to the irrelevance
of the counter anion once a complex is dissolved in cell culture media. Also
previously explained in Section 4.4.1, when the p-cym ligand of complex 11
changed with bip, cell uptake is reduced and could be the result of lower
lipophilicity that was observed for bip complexes. For complexes with alkoxy
side-chains (Figure 4.33, A), when the R-substituent is varied, cell uptake
follows the order Et>>nPr>Me. It is not currently understood why the most
lipophilic complex in this series (14, R= nPr) is taken up into cells to a
considerably lesser extent than analogous complex 10 (R= Et). Cell uptake was
plotted against K for complexes 7-11, 13, 14 and 17-19 and a reasonably good
correlation was found between the two properties (correlation coefficient =
0.78), thus indicating a general overall linear trend between lipophilicity and cell
uptake (see Figure 4.34). However, 14 was treated as an outlier and does not fit
the trend. A possible explanation for its low cell uptake could be a strong affinity
towards binding to proteins in cell culture medium.
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Figure 4.34. Plot of cell uptake vs. capacity factor (K) for complexes 7-11, 13, 14 and 17-19.
Similarly, a previous study in the Sadler group utilised a non-isocratic reverse-
phase HPLC method to determine the relative lipophilicities of chlorido Ir(III) Cp*
complexes with 2-PhPy bidentate ligands.33 Complexes contained either an
electron withdrawing (F or NO2) or electron donating (OH or Me) substituent at
various different positions on the 2-PhPy ligand. A correlation analysis showed
that an increase in complex lipophilicity results in an increase in cellular Ir-
accumulation, which generally results in improved anti-cancer potency. It was
found that the nature and positioning of the substituent dictates the overall
lipophilicity of the complex, and lipophilicity is an important design feature for
complexes that accumulate inside cancer cells in part by passive diffusion.
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4.4.4. Log PHPLC
Figure 4.35. Plot of Log (K/Po/w) vs. Log (Po/w) for complexes 9, 17, 19, 20, 22, 23 and 25.
In Section 4.3.10, the HPLC method used to determine the Log PHPLC values for
complexes proved to have low accuracy and large error margins were obtained.
The calibration plot between Log Po/w and Log K does not have a strong enough
correlation for these purposes. All of the determined Log PHPLC values for the
complexes fall well within the acceptable Ro5 range (-0.4 to 5.6).19 Following an
approach outlined by Sahu et al, Log Po/w was plotted on the x-axis as a
reference indicator against the expression Log (K/Po/w),23 see Figure 4.35. This
method determines if factors other than the lipophilicity contribute towards
partitioning, e.g. chemical interactions with the solvents or hydrolysis. The graph
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shows good correlation between Log (K/Po/w) and Log Po/w (correlation
coefficient = 0.935), indicating that the partitioning of complexes is mainly
determined by their lipophilicity.
4.4.5. Pseudo-halide complexes
Metal based anti-cancer complexes containing thiocyanate monodentate
ligands have been explored previously within other research groups. Human et
al reported on dimeric Ag(I) thiocyanate complexes, [Ag(μ2-SCN)(P{Ar}3)2]2
(where Ar = Ph, 4-MeC6H4, 4-FC6H4 or 4-ClC6H4), that are capable of inducing
apoptosis in SNO-esophageal cancer cells.34 Furthermore, Shi et al have
reported a Cu(II) anti-cancer complex, Cu(Bipy)(N-NCS)2, where interestingly,
the IC50 against OVCAR-3 ovarian cancer cells depended strongly on the
recovery time after drug exposure.35 Thiocyanato complexes of Ru(II) and Os(II)
arenes have been relatively under explored within the Sadler group apart from
one example.36 The complex [Ru(ɳ6-hmb)(en)Cl]+ was found to undergo
aquation to [Ru(ɳ6-hmb)(en)H2O]2+, which then reacted with KSCN to form the
kinetically favoured product S-bound product, [Ru(ɳ6-hmb)(en)S-SCN]+. This
undergoes slow conversion in solution to the thermodynamically favoured N-
bound product, [Ru(ɳ6-hmb)(en)N-SCN]+, which exhibited moderate cytotoxicity
towards A2780 cells (IC50 = 24 µM). Despite not being susceptible to hydrolysis,
it was found to bind favourably to guanine bases in GMP.
In contrast, the chlorido complex complex 8, [Os(ɳ6-p-cym)(5-EtO-AZPY)Cl]+
was heated with 500 mol. equiv. of KSCN in MeOH/H2O (1:1, v/v) under reflux
Chapter 4
218
for 18 h and a mixture of S-bound (34A) and N-bound (34B) isomers were
formed (88.5 and 14.0% respectively). Further heating did not change the ratios
of products. After separating the isomers by HPLC, incubating them at 37 °C for
24 h under physiological conditions did not cause them to hydrolyse and no
interconversion between isomers was observed. The S-bound complex is
kinetically favoured, but it appears that both isomers are thermodynamically
stable with tight binding of the monodentate ligand. Similarly to [Ru(ɳ6-
hmb)(en)N-SCN]+, 34B was cytotoxic towards A2780 cells (IC50 = 25-50 µM),
however the S-bound isomer was inactive. The inactivity of 34A may be due to
a strong Os-S bond, rendering it unable to become activated via hydrolysis in
intracellular conditions.
The azido complex (35) on the other hand exhibited potent activity against
A2780 cells with an IC50 of 1.2 µM. Previous studies on [Ru(ɳ6-hmb)(en)N3]+
showed that unlike its N-SCN analogue, it was capable of hydrolysis, albeit
slower than the chlorido, bromido and iodido analogues.37 It was also more
active than [Ru(ɳ6-hmb)(en)N-SCN]+ with an IC50 of 14 µM. Perhaps the
improved activity of 35 over 34B is down to the fact that the Os-N3 bond is more
susceptible to hydrolysis than the Os-NCS bond, allowing for easier intracellular
activation. Chlorido and bromido analogues (8 and 9) on the other hand have
monodentate ligands that are too labile and susceptible to deactivation before
entering the cell, leading to reduced activities. The iodide monodentate ligand
provides a happy medium where the complex is protected from deactivation in
extracellular conditions, but the Os-I bond is still labile enough to allow for
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cellular activation inside cells (see Chapter 5 for the intracellular activation of
complex 10 and FY026).
4.4.6. Reduction potentials of 10
Complex 10, [Os(ɳ6-p-cym)(5-EtO-AZPY)I]PF6, has two reduction potentials
corresponding to the transfer of two electrons into the π*-orbital centred on the 
azo-bond, at -0.26 and -0.81 V, respectively. The former of which falls within the
biologically relevant range (+0.40 to -0.50 V).29 The first reduction potential of
FY026, [Os(ɳ6-p-cym)(AZPY-NMe2)I]PF6, and its Ru(II) analogue are -0.64 and
-0.40 V respectively.11,25 Due to the presence of a more easily reducible azo-
bond, the Ru(II) analogue is capable of catabolising GSH to GSSG. In contrast,
FY026, which has its first reduction potential outside of the biologically relevant
range, does not catabolise GSH (see Chapter 1, Sections 1.3.3.2 and 1.3.4.3).
The notable low lying reduction potential of 10 might mean it is also capable of
catalytic GSH oxidation, unlike FY026. This highlights how simple variations in
substituents and their positioning on the AZPY ligand can have a profound
effect on the electronic and chemical properties of the complex. Furthermore,
complexes 7, 10, 13, 15, 23 and 31 were all found to significantly raise cellular
ROS levels in A2780 cells in ROS assays. Chapter 6 explores the possible
mechanistic routes in which intracellular ROS levels are raised in cancer cells.
4.4.7. Apoptosis and cell cycle analysis
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Complexes 10, 13, 19 and 31 were tested for their ability to induce apoptosis in
A2780 cells. The proportion of late apoptotic cells induced follows the order
31>10>19>13, where 31 induced the largest proportion. Interestingly and in the
same order, the complexes induced even higher populations of non-viable cells,
suggesting that the main mechanism of cell death is non-apoptotic and could
involve unregulated processes such as necrosis. During necrosis, the cell
membrane's integrity is lost via membrane blebbing, followed by rupturing and
the uncontrolled release of cellular contents into the extracellular environment.38
The cell cycle in mammalian cells consists of four distinct phases.39 The S-
phase is where DNA synthesis occurs and the chromosomes are duplicated.
The M-phase is where the replicated chromosomes are separated into two
separate nuclei and two daughter cells are produced. This step is called mitosis
and requires the formation of mitotic spindles which pull the chromosomes
apart. Finally, G1 and G2 are known as gap phases and occur before the S-
and M-phases, respectively. During these stages the cells priorities are growth,
synthesising cellular proteins and organelles, and for the G2-phase it also
involves re-organising cellular contents in preparation for mitosis. Interestingly,
the complexes tested in this chapter cause arrest at different stages in the cell
cycle of A2780 cells despite having similar structures. Complex 10 caused
moderate S-phase arrest, whereas 19 caused slight elevation in the proportion
of cells in in the G1-phase. Complexes 13, 15, 23 and 31 all caused a small
increase in the proportion of cells in the G2/M-phase. Cell cycle arrest is
advantageous in reducing the proliferation of cancer cells. Due to their ability to
increase cell populations in the G2/M-phase, complexes 13, 15, 23 and 31 may
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be involved in the inhibition of tubulin polymerisation similarly to FY069, [Os(ɳ6-
bip)(5-F-AZPY)I]PF6. However, FY069 causes a much greater degree of G2/M-
phase arrest (see Chapter 1, Section 1.3.4.3).40 None the less it would provide
an insightful further investigation.
4.5. Summary
A total of 31 new Os(II) arene AZPY complexes were developed utilising the
SARs that are currently understood for this class of anti-cancer complex. The
new library of complexes included many different variations: (1) p-cym or bip
arene ligands, (2) a choice of Cl-, Br-, I-, N3-, or SCN- for the monodentate
ligand, (3) PF6-, CF3SO3- or IO3- counter anions, (4) a variety of different
electron donating alkoxy/glycolic substituents situated on the pyridyl ring of the
AZPY ligand, (5) complexes with more than one substituent on its AZPY ligand
(an electron donating OH group situated on the phenyl ring and an electron
withdrawing Br or CF3 group situated on the pyridyl ring).
Nine complexes exhibited anti-cancer activity against A2780 cells with sub
micro-molar activity, and six were further tested against other cells lines and
their SFs were determined. Complex 13 possesses the best activity profile,
exhibiting extremely potent activity against OE19 oesophageal cancer cells and
a SF comparable to that of cis-platin. None of the complexes herein are as
active as the key Sadler group osmium complex, FY026, against A2780 cells, or
as selective. However, it may be possible to improve cancer cell selectivity by
synergistic treatment with L-BSO. Complex 31 exhibited potent anti-cancer
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activity but very poor selectivity. However, it is a novel complex with colouration
that is dependent on pH, and it exists as a zwitterion under physiological
conditions.
The SARs were explored for anti-cancer activity, aqueous solubility, capacity
factor, and cell uptake for the complexes containing alkoxy and glycolic side
chains. This has provided a database of information on some of the key
physical and biological properties of Os(II) arene AZPY complexes. The main
aim was to explore methods of improving solubility without negatively impacting
on activity. Two effective methods were found; changing the anion or changing
alkoxy substituents with branched alkoxy groups. Both involve lowering crystal
packing energy, and the former method was found to be the most effective. The
counter anion plays no role in anti-cancer activity and are interchangeable with
other anions in solution, so large increases in solubility were implemented
without adversely effecting activity and lipophilicity. Iodido complexes were
shown to be considerably more active than their chlorido and bromido
analogues, owing to their enhanced stability under physiological conditions.
They are also more lipophilic, which was attributed to better cellular
accumulation. Bip complexes were mainly more active than their p-cym counter-
parts, however were considerably less soluble and slightly less lipophilic
resulting in reduced cellular accumulation. Moreover, the stability studies reveal
the importance of the Os-X bond strength (where X = monodentate ligand) and
how it plays a role in the activity. Complexes with a weak Os-X bond can be
deactivated in extracellular conditions, whereas an Os-X bond that is overly
strong will not undergo in-cell activation.
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Os(II) complexes with pseudo-halide monodentate ligands were synthesised,
which is the first time they have been explored within the Sadler group.
Complex 8 was reacted with KSCN via exchange of the Cl- ligand to form two
structural isomers; S-bound S-SCN (34A) and N-bound N-SCN (34B), the
former of which was the major product. The isomers were separated by
preparative HPLC and were stable towards hydrolysis inter-conversion of the
isomers. Following a similar synthesis with NaN3, an azido analogue was also
synthesised (35). Their activities against A2780 cells follow the order
35(N3)>34B(N-SCN)>34A(S-SCN). The inactivity of 34A, and lower activity of
34B in comparison to 35 could perhaps be explained by overly strong binding of
the monodentate ligand to Os(II), which does not readily allow for cellular
activation involving dissociation of the monodentate ligand.
Complex 10 was found to have reduction potentials corresponding to the
transfer of two electrons into the π*-orbital of the azo-bond. The first of which, 
falling within the biologically relevant region, is of a low negative value,
indicating an easily reducible azo-bond. The azo-bond is suspected to be
capable of mediating redox reactions inside cells, leading to raised ROS levels.
Consequently, 10 (and also 7, 13, 15, 23 and 31) were capable of elevating
ROS levels inside A2780 cells in ROS assays. Many of the key complexes
herein were also found to raise the proportion of cells in late stage apoptosis in
apoptosis assays. However, apoptosis may not be the primary mechanism of
cell death as even higher proportions of non-viable cells were observed.
Furthermore, key complexes were capable of inducing cell cycle arrest in
different phases of the cell cycle: 10 produced S-phase arrest, 19 slightly raised
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the proportion of cells in the G1-phase, and complexes 13, 15, 23 and 31 each
caused a small increase in the proportion of cells in the G2/M-phase. These
effects could play a role in reducing the proliferation of cancer cells.
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5.1. Introduction
Iodine-131 has long been known as a major fission product from uranium and
plutonium, comprising nearly 3% of the total fission products.1 Interestingly,
because of its relatively short half-life of 8.02 days and decay mechanism
involving the production of β-- and γ-emissions, iodine-131 has been developed
for both clinical treatments and in vivo radio-imaging. Quite notably, the unique
property of thyroid follicular cells to trap and concentrate iodide via Na+/I-
symporters (NIS) for the synthesis of thyroid hormones (triiodothyronine and
throxyine),1,2 allows the effective diagnosis and treatment of thyroid cancers3-5
and hyperthyroidism6 using radio-iodine. Utilising its ability as a β--emitter
(tissue penetration of 0.6 – 2 mm), iodine-131 has been successfully used in the
clinic since 1948 for the treatment of thyroid cancer,7 significantly improving the
prognosis of the patients and making thyroid cancer one of the most
manageable cancers. Due to its capacity to also produce secondary γ-
emissions, there are also numerous applications of iodine-131 labelled
compounds as imaging agents in vivo using Single Photon Emission Computed
Tomography (SPECT).8-11
Os(II) arene AZPY complexes bearing monodentate iodide ligands, such as key
complexes 10 (see Chapter 4, Section 4.3.7) and FY026,12 exhibit potent anti-
cancer activity amongst multiple cell lines. Both structurally similar complexes
incorporate an electron donating group on their AZPY ligand, situated on either
the pyridyl or phenyl ring at positions para to the azo-bond (Figure 5.1). Iodido
complexes of this nature are more lipophilic than their chlorido counterparts and
are accumulated more effectively into cancer cells.13 Owing to the stability of the
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Os-I bond, they are also resistant to hydrolysis in aqueous solutions and it has
been speculated they may undergo intracellular redox reactions mediated
through their azo-ligands.12-14
Figure 5.1. Two Os(II) arene AZPY complexes bearing iodide ligands that were used in these
studies.
According to Breast Cancer UK, 1 in 8 women will be diagnosed with breast
cancer at some point in their lives in the UK, and the rate of breast cancer in
England has increased by 90% since records began in 1971.15 There is always
a demand for new anti-cancer drugs to enter the clinic. Complexes 10 and
FY026 exhibit anti-cancer activity towards MCF-7 human breast cancer cells
with IC50 values of 1.2 and 0.20 μM respectively.12 Exploiting the known stability
of these complexes, the aim of this study is to label 10 and FY026 with iodine-
131 at the monodentate ligand position for the purpose of in vitro and in vivo
tracing in MCF-7 human breast cancer cells. Within this chapter, the cellular
activation of these complexes is investigated and a cellular activation pathway
is proposed.
10 FY026
Chapter 5
231
5.2. Experimental
All research involving use of the radioactive iodine-131 isotope was carried out
at King’s College London at the Division of Imaging Sciences and Biomedical
Engineering in St Thomas’s hospital. Research was carried out under the
supervision of Prof. Phil Blower and with assistance from Dr. Levente Meszaros
and Dr. Maggie Cooper. Further work involving MCF-7 cells was carried out at
The University of Warwick in the School of Life Sciences, with assistance from
Dr. Isolda Romero-Canelón.
5.2.1. Materials
5.2.1.1. Materials used at King’s College London
Iodine-131 was purchased from Perkin-Elmer as an aqueous sodium iodide-131
solution (74 MBq; 185 GBq/mg) in 0.1M NaOH (pH 12-14). Human blood serum
(male, O-positive) was obtained from myself at the St. Thomas’s hospital blood
centre facility. Blood was drawn into 2x 5 mL BD vacutainer tubes with BD
Hemogard closures. The tubes contained a clot activator and a gel for serum
separation. The blood clotted after ~30 min and the serum was separated by
centrifuge (3600 rpm, 10 min). Approximately 5 mL of serum was obtained and
stored in a refrigerator for no more than 4 days. DMEM cell culture medium,
penicillin/streptomycin mixture, foetal bovine serum, L-glutamine, phosphate
buffered saline solution (PBS), trypsin and PI were all purchased from Sigma-
Aldrich. The DMEM cell culture medium was fully prepared as described in
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Chapter 2, Section 2.1.1.2. MCF-7 cells were purchased from the European
Collection of Cell Cultures and used between 15 – 25 passages.
5.2.1.2. Materials used at The University of Warwick
Materials were obtained as described in Chapter 2, Section 2.1.1. FY025 and
FY026 were synthesised following previously described methods,12 and
complexes 8 and 10 were synthesised as shown in Chapter 4, Section 4.2.2.2.
5.2.2. Radio-labelling of complexes
Stock solutions of the precursor osmium chlorido complexes (8 and FY025)
were made in MeOH (5 mg/mL). An aliquot of a stock solution (50 µL) was
transferred into a 2 mL plastic sealable tube and added with NaI-131(aq) (30-70
MBq). Additional water was added to make a water:MeOH (1:1) solvent matrix,
then the solution was heated for 18 h at 60 °C and with 300 rpm stirring. The
reaction progress was monitored by Radio-TLC (see Chapter 2, Section
2.4.3.1). The radio-labelled complexes ([131I]10 and [131I]FY026) were purified
by preparative radio-HPLC (see Chapter 2, Section 2.4.3.2). The purified radio-
tracers were in HPLC solvents containing 0.1% TFA, and so were diluted with
approximately three parts PBS solution to bring the pH to around 6-7, then
immediately stored at -80 °C to minimise degradation.
5.2.3. Methods
All of the meth
in Chapter 2,
University of Warwick
Chemistry, and
5.2.3.1. Manual cell counting
Manual cell counting was required for the cell calibration method. From a single
celled stock solution of MCF
of a plastic disposable invitrogen
bubbles are
Figure 5.2.
ods and instruments used at KCL have been des
Section
are described below.
trapped (Figure 5.2).
Diagram of a hemocytometer showing detection areas A and B.
2.4. Some
in the School of Life Sciences and at the Department of
-
additional methods were carried out at the
7 cells, 10
TM
μL was injected into both side A and B
hemocytometer, ensuring that no
cribed in detail
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air
Figure 5.3.
The central cross
microscope at
hatch were counted
three lines. For the top and
line were counted. For the bottom and right
central border line were not counted. For cell counts greater than 350
sample was diluted first. The average number of
cell counts of sides A and B, then multiplied by 10
cells/mL.
5.2.3.2. Cell calibration method
MCF-7 Cell samples from the cellular accumulation studies of
carried out at KCL were digested in sodium hydroxide, forming cell lysates.
These were transported to the University of Warwick after 8 half
The cross-hatched areas of the hemocytometer under magnification
-
10x
hatch of the two detection areas were examined under a
magnification, and the numbers of cells
(Figure 5.3). The
left hand side, any cells touching the central border
border around the cross
-hand side, any cells touching the
cells was calculated from the
4 to give the number of
.
within the cross
-hatch consists
iodine
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of
, the
-131
-lives had
passed. In order to accurately determine cellular accumulation, the number of
cells per 1 mL was determi
Figure 5.4
cells
From a 10
(1:1, v/v) containing 4
mL) were produced in triplicates: 0, 0.15, 0.25, 0.35, 0.5, 0.6, 0.75, 0.80 and
1.00 (x 10
the supernatants, the cell pellets were digested in 1 M
incubated for 30 min at 37 °C, forming
. Calibration curve for UV absorbance at 245 nm against number of digested MCF
-15 mL single
6/mL cells). After centrifuging (5 min, 1000 rpm, 22 °C) and removing
ned by producing a calibration curve.
-celled stock solution of MCF
-5 x 106/mL cells, the following single
cell lysates. PBS (2 mL) was added to
-7 cells in PBS:
-celled solutions
NaOH (1 mL) and
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the lysates so that they were in the same solvent matrix as the KCL samples.
This method was repeated once more to produce duplicates of triplicates. The
samples were analysed on a UV-Vis absorption instrument at 25 °C, scanning
between 200-400 nm. A calibration curve was generated by plotting absorbance
at 245 nm against number of digested MCF-7 cells (Figure 5.4).
The UV-Vis absorption of the KCL samples were analysed in the same manner
in triplicates, recording the maximum absorbance at 245 nm. Dilutions with 1M
NaOH:PBS (1:2, v/v) were necessary so that samples fell within the calibration
range. Using the calibration curve, the average number of MCF-7 cells and
standard deviation were calculated for each sample.
5.3. Results
5.3.1. Synthesis of iodine-131 labelled complexes
The labelling of radio-tracer complexes with iodide-131 occurs via a halide
exchange process, involving the chlorido analogues of 10 and FY026 (8 and
FY025, respectively, see Scheme 5.1). The chloride ligand is displaced by
iodide which forms a stronger osmium-halide bond. Since sodium iodide-131
(NaI-131) is measured in radioactive units (Becquerel’s, Bq, where 1 MBq of
iodine-131 is equivalent to 5.4 ng), the chlorido complex was added in large
excess, ensuring good conversion and minimising radioactive waste. Typically,
8 or FY025 (0.25 mg) was mixed with NaI-131 (30-70 MBq, 0.0006-0.0015 mol.
equiv.).
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Complex R1 R2 Complex R1 R2
FY025 H NMe2 [131I]FY026 H NMe2
8 EtO H [131I]10 EtO H
Scheme 5.1. Synthesis of radio-tracer complexes, [131I]FY026 and [131I]10, from their chlorido
analogues, FY025 and 8, respectively.
Reactions were followed by radio-TLC chromatograms using silica TLC plates.
Cationic organometallic Os(II) complexes have a strong affinity for silica and
reside close to the baseline. However, NaI-131 strongly solubilises in the eluent
and travels with the solvent front. A distinct separation between the radio-tracer
complex (Rf = 0.03-0.04) and NaI-131 (Rf = 0.95 - 0.96) was observed. Figure
5.5 shows the radio-TLC chromatograms for (A); aqueous NaI-131, and the
radio-synthesis of (B); [131I]10 and (C); [131I]FY026 after two hours reaction. The
halide exchange process occurs more slowly for the radio-labelling of FY026
and so an 18 h reaction period was employed.
Figure 5.5.
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respectively). To confirm that the signals correspond to iodine-131 labelled
complexes, the reactions were also carried out with 0.5 mol. equiv. of naturally
abundant NaI added. This yielded peaks in the UV-Vis chromatograms that
overlap the radio-signals, with retention times of 23.43 and 22.03 min for 10 and
FY026, respectively. The slight off-set in retention times by about 0.4 min
occurs because γ-detection takes place after the UV detection.
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5.3.2. Stability of radio-tracers in extracellular conditions
The stabilities of [131I]10 and [131I]FY026 were tested in human blood serum in
non-carrier added and carrier added conditions (carrier added conditions are
where the non-radiolabelled complex is also added with the radio-tracer at a
concentration comparable to the IC50 value; in this case 0.25 μM). Samples 
were incubated at 37 °C and the amount of free iodide-131 generated in
solution was observed by radio-HPLC, indicating the amount of iodide-131
monodentate ligand dissociated from the complex. [131I]FY026 exhibits good
stability in serum over a 24 h period, showing 9% free iodide-131 generated
after 1h and 11% generated after 24 h. In contrast, [131I]10 exhibits lesser
stability in serum, with 13% and 25% free iodide-131 generated after 1 h and 24
h, respectively. In both cases, the addition of the carrier makes little or no
difference (Figure 5.7).
Furthermore, it was possible to estimate the amount of iodine-131 accumulated
by serum proteins after 24 h by separating the proteins from the supernatants
and using a gamma-counter to measure the activity of the fractions. For [131I]10,
5.2% and 5.3% accumulation was found for the non-carrier and carrier added
experiments, respectively. For [131I]FY026, it was 5.0% and 5.5%, respectively.
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5.3.3. In vitro stability assay
The stabilities of [131I]10 and [131I]FY026 were studied in cell culture medium in
the presence and absence of MCF-7 cells, and in non-carrier and carrier added
conditions (for carrier added conditions, non-radioactive complexes were added
at IC50/3 concentration; 0.40 and 0.06 µM for 10 and FY026, respectively).
Samples were incubated for 2, 4, 8 and 24 h at 37 °C and the amount of free
iodide-131 generated in the supernatants is observable by radio-HPLC. For
both [131I]10 and [131I]FY026, after 24 h incubation with MCF-7 cells, very little
residual radio-tracer complex remains in the supernatants (c.a. 3.3 and 1.0%,
respectively) and a very large amount of free iodide-131 was present (c.a. 96.7
and 99.0%, respectively, see Figure 5.8).
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[131I]FY026 generates free iodide-131 in the supernatants at a faster rate than
[131I]10, as the shape of the curve in the graph changes more dramatically.
Adding the carrier complex makes little difference to the extent or rate of free
iodide-131 generation.
5.3.4. Cellular accumulation of iodine-131
The cellular accumulation of iodine-131 in MCF-7 cells was determined at
different time points when cells were exposed to [131I]10 and [131I]FY026 (15-17
KBq). The % cell uptake in each sample was determined by γ-detection of the 
supernatant and cellular fractions using a gamma counter instrument (LKB
Wallac 1282 Compugamma universal). The number of MCF-7 cells in the
samples were determined via the cell calibration method (Section 5.2.3.2), and
the % cellular accumulation of I-131 /106 MCF-7 cells were calculated and
plotted vs. time (min). Both radio-tracer complexes show an initial small spike in
iodine-131 uptake at 5 min: 0.75 and 1.78% /106 MCF-7 cells, for [131I]10 and
[131I]FY026, respectively. From this point onwards, the amount of accumulated
iodine-131 declines gradually (Figure 5.10).
Figure 5.10
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5.4. Discussion
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discussed in greater detail in Chapter 6). Alternatively, it may be possible for
Os(II) to form S-bonded adducts with sulphur-containing protein/peptide side
chains. Ru(II) arene complexes have been previously shown to undergo similar
behaviour with glutathione.16,17 It is also apparent that the stability of [131I]FY026
is greater than that of [131I]10 as its iodide-131 ligand is released less readily. It
appears that the substituents on the AZPY ligand and their positions on the
N,N-chelating ligand may affect the electronic distribution in the complex in a
way that dictates Os-I bond strength.12
It was also shown that for both radio-tracers there was a 5-6% uptake of iodine-
131 into the serum proteins. However, it was not possible to deduce whether
the accumulated I-131 was in the form of free iodide-131, or complex-bound
iodine-131. It may be possible for both lipophilic complexes to accumulate into
the hydrophobic pockets of serum proteins whilst remaining intact. It has been
reported that lipophilic platinum drugs can accumulate in human albumin, which
can be utilised as a potential mechanism for drug delivery.18
5.4.2. Intracellular activation of radio-tracers and iodide efflux
It was originally theorised that iodido Os(II) arene AZPY complexes remained
intact upon entering cells and undergo redox reactions mediated through the
azo-bond.13 To our surprise, these new data suggest that the Os-I bond is more
labile in intracellular conditions than originally anticipated. In the presence of
MCF-7 cells both radio-tracer complexes rapidly release their iodide-131
monodentate ligand, which was observable in the supernatants. This was not
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found to nearly the same extent in the control experiments where no cells were
present. Despite its stronger stability in extracellular conditions, [131I]FY026 is
shown to release its iodide-131 ligand at a slightly quicker rate than [131I]10 in
the presence of MCF-7 cells. The cellular accumulation of iodine-131 by MCF-7
cells was explored when cells were exposed to radio-tracers at incubation times
of; 5, 10, 30, 60, 120, 360 min. An initial spike in uptake was observed at 5 min,
however the accumulation of I-131 was always very low and declined over time.
I hypothesise that the radio-tracers are taken up by cell,s which then undergo
intracellular release of the iodide-131 monodentate ligand. Iodide-131 is then
most likely pumped out of cells via chloride transport channels (Figure 5.12).
Iodide efflux via the Cystic Fibrosis Transmembrane Regulator (CFTR) chloride
channels has previously been demonstrated in NIH-3T3 fibroblast cells using an
iodine-selective electrode.19 Such processes might activate these complexes
inside cancer cells. Previous studies utilising ICP-MS to determine osmium
concentration show that complex 10 (Chapter 4, Section 4.3.8) accumulates
substantially into A2780 ovarian cancer cells after 24 h incubation (31±2 ng /106
cells was determined). FY026 also shows fast accumulation in A549 cells with
significant uptake after just 30 min of incubation time.13 It is therefore likely that
the rate of cell uptake of the radio-tracers is initially fast, explaining the initial
spike in I-131 observed after 5 min. The rate of uptake is in competition with a
rapid rate of efflux of iodide-131, explaining the decline in cellular I-131
observed after 5 min. We also cannot entirely rule out the possibility that an
activation process involving the dissociation of the iodide at the cellular surface,
occurs in parallel.
Figure 5.12
mechanism of iodido Os(II) arene AZPY complexes.
For [131I]FY026
of I-131 starts to level off and not decline to
radio-tracer becoming trapped inside the cell membrane. It has been previously
shown in cellular distribution studies that
cell membrane and particulate fraction
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with biological targets may occur (see Chapter 6).
Interestingly, breast carcinoma biopsy tissues have been known to uptake more
radio-iodide than their normal breast cancer tissue counterparts.
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sodium iodide symporters (NIS), which allow the coupled transport of one iodide
anion with two sodium cations inside cells.21-23 Despite NIS expression being
identified in breast cancers, only a low percentage of tumours capable of radio-
iodide uptake at detectable levels were confirmed in a later study,24 leading to
the hypothesis that NIS may be incorrectly localized within the cells of some
breast tumours and hence incapable of taking up iodide.1,21 MCF-7 cells have
previously been shown to accumulate radio-iodide. However, this was achieved
only when cells were treated with all-trans retinoic acid (atRA) to stimulate NIS
expression.25 A study by C. Spitzweg et al reports on a synergistic effect; by
pre-treating MCF-7 cells with a combination of atRA and the synthetic
glucocorticoid, dexamethasone (Dex), a 16-fold stimulation of NIS protein
expression was observed, followed by a 3- to 4-fold increase in radio-iodide
uptake in comparison to cells pre-treated with atRA alone.26 However, they
report that no radio-iodide accumulation was observed above background
radiation levels in untreated cells or cells treated only with Dex. This is
consistent with our findings and concludes that MCF-7 cells do not readily
uptake radio-iodide. Furthermore, they study the iodide efflux of MCF-7 cells
and find that cells pre-treated with atRA rapidly efflux iodide, releasing 80% of
the accumulated radio-iodide into the supernatants after 2 min.
5.5. Summary
In order to study the cellular distribution of two key complexes, FY026 and 10,
within MCF-7 breast cancer cells, complexes were labelled with iodine-131 and
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purified using typical radio-labelling procedures. As anticipated, both radio-
labelled complexes exhibit good stability in extracellular conditions over a 24 h
incubation period, owing to the high Os-I bond strength inherent in iodido Os(II)
arene AZPY complexes, as previously observed for this class of
compounds.12,14,27 Unexpectedly, when exposed to MCF-7 cells, iodide-131
readily dissociates from both radio-tracers as observed by radio-HPLC of the
supernatant. From this point forward the study was re-focussed to investigate
cellular activation, as distribution and imaging studies with labile radiolabels
would not be possible.
Cellular accumulation studies of the radio-tracers in MCF-7 cells were
performed by analysing I-131 uptake via gamma ray detection. A very low
uptake of iodine-131 was observed for both radio-tracer complexes, peaking at
the initial measurement at 5 min, after which cellular iodine-131 levels decline.
Meanwhile, it has been shown previously that both complexes can accumulate
in other cancer cell lines when osmium uptake is measured by ICP-MS. These
observed trends can be explained by our hypothesis: complexes are rapidly
taken up into cells, where an activation process takes place involving
dissociation of the iodide ligand. The rate of uptake of the complex is in
competition with a rapid rate of iodide efflux, likely involving cellular transport
channels. Further studies would need to be performed to support this
hypothesis. A cellular accumulation assay involving the simultaneous detection
of osmium and iodine by ICP-MS may provide a good comparative means of
measurement.
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Furthermore, it was shown for [131I]FY026 that the cellular accumulation of
iodine-131 levels off after 6h and a residual portion remains inside the cells. A
study by C. Spitzweg et al concludes that MCF-7 cells do not readily uptake
iodide and no radio-iodide was observable above background radiation levels.26
This suggests that the observed residual iodine-131 is most likely to be in the
form of intact radio-tracer complex trapped inside the cell membrane.
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6.1. Introduction
In Chapter 4, Os(II) arene complexes bearing AZPY ligands were shown to be
effective at elevating ROS levels within A2780 cancer cells, as well as causing
apoptotic and non-apoptotic cell death and cell cycle arrest in different phases
of the cell cycle. Chapter 5 showed that the seemingly stable iodido complexes
undergo an unexpected cellular activation pathway, whereby the iodido
monodentate ligand dissociates in vitro and is rapidly expelled from MCF-7
cancer cells. Herein, we explore the potential mechanisms of action that lead to
elevated intracellular ROS levels and also address the mechanism of cellular
activation involving iodide ligand loss and the subsequent formation of the
hydroxido-adduct. The reactivity of Os(II) arene AZPY complexes is explored
with several biological targets present in cancer cells, including H2O2, GSH and
NADH.
Scheme 6.1 briefly summarises some of the cellular redox processes of
mammalian cells.1 NADPH oxidases (Nox) are responsible for the generation of
O2·- radicals and are situated on the cell membrane.2 These radical species
have relatively low reactivity in physiological conditions and the damage they
cause is based on reactions with other radicals and metal ions.3 Superoxide
dismutases (SOD) which are present in the mitochondria and cytosol, catalyse
the dismutation of O2·- to O2 and the weakly oxidising H2O2.3 Catalase is located
inside peroxisome organelles and very effectively convert H2O2 to H2O and O2
at one of the fastest turnover rates known for any enzyme.3 Glutathione (GSH)
is a tripeptide produced intracellularly in the body from its constituent amino
acids: glutamic acid, cysteine and glycine. It is a crucial cellular antioxidant and
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detoxifier present in mammalian cells at concentrations of 1-10 mM, mediating
redox processes via its thiol side-chain.4 It is capable of directly scavenging
HO· and O2·- radicals generating glutathione disulfide (GSSG) in the process,
and also serves as a substrate for GSH peroxidases (GPx) for the reduction of
H2O2 to H2O.3 Due to the highly efficient NADPH-dependent reduction of GSSG
by GSH reductase (GR), low cellular levels of GSSG are maintained at around
5-50 µM.4
Scheme 6.1. Cellular redox and oxidative stress pathways occurring within the cytosol and
mitochondria of mammalian cells. Nox = NADPH oxidase, SOD = superoxide dismutase, GPx =
glutathione peroxidases, and GR = glutathione reductase.
Whilst playing a vital role in the detoxification of ROS in cells, GSH is often
present at elevated concentrations amongst some cancer cell lines, increasing
their resistance to certain chemotherapeutic agents.5,6 Quite notably, platinum-
drug resistant cell lines such as A2780cis (human ovarian cancer cells)
generate higher levels of GSH in order to detoxify platinum drugs.7 There are
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numerous examples of platinum,8,9 and even some ruthenium10,11 anti-cancer
complexes that are capable of binding and forming adducts with GSH.
Moreover, ruthenium complexes of the form [Ru(ɳ6-arene)(AZPY-R)I]PF6
(where R = OH or NMe2 and arene = p-cym or bip), were found to catalytically
oxidise GSH to GSSG.10 The process is believed to involve ligand centred
reduction of the azo-bond by GSH where the reduction potentials of the azo-
bond were found to fall within the biologically accessible range (-0.50 to +0.40
V).12 Such catalytic drugs could be capable of vastly depleting cancerous cells
of their GSH source, causing ROS levels to rise above a threshold where
apoptosis is triggered. Interestingly, the analogous osmium complexes with
AZPY or IMPY ligands are not capable of catalytic GSH oxidation because their
reduction potentials fall outside the biologically accessible range.13,14
In mammalian cells, the intracellular physiological concentrations of H2O2 can
vary from as low as ~0.001 µM and reach maximum concentrations of 0.5-0.7
µM.15 These sub-micromolar quantities are a necessity for the normal
functioning of cellular signalling pathways.16 Elevated levels of H2O2 have been
reported in extracellular conditions. Suspensions of mammalian cells in cell
culture medium have been shown to generate extracellular levels of 0.02 - 2
µM,15 and levels of 0.25-5 µM are found in blood plasma.17 Numerous studies
show that H2O2 plays a vital role in cancer development and cancer cells are
well known for producing H2O2 in large quantities.18-20 Szatrowski et al studied
the H2O2 production of 10 tumour cell lines and found 7 of which exhibited fast
rates of H2O2 production ranging from 0.2-0.5 nmol/104 cells h-1.21 NADPH
oxidases are over-expressed in certain cancer cell lines and have been
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attributed to increased ROS and H2O2 production. When Nox1 was expressed
in NIH3T3 fibroblast cells, they developed malignant characteristics and showed
a 10-fold increase in H2O2 levels. However, when catalase was expressed in
the transformed Nox1 expressing cells, H2O2 concentrations decreased and the
cells reverted back to normal appearance and growth rates (Arnold et al).2
In comparison to the weakly oxidising H2O2 species, HO· is the most reactive
ROS, reacting immediately with almost every molecule found in living cells.3
Briefly mentioned in Chapter 1, Section 1.2.3, is a novel approach to treating
cancerous cells, whereby their over-production of H2O2 can be exploited.18
Ferrocenium salts,22,23 and water soluble ferrocene derivatives19 (Figure 6.1)
are understood to cleave DNA via the production of HO· radicals from H2O2.
Figure 6.1. Molecular structures of (A) ferrocenium salts,22 and ferrocene derivatives; (B)
ferrocifen, and (C) ferrocene-tamoxifen complex.19
This is the first class of compounds found to utilise the selective accumulation of
H2O2 in cancer cells as a pro-drug. Although the mechanism of HO· formation is
not well understood, it has been proposed that the Fenton reaction is likely,
FeII O
N
(A) (B) (C)
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which involves the Fe(II) metal centre undergoing redox reactions with H2O2
(Scheme 6.2).24
Scheme 6.2. The Fenton reaction where Fe(II) is oxidised to Fe(III) by H2O2, generating the
highly reactive HO· radical species. In intracellular conditions, O2·-, ascorbate and GSH are
capable of reducing Fe(III) back to Fe(II).3
Nicotinamide adenine dinucleotide (NADH) is a naturally occurring coenzyme
found in all living cells that plays an important role in cellular metabolism.25 In
normal cells, adenosine triphosphate (ATP) is produced via oxidative
phosphorylation in the mitochondrial inner membrane where NADH is oxidised
to NAD+, accompanied by the reduction of O2 to H2O by electron transfer
processes.26 ATP is an important chemical energy source for a variety of
cellular processes including DNA repair and cell division. Cancerous cells rely
primarily on high rates of glycolysis (involving conversion of NAD+ to NADH) in
the cytosol to produce ATP, rather than mitochondrial respiration. Dependence
on glycolysis is due to the mitochondrial defects associated with cancer cells
and their adaptation to the hypoxic tumour microenvironment (the Warburg
effect).27 The balance of NADH/NAD+ plays an integral role in providing energy
for cancer cells, which have greater energy demands than normal cells.
Furthermore, NADH behaves as a cellular antioxidant and NADH/NAD+ forms a
part of a cellular redox balance system (Figure 6.2).25
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Figure 6.2. The conversion of NADH to NAD+ via hydride transfer.
Targeting the NADH/NAD+ redox system using catalytic drugs is an attractive
prospect as it could allow low doses of drugs to be administered and introduce
a novel mechanism of activity for overcoming resistance to platinum anti-cancer
drugs.28 Previous studies in the Sadler group have shown Ru(II) and Ir(III)
catalysts that are capable of reducing NAD+ to NADH by working synergistically
with formate, which is added in non-toxic amounts to provide a source of
hydride.28-30 Such complexes are capable of inducing reductive stress on
cancer cells. In contrast, there also exists Ir(III) and Os(II) catalysts from the
Sadler group capable of oxidising NADH, hence inducing oxidative stress.14,31,32
The common theme in both cases are complexes that form a M-H bond in situ
and transfer hydride from one species to another.
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6.2. Experimental
6.2.1. Materials
[Os(η6-p-cym)Cl2]2 was prepared as described in Chapter 2, Section 2.1.2, and
5-EtO-AZPY as shown in Chapter 4, Section 4.2.2.1. FY026 was synthesised
following literature procedures.33 Silver nitrate, hydrogen peroxide 30 wt.%,
perchloric acid 70 wt.%, reduced and oxidised forms of glutathione, 9-
ethylguanine, N-acetyl-L-cysteine and β-nicotinamide adenine dinucleotide 
(reduced dipotassium salt) were all purchased from Sigma Aldrich. Sodium
hydroxide was purchased from Fisher Scientific. Quantofix® peroxide 25 (0.5-25
mg/L) H2O2 semi-quantitative strips were purchased from Sigma Aldrich and
used for H2O2 concentration determinations. EPR tubes were purchased from
Wilmad Labglass, and the spin trap 5-(diethoxyphosphoryl)-5-methyl-1-
pyrroline-N-oxide (DEPMPO) was obtained from Enzo Life Sciences.
Lysozyme, ≥40,000 U/mg (from chicken egg white) was purchased from Sigma 
Aldrich. Deionised water was prepared as described in Chapter 2, Section
2.1.1.1. Deuterated solvents used for NMR spectroscopy were purchased from
Cambridge Isotope Laboratories Inc. and Sigma Aldrich and phosphate buffer
solution was prepared as described in Chapter 2, Section 2.1.1.1.
6.2.2. Synthesis of 10-OH
[Os(η6-p-cym)(5-EtO-AZPY)OH]PF6 (10-OH). To a stirring solution of [Os(η6-p-
cym)Cl2]2 (100.0 mg, 126.5 µmol) in MeOH (3 mL), AgNO3 (58.867 g/L, 1459
µL) in water was added. The mixture turned yellow and a white precipitate
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formed, which was removed via filtration. A solution of 5-EtO-AZPY (60.4 mg,
265.6 µmol) in MeOH (5 mL) was added drop-wise to the yellow solution and it
turned brown. The mixture was stirred for 18 h at ambient temperature, then
NH4PF6 (206.2 mg, 1.27 mmol) was added. The product was extracted with
DCM (10 mL) and washed with water (2 x 10 mL). DCM was removed under
reduced pressure and the product was re-dissolved in a minimum amount of
MeOH (~2 mL), and placed in a freezer overnight. A brown precipitate formed,
which was collected via vacuum filtration then washed with ice-cold EtOH (2 x 1
mL) and Et2O (2 x 5 mL), and dried overnight in a vacuum desiccator. Yield:
160.6 mg, (89%). 1H NMR (D2O): δ 9.04 (d, 1H, J = 2.2 Hz), 8.76 (d, 1H, J = 9.1 
Hz), 7.98-7.95 (m, 3H), 7.76-7.73 (m, 3H), 6.51-6.50 (m, 1H), 6.16-6.15 (m, 1H),
6.01-5.98 (m, 2H), 4.48-4.44 (m, 2H), 2.34 (s, 3H), 2.17 (sept., 1H, J = 6.9 Hz),
1.54 (t, 3H, J = 7.0 Hz), 0.80 (d, 3H, J = 6.9 Hz), 0.68 (d, 3H, J = 6.9 Hz). ESI-
MS calculated for C23H28N3O2Os+: m/z 570.2. Found: 570.2. CHN analysis:
Found: C, 35.54%; H, 3.64%; N, 5.86%. Calculated for C23H28F6N3O2OsP +
CH2Cl2: C, 36.10%; H, 3.79%; N, 5.26%.
6.2.3. Measuring the pKa of 10-OH34
A 2 mM solution of 10-OH was prepared in D2O and 4 mM dioxane was added
as an internal 1H NMR standard (at 3.75 ppm). The solution was aliquoted into
8 samples of 600 μL and the pH* values of the samples were adjusted 
sequentially by the addition of 1-10 μL of either KOD or DClO4 (0.01, 0.1, 1, 2,
3, 4, 6, 8 or 10 M) in D2O. The pH* of the samples were measured over a range
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of 1.50 – 13.5 using a portable pH meter as described in Chapter 2, Section
2.2.7.2 (without correction for the effect of deuterium on the glass electrode).
Changes in the chemical shifts of the peaks of complex 10-OD were followed by
1H NMR. The pH* values were corrected using the equation; pH = 0.936(pH*) +
0.412,35 and the data were fitted to the Henderson-Hasselbalch equation using
Origin 8.5.
6.2.4. Measuring the stability of 10-OH in aqueous media
6.2.4.1. 1H NMR spectroscopy
A sample of 10-OH (1 mM) was prepared in D2O with phosphate buffer (100
mM, pH* 7.4). The 1H NMR spectrum was recorded on a 600 MHz instrument
before incubation (512 scans), and after 24 h incubation (1024 scans) at 37 °C.
6.2.4.2. HPLC
Two samples of 10-OH (1 mM) were prepared in phosphate buffer (100 mM, pH
7.4). One sample was incubated at 37 °C for 24 h, while the other was prepared
without incubation to be analysed immediately. The samples were diluted by
10x in water, then analysed via HPLC (see Chapter 2, Section 2.2.9 for the
instrumental parameters used). The wavelength of detection observed was 254
nm (referenced to 510 nm). Integrals of the peaks were used to estimate how
much compound was lost through precipitation.
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6.2.5. Reactions of complexes with H2O2
6.2.5.1. UV-Vis spectroscopy
Solutions of 8, 10-OH and 11 (75 µM) were prepared in phosphate buffer
solution (75 mM, pH 7.4) either with or without 7.5% EtOH, and with H2O2 (50 or
100 mol. equiv.). UV-Vis experiments were conducted at 37 °C in scanning
kinetics mode and a spectrum was scanned at different time intervals.
Quantofix® peroxide test sticks were used to quantify the concentrations of H2O2
remaining in solution. Control experiments were also conducted with no H2O2
added.
6.2.5.2. 1H NMR spectroscopy
A solution of 10-OH (3 mM) was prepared in D2O with phosphate buffer (300
mM, pH* 7.4) and H2O2 (10 mol. equiv.). Using a kinetic 1H NMR experiment, a
spectrum was collected every 10 min at 5 °C for 2 h on a 600 MHz instrument.
6.2.5.3. Detection of free radicals by EPR spectroscopy
Solutions of complexes (1 mM) were prepared in phosphate buffer (75 mM, pH
7.4) with diethoxyphosphoryl-5-methyl-1-pyrroline N-oxide (DEPMPO, 6 mM)
and H2O2 (10 mM). For complexes 8 and 11, DMF (50%) was used to solubilise
the complexes to 1 mM. The EPR spectra were recorded immediately after
sample preparation (see Chapter 2, Section 2.2.12 for the instrumental
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parameters used). Three control studies were also conducted: H2O2 control
(complex absent), 10-OH control (H2O2 absent), Complex 10-OH + H2O2 in the
presence of one drop of EtOH (HO· quench).
6.2.5.4. Lysozyme cleavage assay36
Lysozyme (75 μM) was incubated with different concentrations of H2O2 (0, 0.1,
1 and 10 mM) in the presence of either 10-OH, 8 or 11 (10 µM) in phosphate
buffer (60 mM, pH 7.4) for 2 h at 37 ºC, and analysed by gel electrophoresis (4-
12% polyacrilamide mini stacking gel; 90 min at 100 V in MES buffer). The
protein was stained using coomasie blue and quantified using the ImageJ and
Origin software.
6.2.6. Binding experiments of complexes with 9-EtG, NAC, GSH and GSSG
6.2.6.1. 1H NMR spectroscopy
Solutions of 10-OH (1 mM) with either 9-ethylguanine (9-EtG), N-acetyl-L-
cysteine (NAC), reduced glutathione (GSH), or oxidised glutathione (GSSG) (1
mol. equiv.) were prepared in D2O with phosphate buffer (100 mM, pH* 7.4).
The 1H NMR spectrum was recorded before (512 scans) and after (1024 scans)
incubation at 37 °C for 24 h, using either a 500 or 600 MHz instrument. Control
experiments were also conducted where NAC and GSH were incubated in the
absence of 10-OH to determine the extent of oxidation under aerobic
conditions.
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6.2.6.2. HPLC/LC-MS
Samples of 10-OH (1 mM) were prepared in phosphate buffer (100 mM, pH 7.4)
with either NAC, GSH, or GSSG (1 mol. equiv.), or no substrate (control).
Samples were incubated at 37 °C for 0 and 24 h, then stored in a freezer. The
samples required 10x dilution in water before HPLC analysis was carried out
(see Chapter 2, Section 2.2.9 for the instrumental parameters used). The
samples that received 24 h incubation were later analysed via LC-MS to identify
the species in solution (see Chapter 2, Section 2.2.10 for the instrumental
parameters used).
Likewise, complexes 11 and FY026 (75 µM) were prepared in phosphate buffer
(75 mM, pH 7.4) with either 1 or 100 mol. equiv. of NAC, GSH or GSSG, or no
substrate. Samples were incubated for 0, 3, 6, 12 and 24 h, and did not require
dilution prior to HPLC or LC-MS analysis. The HPLC wavelengths of detection
used were 254 nm (referenced to 510 nm) for 10-OH and 11 and 610 nm
(referenced to 360 nm) for FY026.
6.2.7. Reactions of complexes with NADH
6.2.7.1. UV-Vis spectroscopy
Complexes 10-OH, 11 and 31 (4 µM) were prepared in phosphate buffer
solution (1 mM, pH 7.4) with NADH (200 µM, 50 mol. equiv.). The samples were
incubated at 37 °C and spectra were collected every hour for 24 h. A control
study was also conducted to monitor NADH oxidation in the absence of any
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complex. For the kinetic study, the Cary software was used in kinetics mode
and the same sample concentrations were used as above. The absorption at
339 nm was monitored over a 24 h period at 37 °C, with measurements
determined every 5 min.
6.2.7.2. HPLC
Complexes 10-OH, 11 and 31 (50 µM) were prepared in phosphate buffer (5
mM, pH 7.4) with NADH (200 µM, 4 mol. equiv.). Samples were incubated at 37
°C for time periods of 0, 3, 6, 12 and 24 h, then stored in a freezer before
analysing via HPLC. See Chapter 2, Section 2.2.9 for the instrumental
parameters used. Control studies were conducted where 11 and 31 were
incubated in the absence of NADH. The HPLC wavelength of detection used
was 254 nm (referenced to 360 nm) for all complexes.
6.2.7.3. 1H NMR spectroscopy
Solutions of complex 10-OH (2 mM) were prepared in D2O with phosphate
buffer (200 mM, pH* 7.4) and NADH (3 mol. equiv.). The solutions were
incubated at 37 °C for different time periods (0, 4 and 23 h), then the 1H NMR
spectrum was recorded on a 600 MHz field instrument with 512 scans.
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6.3. Results
In this chapter the synthesis of complex 10-OH is described. Complex 10-OH is
analogous to 10 and contains a monodentate hydroxide ligand instead of an
iodide ligand. Its reactivity with different biological targets was explored and
compared with complex 11. Complex 11 is analogous to 10 with a CF3SO3-
counter anion in place of PF6-, and was used in these studies instead of 10
because of its increased solubility in water. As shown in Chapter 4, Section
4.3.7, the change of anion has no effect on anti-cancer activity, only water
solubility. This chapter also explores the reactivity of complexes 8 (analogous to
10 with a chloride monodentate ligand), 31, and FY026 with biological targets
for comparison. Figure 6.3 lists the molecular structures of all the complexes
explored within this chapter.
Figure 6.3. Structures of the complexes studied in this chapter, where X is a monodentate
ligand, Y is a negatively charged counter ion, and R1 & R2 are substituents on the bidentate
AZPY ligand.
6.3.1. The pKa of 10-OH
Complex X Y R1 R2
8 Cl PF6 OEt H
10-OH OH PF6 OEt H
10 I PF6 OEt H
11 I CF3SO3 OEt H
31 I PF6 Br OH
FY026 I PF6 H NMe2
The pKa*
by observing the change in chemical shift of an aromatic
pH* in D2
solution using a H
pH values
The pKa
The error was obtained as a computer fitting error using Origin 8.5, see
6.4. Under physiological and basic conditions
adduct with an overall +1 charge, and under acidic conditions the hydroxide
ligand is protonated yielding the aqua species with an overall +2 charge
(Scheme 6.3).
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Scheme 6.3. Protonation and deprotonation of 10-OH under acid and basic conditions,
respectively.
6.3.2. Aqueous stability of 10-OH
6.3.2.1. 1H NMR spectroscopy
The 1H NMR spectrum of 10-OH in D2O (pH* 7.4) was recorded before and
after 24 h incubation at 37 °C (see Figure 6.5). Complex 10-OH is not entirely
stable in aqueous media, giving rise to more than one unknown species. The
peaks labelled in blue are protons belonging to 10-OH. After incubation these
peaks diminish in intensity and a new set of peaks are present labelled in red,
most likely corresponding to free p-cym. Also present are several broad peaks
denoted by ‡. The presence of a black insoluble precipitate was also noted after
incubation.
Figure 6.5.
at 37 °C. Spectra were collected on a 600 MHz instrument.
6.3.2.2. HPLC
HPLC analysis was carried out for
h incubation at 37 °C, shown in Figure 6.6. The samples
analysis and the presence of a black precipitate was noted again after the
sample had been incubated. Due to presence of TFA in the HPLC mobile
phase, 10
Complex
impurity is observable in the chromatogram with a retention time of 12.05 min.
This is most likely due to reaction of
1H NMR spectra of
-OH will predominantly exist
10-OH has
10-
a retention time of 12.68 min. Before incubation, a minor
OH (2mM) in D
10-OH
2O (pH* 7.4) before and after 24 h incubation
(1 mM) at pH 7.4
as the aqua species inside the column.
10-OH/OH2 with MeCN in the mobile
before and after 24
were filtered before
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phase. By assessing the integrals of the peaks, there was an estimated 62%
loss of 10-OH through degradation after the sample was incubated (the black
precipitate accounts for approximately 58% and other peaks in the
chromatogram account for approximately 4%).
Figure 6.6. HPLC chromatograms of 10-OH before and after 24 h incubation at 37 °C and pH
7.4 (254 nm wavelength of detection).
6.3.3. Reactivity of complexes with H2O2
6.3.3.1. UV-Vis spectroscopy
The reactivity of 8, 10-OH and 11 with H2O2 was explored using UV-Vis
spectroscopy. Complexes (75 µM) were incubated at 37 °C and pH 7.4 with
H2O2 (50 mol. equiv.). Figure 6.7 shows UV-Vis spectra of 8, 10-OH or 11 in the
presence of H2O2 recorded every 2 min. A decline in the intensity of the
complexes absorption bands is observed in each case. After the intensity of the
5 10 15 20 25 30 35
Time (min)
0 h
24 h
0 h
24 h
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absorption bands is lost the bands continue to flatten out towards the baseline
with respect to time, thus indicating decomposition of the complexes. After 30
min incubation, bubbles were observed in the cuvettes together with complete
loss of colour of the solution. The rates of decomposition follow the trend 10-
OH>8>11.
Figure 6.7. UV-Vis spectra showing the decomposition of; (A) 10-OH, (B) 8, and (C) 11, in the
presence of 50 mol. equiv. of H2O2 at pH 7.4 and 37 °C.
Further experiments were conducted with complexes in the presence of 100
mol. equiv. H2O2 in phosphate buffer solution using Quantifix® H2O2 semi-
quantitative testing sticks to measure the presence of H2O2, as well as
measuring the UV-Vis spectra. Figure 6.8 shows the spectra recorded for 10-
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OH, 8 and 11 after every 30 min for 2 h at 37 °C. Control studies included
samples of the complexes incubated in the absence of H2O2. Table 6.1 shows
the levels of H2O2 remaining after each 30 min intervals, including a control
study of H2O2 with no added complex. All three complexes are stable over a 2 h
period in the control studies. However, in the presence of H2O2 all three
complexes show significant levels of decomposition within the first 30 min of
exposure. Furthermore, H2O2 levels are depleted to 0 ppm within the initial 30
min of exposure time with all three complexes. In the control study where H2O2
is incubated without complexes, the level of H2O2 remains greater than 25 ppm
throughout the entire 2 h period.
Table 6.1. Measurements of H2O2 levels for the reactions of 10-OH, 8 and 11 with 100 mol.
equiv. of H2O2 at pH 7.4 with 37 °C incubation. Measurements made using H2O2 semi-
quantitative testing sticks.
10-OH 8 11 Control
0 min >25 ppm >25 ppm >25 ppm >25 ppm
30 min ~0 ppm ~0 ppm ~0 ppm >25 ppm
60 min ~0 ppm ~0 ppm ~0 ppm >25 ppm
90 min ~0 ppm ~0 ppm ~0 ppm >25 ppm
120 min ~0 ppm ~0 ppm ~0 ppm >25 ppm
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Figure 6.8. UV-Vis spectra of the reactions of complexes (75 µM) in the presence of 100 mol.
equiv. of H2O2 at pH 7.4; (A) 10-OH, (C) 8, and (E) 11, and control studies in the absence of
H2O2; (B) 10-OH, (D) 8, and (F) 11. Spectra were recorded every 30 min for 2 h with 37 °C
incubation.
The same experiment was repeated as above but in the presence of 7.5%
EtOH, which is known for its ability to quench HO· radicals.37 Figure 6.9 shows
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the variation in the UV-Vis spectra and Table 6.2 shows how H2O2 levels vary
over the 2 h incubation period.
Figure 6.9. UV-vis spectra showing the reactions of complexes (75 µM) in the presence of 100
mol. equiv. of H2O2 and 7.5% ethanol at pH 7.4; (A) 10-OH, (C) 8, and (E) 11, and control
studies in the absence of H2O2; (B) 10-OH, (D) 8, and (F) 11. Spectra were recorded every 30
min for 2 h after incubation at 37 °C.
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Table 6.2. Measurements of H2O2 levels for the reactions of 10-OH, 8 and 11 with 100 mol.
equiv. of H2O2 in phosphate buffer solution (7.5% ethanol) at 37 °C. Measurements made using
H2O2 semi-quantitative testing sticks.
10-OH 8 11 Control
0 min >25 ppm >25 ppm >25 ppm >25 ppm
30 min >25 ppm >25 ppm >25 ppm >25 ppm
60 min ~25 ppm ~25 ppm >25 ppm >25 ppm
90 min ~2 ppm ~5 ppm >25 ppm >25 ppm
120 min ~0 ppm ~0 ppm ~25 ppm >25 ppm
All three complexes are stable in the control experiments and no drastic
changes in the UV-Vis spectra were observed in the presence of H2O2 when
EtOH was added. Moreover, the complexes produce a much slower decline in
H2O2 levels in the presence of EtOH than in its absence. The extent of
degradation of H2O2 produced by the complexes follows the trend 10-OH>8>11.
6.3.3.2. 1H NMR spectroscopy
A kinetic 1H NMR study was carried out for the reaction between 10-OH and
H2O2 (10 mol. equiv.) in phosphate buffered D2O at 5 °C. The spectra in Figure
6.10 show that the peaks of 10-OH broaden and disappear within 90 min. A
dark brown precipitate was observed in the NMR tube after the experiment. The
line broadening may be a result of increasingly poorer shimming of the sample
over time. The disappearance of 10-OH peaks suggest that it decomposes,
however,
observed in the spectra.
Figure 6.10.
(pH* 7.4) at 5 °C. Spectra obtained every 10 min
6.3.3.3. Mass spectrometry
Complexes
37 °C then analysed by mass spectrometry. For complex
a peak corresponding to unreacted complex (
no other
1H NMR spectra for the reaction between
8 and 11
peaks corresponding to its break
were incubated with H
10-OH
on a 600 MHz instrument
2O2
-down pr
and 10 mol. equiv. of
(10 mol. equiv
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8-PF6), C
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the spectrum shows
23H27ClN3OOs: m/z
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588.0, and a peak corresponding to the hydroxido-adduct (10-OH-PF6),
C23H28N3O2Os: m/z 570.1, where the chloride ligand is replaced by hydroxide.
Also an unidentified peak was observed with a m/z value of 604.0 (+16 units
greater than 8-PF6). Similarly, the spectrum for 11 showed the following peaks;
C23H27IN3OOs: m/z 680.0 (11-CF3SO3), C23H28N3O2Os: m/z 570.1 (11-OH-
CF3SO3), and an unidentified peak with a m/z value of 696.0 (+16 units greater
than 11-CF3SO3).
6.3.3.4. Detection of generated free radicals by EPR spectroscopy
The ability of 8, 10-OH and 11 to generate free radicals from H2O2 was explored
using Electron Paramagnetic Resonance (EPR) Spectroscopy, utilising 5-
diethoxyphosphoryl-5-methyl-1-pyrroline N-oxide (DEPMPO) as a spin trap. As
shown in Scheme 6.4, DEPMPO is capable of trapping HO· radicals yielding an
8-peak spectrum (DEPMPO-OH),38 O2-· radicals yielding a 12-peak spectrum
(DEPMPO-OOH),38-41 and H· radicals yielding a 16-peak spectrum (DEPMPO-
H).42 A sample of 10-OH (1 mM) was prepared with H2O2 (10 mol. equiv.) and
DEPMPO (6 mol. equiv.) at pH 7.4 and the EPR spectrum was recorded (Figure
6.11). The observed spectrum was an 8-peak signal corresponding to
DEPMPO-OH (trapped HO· radicals).
Scheme 6.
trapping O
(formed after trapping H
the 12-peak, 8
respectively.
A large accumulation of bubbles in the EPR tube was also observed
6.12). When the experiment was r
EtOH the signal was significantly reduced as EtOH scavenges HO· radicals,
preventing formation of DEPMPO
out; one in the absence of H
showed no EPR signal, hence proving that
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6.3.3.5. Lysozyme cleavage assay
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protein. The gel shown in Figure 6.14 shows smearing after the
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6.3.4. Binding of complexes to biological targets
In this section, the binding capabilities of 10-OH, 11 and FY026 were studied
with 9-ethylguanine (9-EtG), N-acetyl-L-cysteine (NAC), and glutathione in its
reduced (GSH) and oxidised (GSSG) forms. NAC is structurally similar to L-
cysteine with an acetyl group protecting its reactive primary amine moiety. It
provides a biomolecule model to explore the complexes ability to bind to thiol
containing cysteine residues which are found extensively in cellular proteins.
The binding was studied via HPLC and LC-MS. Since 10-OH can be made into
solutions of concentration >1 mM its binding was also studied by 1H NMR.
6.3.4.1. 1H NMR Spectroscopy
The ability of 10-OH (1 mM) to bind to 9-EtG, GSH, GSSG and NAC (1 mol.
equiv.) was studied in phosphate buffered D2O at 37 °C. A 1H NMR spectrum
was recorded before and after 24 h incubation with the different biomolecule
models. When 10-OH was incubated with 9-EtG no binding was observed in the
spectrum (Figure 6.16). The only peaks observed after incubation were the
original peaks belonging to 10-OH and 9-EtG, and peaks belonging to p-cym
which are a product of 10-OH degradation (as shown in Section 6.3.2). After
incubation with NAC, various species were observed in the 1H NMR spectrum
(Figure 6.16). The vast majority of 10-OH binds with NAC to form a thiolato
adduct (10-NAC, as shown in Section 6.3.4.2), where binding occurs between
Os(II) and the sulfur atom of the NAC thiol side chain, replacing the
monodentate hydroxide ligand. Interestingly, since both NAC and 10-OH have
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chiral centres, 10-NAC has two diastereomers and therefore two sets of peaks
were observed in some instances. No free NAC was observed after 24 h
incubation, however un-reacted 10-OH, p-cym peaks corresponding to complex
degradation, and oxidised NAC were observed. NAC has a tendency to oxidise
in aerobic conditions forming a S-S bridged disulfide species (Scheme 6.5.),
which gave rise to a set of peaks (marked in yellow in Figure 6.16).43 In a
control study, NAC was incubated in the absence of 10-OH for 24 h and over
50% conversion to oxidised NAC was observed.
Scheme 6.5. Oxidation of (A) NAC, and (B) GSH in aerobic conditions involving the formation of
S-S bridged dimeric disulfide species.
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Figure 6.17.
prepared in D
1H NMR spectra
2O (pH* 7.4). Spectra were collected on a 500 or 600 MHz instrument.
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Similarly, the incubation of 10-OH with GSH resulted in the formation of a
thiolato-adduct (10-SG) as shown in Section 6.3.4.2, also having two
diastereomers due to the chiral centre in GSH (Figure 6.17). Likewise, GSH
also oxidises in aerobic conditions to form a bridged disulfide species (GSSG,
Scheme 6.5), which was observable in the 1H NMR spectrum. A control study
where GSH was incubated by itself showed 100% conversion to GSSG after 24
h. Also observable are peaks belonging to un-reacted 10-OH and p-cym peaks.
Interestingly, upon incubation with GSSG, 10-OH was also able to form the 10-
SG adduct (Figure 6.17), but to a much lesser extent. Due to the presence of
multiple species and precipitation occurring in the NMR tubes, it proved difficult
to identify all of the peaks (particularly for the reaction between 10-OH and
GSH). To overcome this problem the reactions were monitored by HPLC.
6.3.4.2. HPLC/LC-MS
The binding of complex 10-OH with NAC, GSH and GSSG was also explored
using HPLC. Complex 10-OH (1 mM) was incubated with NAC, GSH or GSSG
(1 mol. equiv.) at 37 ºC and pH 7.4 for 24 h, and samples were analysed before
and after incubation (Figure 6.18). Furthermore, samples were analysed by LC-
MS to identify the species in the chromatograms and the mass spectroscopy
peaks are shown in Figure 6.21, observed as positively charged complexes
without their counter ions (PF6- or CF3SO3-). Remarkably, when 10-OH was
incubated with NAC and GSH, not only were thiolato-adducts 10-NAC and 10-
SG observed but also sulfenato-adducts, 10-NAC(O) and 10-SOG, likely
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occurring due to oxidation of sulfur in aerobic conditions. Moreover, incubating
10-OH with GSSG was shown again to produce the 10-SG adduct in small
quantities.
For comparison, the binding capabilities of 11 and FY026 were also analysed to
determine whether the presence of a stable Os-I bond could block the binding
to biological targets. Because of their poor solubility in aqueous media samples
were prepared with 75 µM of complex. When 11 and FY026 were incubated
with 1 mol. equiv. of either NAC, GSH or GSSG no substrate binding was
observed (Figure 6.19). Interestingly however, formation of the hydroxido
species (11-OH and FY026-OH) was observed. As the HPLC method was
carried out with 0.1% TFA ion-pairing agent in the mobile phase, both 10-OH
and 11-OH lose their PF6- and CF3SO3- counter-ions in exchange for CF3CO2-.
Hence, 10-OH and 11-OH are observed as the same species in HPLC and
exhibit identical retention times. The extent of complex hydrolysis caused by
each biological target follows the order GSH>NAC>GSSG, where GSH
produced the greatest conversion to the hydroxido-adduct. Furthermore, FY026
was less prone to hydrolysis than 11. In a control study where 11 and FY026
were incubated in the absence of a substrate in phosphate buffer solution,
complexes remained stable over 24 h with <1% hydroxide-adducts generated.
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Figure 6.18. HPLC chromatograms (254 nm wavelength of detection) of 10-OH (1 mM) before
and after 24 h incubation at 37 °C with; (A) 1 mM NAC, (B) 1mM GSH, and (C) 1 mM GSSG.
Species b to f are shown in Figure 6.21 with their mass spectrometry peaks. Assignments: (b)
10-OH, (c) 10-NAC, (d) 10-NAC(O), (e) 10-SG, (f) 10-SOG.
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When 11 and FY026 were incubated with 100 mol. equiv. of NAC or GSH (7.5
mM), the formation of thiolato-adducts 11-SG, 11-NAC, FY026-SG and FY026-
NAC was observed (Figure 6.20). Complex 11 was the most reactive,
completely binding to NAC and GSH (accompanied by the disappearance of 11)
after 3 h incubation. Complex FY026 binds more slowly and was entirely
consumed after 12 h and 6 h of incubation for NAC and GSH, respectively.
Moreover, both 11 and FY026 were also capable of forming sulfenato-adducts,
11-SOG, 11-NAC(O), FY026-SOG and FY026-NAC(O), with small peaks
observable in HPLC chromatograms. Unlike 10-OH, complexes 11 and FY026
were not capable of forming adducts thiolato-adducts upon incubation with
GSSG. Increasing the amount of GSSG from 1 to 100 mol. equiv. produced a
greater extent of hydrolysis, but no thiolato-adduct was observed. All samples
incubated for 24 h were further analysed by LC-MS and all mass-spectrometry
peaks of the species are also shown in Figure 6.21. Table 6.3 summarises all of
the species identified by HPLC and LC-MS.
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Figure 6.19. HPLC chromatograms of 11 and FY026 (75 µM) after incubation with 1 mol. equiv. NAC, GSH or GSSG for 0, 3, 6, 12 and 24 h at 37 °C and pH
7.4. (A) 11 with NAC. (B) 11 with GSH. (C) 11 with GSSG. (D) FY026 with NAC. (E) FY026 with GSH. (F) FY026 with GSSG. The wavelengths of detection
used for 11 and FY026 were 254 and 610 nm respectively. Assignments of (a), (b), (g) and (h) are shown in Figure 6.21 and Table 6.3.
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Figure 6.20. HPLC chromatograms of 11 and FY026 (75 µM) after incubation with 100 mol. equiv. NAC, GSH or GSSG for 0, 3, 6, 12 and 24 h at 37 °C and
pH 7.4. (A) 11 with NAC. (B) 11 with GSH. (C) 11 with GSSG. (D) FY026 with NAC. (E) FY026 with GSH. (F) FY026 with GSSG. The wavelengths of
detection used for 11 and FY026 were 254 and 610 nm respectively. Assignments of (a)-(l) are shown in Figure 6.21 and Table 6.3.
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Figure 6.21. LC-MS data showing all the species found in the HPLC studies for 10-OH, 11 and FY026 when incubated with NAC, GSH and GSSG. All mass
spectrometry peaks were observed as positively-charged ions without their counter ions (PF6- or CF3SO3-).
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Table 6.3. All of the species identified by HPLC/LC-MS and their molecular formulas, calculated and observed m/z values, and HPLC retention times
Assignment Species Molecular formula Calculated m/z Observed m/z HPLC retention(min)
(a) 11(-CF3SO3) C23H27IN3OOs+ 680.08 680.00 24.05
(b) 10-OH(-PF6) or 11-OH(-CF3SO3) C23H28N3O2Os+ 570.18 570.11 12.61
(c) 10-NAC(-PF6) or 11-NAC(-CF3SO3) C28H35N4O4OsS+ 715.20 715.11 16.39
(d) 10-NAC(O)(-PF6) or 11-NAC(O)(-CF3SO3)
10-NAC(O)(-PF6+H+) or 11-NAC(O)(-CF3SO3+H+)
C28H35N4O5OsS+
C28H36N4O5OsS2+
731.19
366.10
731.06
366.14
13.25
(e) 10-SG(-PF6) or 11-SG (-CF3SO3)
10-SG(-PF6+H+) or 11-SG (-CF3SO3+H+)
C33H43N6O7OsS+
C33H44N6O7OsS2+
859.25
430.13
859.16
438.07
13.38
(f) 10-SOG(-PF6) or 11-SOG(-CF3SO3)
10-SOG(-PF6+H+) or 11-SOG(-CF3SO3+H+)
C33H43N6O8OsS+
C33H44N6O8OsS2+
875.25
438.13
875.14
438.07
11.68
(g) FY026 (-PF6) C23H28IN4Os+ 679.10 679.02 23.02
(h) FY026-OH (-PF6) C23H29N4OOs+ 569.20 569.17 12.53
(i) FY026-NAC (-PF6) C28H36N5O3OsS+ 714.22 714.15 16.09
(j) FY026-NAC(O) (-PF6)
FY026-NAC(O) (-PF6+H+)
C28H36N5O4OsS+
C28H37N5O4OsS2+
730.21
365.61
730.14
365.67
12.68
(k) FY026-SG (-PF6)
FY026-SG (-PF6+H+)
C33H44N7O6OsS+
C33H45N7O6OsS2+
858.27
429.64
858.19
429.65
13.29
(l) FY026-SOG (-PF6)
FY026-SOG (-PF6+H+)
C33H44N7O7OsS+
C33H45N7O7OsS2+
874.26
437.64
874.15
437.64
11.54
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6.3.5. Oxidation of NADH
6.3.5.1. UV-Vis spectroscopy
Complexes 10-OH, 11, and 31 (4 µM) were incubated at 37 °C and pH 7.4 with
NADH (50 mol. equiv.), and the UV-Vis spectrum was recorded every 1 h for 24
h. NADH has two major absorption bands at 260 and 339 nm. As NADH is
oxidised to NAD+, the intensity at 339 nm declines and the intensity at 260 nm
increases.31
Figure 6.22. UV-Vis spectra of 200 µM NADH incubated at 37 °C and pH 7.4 for 24 h. (A)
control experiment with no complex added. (B) with 4 µM 10-OH. (C) with 4 µM 11. (D) with 4
µM 31.
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In a control experiment where no complex was added, only a small degree of
NADH oxidation was observed (noted by the decline in intensity at 339 nm). In
comparison to the control, 10-OH caused the greatest extent of NADH
oxidation, followed by 11. Complex 31 on the other hand caused little more
NADH oxidation than that observed in the control study (Figure 6.22). Using the
same sample concentrations, a kinetic UV-Vis experiment was conducted
where the intensity of the absorption band at 339 nm was monitored over a 24 h
period every 5 min at 37 °C. The ‘absorbance/(absorbance at t = 0)’ min was
plotted versus time to display the extent of decline in NADH over a 24 h period
(see Figure 6.23).
Figure 6.23. Reaction profiles for the oxidation of NADH to NAD+ caused by complexes 10-OH,
11, 31 and no complex (control). Showing the normalised absorbance at 339 nm vs. time (min).
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Complex 10-OH produces the fastest rate of NADH oxidation followed by 11,
then 31 which produces little or no more NADH oxidation than the auto-
oxidation of NADH observed in the control experiment. Since the complexes
also absorb light at 339 nm it was not possible to accurately determine [NADH]
at varying time points from absorption at 339 nm. The reaction profile between
NADH and 11 follows a different non-linear path, where the rate of conversion
of NADH to NAD+ is initially slow and gradually increases with the progression
of time until it is comparable to that of 10-OH with NADH.
6.3.5.2. HPLC
Complexes 10-OH, 11 and 31 (50 µM) were incubated at 37 °C with NADH (4
mol. equiv.) with phosphate buffer (5 mM, pH 7.4) for 0, 3, 6, 12 and 24 h, and
the HPLC chromatograms were recorded. NADH and NAD+ both have very low
retention times of below 5 min and it was therefore not possible to distinguish
between them. However, HPLC proves useful for determining the stabilities of
the complexes in the presence of NADH (Figure 6.24).
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Figure 6.24. Chromatograms for complexes (50 µM) after incubation with 4 mol. equiv. NADH
at 37 °C and pH 7.4, after 0, 3, 6, 12 and 24 h. (A) 10-OH, (B) 11 and (C) 31.
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Complex 10-OH remains reasonably stable over the initial 6 h incubation period,
but major degradation was observed after 12 h. This is consistent with the
stability testing of 10-OH shown in Section 6.3.2. Complex 11 hydrolyses in the
presence of NADH to form the hydroxido-adduct, showing 30% 11-OH after 24
h incubation. In contrast, complex 31 remains almost entirely stable upon
incubation with NADH, forming only 2% hydroxido-adduct (31-OH) after 24 h
incubation. In the control experiments where 11 and 31 were incubated in the
absence of NADH, 1% and 0% of the hydroxido-adducts (11-OH and 31-OH)
were observed, respectively, in the chromatograms after 24 h.
6.3.5.3. 1H NMR Spectroscopy
Complex 10-OH (2 mM) was prepared in phosphate buffered D2O (pH* 7.4) with
NADH (3 mol. equiv.). A 1H NMR spectrum was obtained after 0, 4 and 23 h
incubation at 37 °C. Figure 6.25 shows the aromatic region of the spectra
between 5.8 - 9.6 ppm and part of the aliphatic region between 2.6 - 2.8 ppm.
The peaks corresponding to NADH, NAD+ and 10-OH were characterised. With
no sample incubation the presence of NAD+ peaks was already observable, as
a small amount of NADH oxidation occurred between preparing the sample and
acquiring the 1H NMR spectrum at ambient temperatures. After 23 h incubation,
all of the NADH peaks completely disappeared and NADH was completely
oxidised to NAD+. Peaks corresponding to 10-OH also show a decline after 24
h, owing to the characteristic degradation of 10-OH shown previously. Aliphatic
NADH proton peaks, d1 and d2 correspond to the site where dehydrogenation
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occurs. These peaks characteristically disappear as NADH is oxidised to NAD+
and are replaced by a single aromatic doublet at 8.81 ppm, proton d.
Furthermore, 10-OH (75 µM) was incubated at 37 °C with NADH (100 mol.
equiv.) in phosphate buffer and the solution was tested for the presence of H2O2
using Quantifix® H2O2 semi-quantitative test sticks. Low levels of H2O2 (~0.5
ppm) were observed in solution after 30 and 60 min, after which the levels of
H2O2 were undetectable (see Table 6.4).
Table 6.4. Measurements of H2O2 levels during the reaction between 10-OH and 100 mol.
equiv. NADH in phosphate buffer solution at 37 °C. Measurements made using H2O2 semi-
quantitative testing sticks.
Time (min) H2O2 levels(ppm)
0 min 0.0
30 min ~0.5
60 min ~0.5
120 min ~0.0
180 min ~0.0
Figure 6.25.
buffered D
1H NMR spectra recorded during the reaction between 2mM
2O (pH* 7.4) and spectra were recorded after incubations of 0, 4 and 23 h at 37 °C. Spectra were collected on a 600 MHz instru
10-OH and 3 mol. equiv. NADH. The experiment was performed in phosphate
ment.
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6.4. Discussion
6.4.1. The pKa and stability of 10-OH
The pKa measurement of the coordinated water molecule in an aqua-complex is
an important measure of drug activity. It determines whether the active aqua-
adduct species (Os-OH2) will predominate, or the more stable hydroxido
species (Os-OH) at any given pH.44 Since iodido Os(II) arene AZPY pro-drugs
(10 and 11) do not readily hydrolyse in aqueous media, complex 10-OH was
synthesised for study. The low pKa value of 10-OH is consistent with the low
values observed for Ru(II) arene AZPY complexes,45 showing that under
physiological conditions (pH 7.4) the hydroxido species predominates. Strong
π-acceptor ligands such as AZPYs draw electron density away from the metal 
centre rendering it more electropositive, which in turn makes the H2O ligand
more acidic (lower pKa).44 In contrast, anionic ligands such as acetylacetone
and picolinate place more electron density around the metal centre, hence
producing the opposite effect (Figure 6.26).46-48 Moreover, Os(II) arene
complexes have a greater tendency for lower pKa values in their aqua-adducts
than their Ru(II) analogues.44 Interestingly, when compared to the diverse range
of aqua-species of Os(II) and Ru(II) arene anti-cancer complexes from the
Sadler group, 10-OH is the most acidic species to be determined to date. Its
acidity is even greater than that of [Os(ɳ6-p-cym)(IMPY-NMe2)H2O]2+
(containing an IMPY bidentate ligand,14 which is analogous to the AZPY ligand
in FY026), and the Ru(II) AZPY complex, [Ru(ɳ6-p-cym)(AZPY-NMe2)H2O]2+.45
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Figure 6.26. A comparison of the pKa* values for M-OD2 found in various aqua-species of Sadler group complexes. The pKa* values shown were determined
by 1H NMR in D2O where pH* was not corrected for the effect of deuterium on the glass electrode. The complexes shown are Os(II) and Ru(II) ɳ6-arene
complexes with different bidentate ligands capable of tuning electron density around the metal centre, hence dictating the acidity of the monodentate D2O
ligand. Complex 10-OH is the most acidic aqua-species.14,45-51
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Complex 10-OH was shown to be unstable upon incubation in phosphate buffer
solution (pH 7.4), with only 38% remaining intact after 24 h and approximately
58% lost as an unknown black precipitate. In the 1H NMR experiment unknown
peaks corresponding to 10-OH degradation products were also observed. Large
broad unidentified peaks were observable at 6.65, 1.85, 1.45 and 0.86 ppm. It
may be possible for higher oxidation states of osmium species to form (e.g.
Os(III)), which would yield broad peaks due to the shorter relaxation times
associated with paramagnetic species. Also present was a new set of p-cym
peaks with two aromatic doublets at 7.26 and 7.22 ppm, which are speculated
to belong free p-cym. However, p-cym is insoluble in D2O and therefore not
likely to show peaks in the spectrum. Peacock et al previously reported the
formation of a hydroxido-bridged dimeric species, [(ɳ6-p-cym)Os(µ-OD)3Os(ɳ6-
p-cym)]+, after preparing Os(II) p-cym maltolato complexes in D2O (pH* 7.3).52
However, the aromatic p-cym doublets are reported to be at 6.04 and 5.82 ppm
and are therefore not consistent with these findings.
6.4.2. Generation of HO· radicals from H2O2
Complexes 8, 10-OH and 11 fully decompose 50-100 mol. equiv. H2O2 within 30
min of incubation at 37 °C. The depletion of H2O2 is accompanied by
degradation of the complexes as observed by UV-Vis spectroscopy, and the
generation of gases. In Chapter 4, Section 4.3.15, it was shown that Os(II)
arene AZPY complexes are capable of raising ROS levels, including O2·-
radicals, within A2780 cancer cells. However, EPR spin trapping experiments
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prove that 8, 10-OH and 11 generate HO· and not O2·- radicals in the presence
of H2O2.
Since relatively high concentrations of H2O2 (3-10 mM) were used in these
experiments in comparison to physiological concentrations, it was suspected
that HO· radicals were being produced in large amounts and contributing to the
degradation of the complexes. When UV-Vis spectroscopy experiments were
repeated in the presence of 7.5% (v/v) EtOH (a known HO· quencher),37
decomposition of the complexes was mainly prevented over a 2 h period,
suggesting that HO· is responsible for their degradation. However, the rates of
decomposition of H2O2 were also significantly reduced when EtOH was
introduced. These observations suggest that the complexes are decomposed
by HO·, generating new species in situ which in turn causes further rapid H2O2
degradation. Currently the mechanism(s) of HO· production are not yet
understood, but are likely to involve the oxidation of Os(II) to higher oxidation
states. Further experimentation involving X-ray Absorption Near Edge
Spectroscopy (XANES) could be used as a means to determine which oxidation
states of osmium are present in solution.53 Furthermore, it was speculated that
when 8 and 11 react with H2O2, H· radicals could also be produced alongside
HO·, but the EPR signal of DEPMPO-H was weak and its presence is not
entirely certain. DEPMPO has been previously reported to trap both H· and 
HO· radicals simultaneously in plant plasma membranes.42 Gas
chromatography could be utilised to determine if hydrogen is being produced
upon H2O2 degradation with these complexes.30 Until more is understood about
the mechanism of action and whether a catalytic cycle takes place, it cannot be
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said with any certainty whether the process of HO· production resembles that of
Fenton chemistry.24
The rate of decomposition of the complexes with H2O2 occurs in the order 10-
OH>8>11, as does the speediness of H2O2 degradation. Moreover, the activity
towards HO· radical production occurs in the order 10-OH>8~11, and the extent
of lysozyme degradation (via HO· production) follows the order 10-OH~8>11.
Lysozyme degradation might occur indiscriminately with no site specific pre-
binding of an active species occurring before protein cleavage, as indicated by
the smearing on the electrophoresis gels. The extent of protein cleavage
increases with higher concentrations of H2O2, showing that the high H2O2 level
microenvironment of a tumour is more likely to sustain damage caused by
HO· generation than the lower H2O2 level environments of normal cells.
However, substantial lysozyme damage (>70%) was only observed in 10 mM
H2O2, which is significantly higher than the typical H2O2 levels found within
tumour microenvironments.2,15,21
Finally, it was shown that pro-drugs 8 and 11 are not as reactive with H2O2 as
their hydroxido analogue 10-OH. Furthermore, MS data shows the presence of
10-OH when 8 and 11 were incubated with H2O2, suggesting that the initial
barrier in the formation of HO· radicals could involve loss of the halido
monodentate ligand. The chlorido complex (8) was found to degrade lysozyme
to a much greater extent than the iodido complex (11) in 10 mM H2O2. Likely
because the chloride ligand is considerably more labile than iodide, hence
enabling faster conversion to the activated complex 10-OH. However, it is not
yet fully understood.
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6.4.3. Binding to cellular targets
Complex 10-OH was found not to bind to the guanine derivative, 9-EtG. This
observation might be partly explained by the very low pKa* (4.4) of [Os(ɳ6-p-
cym)(5-EtO-AZPY)H2O]2+, which exists predominantly as a hydroxido-adduct
under physiological conditions. Hydroxido-adducts are generally less reactive
than aqua-adducts, in this case showing no interaction with neutral N-lone pair
donor ligands, such as DNA nucleobases.44 In contrast, [Os(ɳ6-p-cym)(5-IMPY-
NMe2)H2O]2+ and [Ru(ɳ6-p-cym)(AZPY-NMe2)H2O]+, also exhibiting low pKa*
values for their monodentate water ligands (5.2 and 4.6 respectively) are both
capable of limited binding to 9-EtG under physiological conditions.14,45 However,
quicker and more extensive binding to 9-EtG is generally observed for Os(II)
and Ru(II) arene aqua-complexes with anionic or strong σ-donor bidentate 
ligands, which exhibit higher pKa* values for their monodentate water
ligands.46,47
Unlike neutral guanine bases that bind through N-lone pairs and form
complexes in a +2 charged state, the nucleophilic thiolate side chains of GSH
and NAC were found to bind readily with 10-OH to form +1 charged complexes
(Scheme 6.6). Sulfur containing amino acid side chains are known for their
ability to bind to platinum group metals like ruthenium, due to the good
interaction between a soft acid (Ru+) and soft bases (RS-).10,11 However, this is
the first report of Os(II) arene AZPY complexes binding to GSH. Complex 10-
OH was also capable of forming a 10-SG adduct when incubated with GSSG.
Such a process would require reduction of the stable S-S bond. The mechanism
of this process is unknown, but could potentially involve the transfer of an
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electron from Os(II) to GSSG (see Scheme 6.7). New broadened peaks were
present in the 1H NMR spectrum when 10-OH was reacted with GSSG, which
are not present when it was reacted with GSH. This could indicate the presence
of Os(III) paramagnetic species. However, no peak broadening was observed
for the peaks corresponding to 10-OH or 10-SG.
Scheme 6.6. The nucleophilic substitution reaction between 10-OH and GSH or NAC.
Scheme 6.7. Possible mechanism for the reduction of GSSG with 10-OH, involving one
electron transfer from the Os(II) metal centre to form Os(III).
When 11 and FY026 were incubated with 1 mol. equiv. of GSH or NAC (75 µM),
no binding to the thiol side chains were observed, however formation of the
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hydroxido/aqua-adducts occurred (see Scheme 6.8). Furthermore, FY026 was
less prone to hydrolysis than 11, showing a similarity to the results shown in
Chapter 5, Section 5.3.2. In comparison, in control studies where 11 and FY026
were incubated in the absence of GSH and NAC no more than 1% hydrolysis
occurred. This suggests that such reactions with peptides/proteins containing
thiol side chain groups may be responsible for the activation of iodido pro-drugs
inside cells, to generate the less inert hydroxido-adducts. Further investigations
are required to uncover the mechanism of activation.
Scheme 6.8. Reaction between 11 or FY026 (75 µM) and R-SH (GSH or NAC). (A) 1 mol.
equiv. of R-SH. (B) 100 mol. equiv. R-SH. Oxidation by O2 is denoted by [O].
11: R1 = OEt, R2 = H
FY026: R1 = H, R2 = NMe2
(B)
(A)
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However, when 11 and FY026 were incubated with 100 mol. equiv. of GSH or
NAC, no hydroxido-adducts were observed in the chromatograms, except when
FY026 was reacted with GSH or NAC a very small peak occurred after 3h which
later disappeared. After less than 24 h, 11 and FY026 completely reacted with
GSH or NAC to form a thiolato-adduct (major product) and a sulfenato-adduct
(minor product). The latter of which is likely a consequence of O2 oxidation as
samples were not purged with N2 prior to incubation. Likewise, a sulfenato-
species was previously observed in the Sadler group when [Ru(ɳ6-
bip)(en)Cl]PF6 was incubated with GSH in aerobic conditions. Its formation was
largely suppressed when incubation occurred under anaerobic conditions.11
The iodido-species might undergo direct binding to GSH or NAC via the thiol
side chain, accompanied by the loss of the iodide monodentate ligand (Scheme
6.8). Similarly, a ruthenium complex, [Ru(ɳ6-bip)(AZPY-NMe2)I]PF6, was also
found to directly bind with GSH, involving complete substitution of the iodide
ligand with GS- to produce a thiolato-adduct.10 Given that intracellular levels of
GSH are high (1-10 mM)4 it is probable that thiolato-adducts (11-SG and
FY026-SG) would form predominantly in vitro. However, such species are not
necessarily 'dead end' products with no further involvement in anti-cancer
activity. The sulfenato-species previously observed when [Ru(ɳ6-bip)(en)Cl]PF6
was incubated with GSH in aerobic conditions was capable of binding to DNA
nucleobases.11 Moreover, an Ir(III) cyclopentadienyl complex, Ir(ɳ5-Cpxbip)(2-
PhPy)Cl, was found to form a stable thiolato-adduct with GSH.54 However, in
the presence of H2O2 it was able to form sulfenato- and even sulfinato-adducts
that are believed to play a further role in anticancer activity and could interact
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with other cellular targets. Further studies mimicking these conditions are
required to determine whether such reactions are reproducible for 11 and
FY026.
6.4.4. Catalytic oxidation of NADH to NAD+
Complexes 10-OH, 11 and 31 were capable of oxidising NADH to NAD+ with
capabilities following the order 10-OH>11>31. Furthermore, the control study
shows a small degree of NADH oxidation occurring in the absence of a
complex, likely a consequence of O2 exposure. Interestingly, iodido pro-drugs
(11 and 31) were less capable of oxidising NADH than the hydroxido complex
(10-OH), which is proposed to be the species occurring after cellular activation
of 10 (or 11). Moreover, the HPLC studies showed that 11 undergoes 30%
hydrolysis after a 24 h incubation period in the presence of 4 mol. equiv. of
NADH. However, in the absence of NADH only 1% hydrolysis of 11 was
observed, thus indicating that NADH is capable of activating iodido pro-drugs.
These results reveal the importance of the presence of hydroxido species in the
oxidation of NADH to NAD+. Complex 11 starts initially with a slow rate of NADH
oxidation. However, as 11-OH is produced in-situ through hydrolysis of the Os-I
bond, the reaction rate gradually increases until it resembles the rate of NADH
oxidation found for 10-OH. Complex 31 on the other hand remains almost
entirely stable throughout the 24 h period, showing only 1% hydrolysis, and
oxidises NADH at a rate only marginally quicker than that of the control study.
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The mechanism of NADH oxidation may be catalytic and similar to the
mechanism of action proposed for Os(II) arene IMPY complexes (analogous to
AZPY complexes), where a Os-H species is formed.14 However, the presence
of the hydride species was not confirmed herein and more studies are required
to prove that the reaction occurs catalytically. A hydride species has previously
been observed by 1H NMR in H2O for Os(II) arene IMPY complexes,14 and also
for Ir(III) Cp* complexes.31,32 Some Ir(III) Cp* complexes were found to produce
H2 in GC experiments when incubated with NADH, confirming that the hydride
species is converted back to the aqua-species via the release of gaseous H2.30
In contrast, Os(II) arene IMPY complexes did not produce H2 and a mechanism
involving hydride transfer to O2, resulting in the formation of H2O2 was
proposed. When 10-OH was incubated with NADH, low levels of H2O2 were
detected using H2O2 semi-quantitative test sticks, hence providing partial
evidence that 10-OH could behave similarly to Os(II) arene IMPY complexes.
6.5. Summary
Following on from the findings in Chapter 5, hydroxido-species of the form
[Os(ɳ6-arene)(R1-AZPY-R2)OH]+ were proposed to be the active species formed
via cellular activation of their iodido pro-drug counterparts. A hydroxido complex
was synthesised (10-OH) and the pKa of its monodentate aqua ligand was
determined as 4.55(±0.01). The very low observed pKa is a signature of Os(II)
arene complexes featuring bidentate ligands with strong π-acceptor/weak σ-
donor capabilities, and suggests that under physiological conditions it exists
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predominantly as the hydroxido-species as opposed to the more reactive aqua-
species. Unlike its iodido analogue which is stable upon incubation, 10-OH was
shown to undergo 62% degradation. However, it is more reactive towards
biological targets: H2O2, NAC, GSH, GSSG and NADH.
Complexes 8, 10-OH and 11 were all found to generate HO· radicals in the
presence of H2O2, which were observed in EPR experiments employing
DEPMPO as a spin trap. The mechanism of HO· generation is not understood,
but it was found that generated HO· radicals caused degradation of the
complexes and higher oxidation states of osmium are likely generated, which in
turn caused rapid decomposition of H2O2. It was shown that the HO· radicals
generated from H2O2 by these complexes can be utilised to break down the
protein lysozyme. Hence, it is proposed that raised H2O2 levels present in
cancerous cells could be utilised, which upon incubation with the complexes
would generate HO· radicals capable of damaging/destroying the cells, whilst
leaving normal cells with considerably lower levels of H2O2 relatively unscathed.
In the presence of H2O2, complex 10-OH was found to decompose more quickly
and generate HO· radicals more efficiently, causing more damage to lysozyme
in comparison to its halido analogues. Thus adding weight to the notion that the
hydroxido-adduct is the activate species inside cells.
Complexes 10-OH and 11 were found to oxidise NADH to NAD+. The reaction
profile for 11 followed a particular path, whereby the initial reaction rate is slow
and did not speed up until ~12 h of incubation. HPLC analysis revealed that 11
undergoes slow hydrolysis in the presence of NADH to form 11-OH, showing
that the presence of the hydroxido-adduct is necessary for NADH oxidation.
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Interestingly, incubation with NADH also provides an activation route for iodido
pro-drugs to form their corresponding hydroxido-adducts. The rate of NADH
oxidation caused by 31 was only slightly greater than that found in the control
study where NADH was incubated by itself. HPLC analysis showed that 31
does not readily hydrolyse with NADH, which could account for its poor activity.
The mechanism of NADH oxidation is unknown, but is suspected to follow a
catalytic cycle similarly to the catalytic cycle proposed for Os(II) arene IMPY
complexes by Ying Fu.14 However, further studies are required to confirm the
reaction is occurring catalytically and confirm the presence of a hydride species
(Os-H bond) by 1H NMR.
Complex 10-OH does not to bind to 9-EtG. This was explained by its acidic
nature and its tendency to form the +1 charged hydroxido-adduct over the +2
charged aqua-species under physiological conditions. Complex 10-OH was
however capable of binding to NAC and GSH via their thiol groups to form +1
charged thiolato-adducts (major product) and sulfenato-adducts (minor
product). The latter was likely formed by O2 oxidation of the thiolato-adduct
under aerobic conditions. Interestingly, 10-OH was also capable of forming
small amounts of the thiolato-adduct when incubated with GSSG. Such a
process requires the reduction of GSSG, which is speculated to occur via
electron transfer from Os(II).
When iodido pro-drugs, 11 and FY026, where incubated with 1 mol. equiv. of
NAC or GSH (75 µM), formation of the hydroxido-species occurred. Interactions
with such species at low concentrations could provide activation routes for
iodido complexes inside cells. However, When 11 and FY026 were incubated
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with 100 mol. equiv. of NAC or GSH (7.5 mM), formation of the thiolato-adducts
were observed with sulfenato-adducts present as a minor product. Since GSH
levels are present in milli-molar concentrations in intracellular conditions, the
most likely scenario would involve 11 and FY026 binding to GSH in vitro
forming thiolato- and sulfenato-adducts. However, such species are not
necessarily ‘dead end’ products and could play a role in other biological
activities.11,54
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7.1. Introduction
This chapter explores potential areas of future work in the research of Os(II)
arene complexes containing bidentate azo-ligands. It is mainly based on the
results of previous chapters and preliminary data that were not included. Herein
I discuss further studies required to develop our understanding of the
mechanisms of action of the complexes shown in previous chapters. I also
discuss new areas of research to explore, including the synthesis of novel
pharmacophoric species.
7.2. Solubilisation of Os(II) arene AZBTZ complexes
In Chapter 3, Os(II) p-cym complexes containing novel bidentate
phenylazobenzothiazole (AZBTZ) ligands were shown to exhibit unique
chemical and structural properties. Unfortunately these species (particularly
neutral N,C-coordinated species) have extremely poor solubility in aqueous
media (<10 µM determined by ICP-MS for saturated solutions in water with 5%
DMSO), likely owing to the highly conjugated aromatic AZBTZ ligands. As such,
it was not possible to progress to biological evaluations. Further complexes
were synthesised with various electron withdrawing or water solubilising
substituents on the AZBTZ ligand in an attempt to improve water solubility (see
Figure 7.1), however, it proved relatively ineffective. Further attempts included
incorporating complexes into water soluble cyclic sugars (α- and β-
cyclodextrin), but it provided only very limited increases in solubility due to the
size and shape specific cavities of the cyclodextrins.1,2
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Figure 7.1. Structures of other novel complexes that were synthesised with electron
withdrawing groups; (A) Os(ɳ6-p-cym)(N,C-6-F-AZBTZ-NMe2)Cl, and (B) Os(ɳ6-p-cym)(N,C-6,8-
F,F-AZBTZ-NMe2)Cl, and complexes synthesised with water solubilising groups, (C) Os(ɳ6-p-
cym)(N,C-AZBTZ-N{CH2CH2OH}2)I, and (D) Os(ɳ6-p-cym)(N,C-6-MeSO2-AZBTZ-
N{CH2CH2OH}2)I.
A feasible method for improving the water solubility of lipophilic metal
complexes is to encapsulate them into a water soluble polymer. This has
previously been achieved for strongly hydrophobic ruthenium arene dithiolato-
carborane complexes designed for boron neutron capture therapy.3 These
insoluble complexes were encapsulated into Pluronic® triblock copolymer P123
to form water soluble micellar structures with potent anti-cancer activity and
enhanced selectivity towards cancerous cells over normal cells. Copolymer
P123 exhibits central lipophilic side-chains and terminal hydrophilic groups.
Os
Cl
S
N N N
NMe2
F
Os
Cl
S
N N N
NMe2
F
F
(A) (B)
(C) (D)
After self
whilst the hydrophilic groups surround the surface of the micelle structure
(Figure 7.2). Such methods could also be
arene AZBTZ complexes for the purpose of solubilising them in aqueous media
and selectively transporting them inside cancer cells.
Figure 7.2.
Pluronic® triblock copolymer P123
from reference.
7.3. Simultaneous detection of Os and I by ICP
accumulation studies
In Chapter 4, complex
31(±2) ng Os /10
used was ICP
complex
and very low levels of accumulated iodide were observed using radio
methods. To pro
-assembly, the complex sits inside the hydrophobic core of the micelle
The encapsulation of lipophilic
3
6 cells observed after 24 h incubation. The method of
-MS, which determined the levels of
10 was shown to release its iodide monodentate ligand in MCF
vide a good comparative means of simultaneous detection of
10 was found to accumulate in A2780 cancer cells
Ru(II)
to form water soluble micelles. Graphics are taken directly
utilised to encapsulate lipophilic Os(II)
p-cym dithiolato-carborane complexes in
189Os isotope. In Chapter 5,
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accumulated iodide and osmium levels inside cancer cells after incubation with
complexes, the development of an ICP-MS methodology for the dual detection
of osmium and iodine may be possible. Cell samples are typically digested in
concentrated HNO3 because its combined strong acid and oxidising properties
enable the effective break down of all cellular components into a homogeneous
sample.4 Osmium has a tendency to be oxidised and generate the volatile OsO4
species in the presence of HNO3, which can lead to false high readings for
osmium.5 However, this can be prevented by the addition of ascorbic acid and
thiourea.6 The digestion of samples containing iodide is even more problematic.
Under low pH environments iodide can be easily oxidised to volatile I2 by O2
exposure in the samples (Scheme 7.1), leading to erroneous measurements.7
Furthermore, other volatile iodine species can form in acidic conditions such as
HI.8
Scheme 7.1. The oxidation of iodide to molecular iodine by exposure to oxygen in acidic
conditions.7
Preventing the formation of volatile iodine species can be achieved using
digestion processes under basic conditions,9 which has been proven successful
in several reports.7,9-11 The digestion of cells under various basic conditions was
tested and it was found that MCF-7 cells are readily digested in 1M KOH.
However, the ICP-MS instrument does not tolerate levels of KOH greater than
around 10 mM, and subsequent sample dilutions are likely to leave the levels of
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Os/I below the detection limits of the instrument. Cellular digestion conditions of
100 mM KOH at 80 °C for 18 h were tested and were found to be not extreme
enough to homogenise samples. Further cell digestion media tested included
32% NH3 solution, and the combination of 100 mM KOH or 32% NH3 with 30%
H2O2. None of these methods were capable of homogenising cell samples after
heating at 80 °C for 18 h, and H2O2 caused excessive foaming of the samples
and pressure build up inside the wheaton vials, making them difficult to
manipulate. Microwave-assisted digestion could prove to be an effective
method for digesting cell samples in basic media as it allows heating to take
place at temperatures greater than the boiling point of water. The reports
referenced also demonstrate the use of microwave digestion in basic media and
subsequent analysis of iodine content. However, little is known about the effect
of basic conditions in the ICP analysis of osmium. One report suggests that ICP
analysis of osmium in basic conditions leads to a decrease in ICP sensitivity.12
7.4. Sub-cellular distribution of complexes and mitochondrial uptake
The cellular distribution of a complex can be determined using cell fractionation
kits to break down cells into their cytosolic, membrane, nuclear, and
cytoskeletal fractions. HNO3 digestion followed by ICP-MS analysis of the
samples is then used to determine accumulated metal content.13 The cellular
distributions of my Chapter 4 complexes were not determined. However,
previous Os(II) arene AZPY complexes synthesised by Ying et al were reported
to be largely accumulated into the membrane fraction,13,14 which consists of the
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cellular membrane and its proteins, and cellular organelles and their
membranes (including mitochondria).
A membrane potential of -180 mV is maintained across the lipid bilayer of
mitochondria, larger in magnitude than that of any other organelle, providing an
opportunity for selective chemical targeting.15 Mitochondria are understood to
be the cellular target of FY026 and other analogous lipophilic positively charged
complexes. As previously reported, FY026 is capable of altering the potential of
the mitochondrial membrane in both A2780 and A549 cancer cell lines,
observed using a JC-10 mitochondrial membrane potential assay kit and flow
cytometry.16,17 The mitochondrial stain produces a red intensity when inside
mitochondria. Upon changes in the mitochondrial membrane potential, the dye
is released into the cytosol and converted into its monomeric green form and
detected via flow cytometry. These changes indicate the induction of
mitochondrial dysfunction brought about by the complex. Lipophilic cationic
species are well known for their targeting of the mitochondrial membrane,
exploiting its negative potential gradient as an electrostatic driving force.15 The
complexes of Chapter 4 are all cationic and mainly lipophilic as shown by their
Log Po/w values and HPLC capacity factor measurements. Studies into the
mitochondrial uptake of FY026 and Chapter 4 complexes could provide further
insight and help establish the importance of targeting mitochondria inside
cancer cells. Similar to cell fractionation kits, mitochondria isolation assay kits
are also commercially available and are used to isolate mitochondria from other
cellular organelles and components, which with ICP-MS analysis can be used to
determine the accumulation of osmium.
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7.5. Further studies into mechanisms of cellular ROS elevation
Chapter 6 provided insight into the potential mechanisms of ROS elevation
within cancer cells caused by complexes 8, 10, 10-OH, 11, 31 and FY026. The
three main cellular targets explored were H2O2, GSH and NADH. Further
studies are required to gain a fuller understanding of the roles that these
species play in the mechanism of cell death.
7.5.1. Hydrogen peroxide (H2O2)
In Chapter 6, complexes 8, 10-OH and 11 were all capable of catabolising 100
mol. equiv. of H2O2, producing HO· radicals in the process which are capable of
destroying cellular proteins. The mechanism of HO· generation is currently
unknown but is expected to involve the formation of higher oxidation states of
osmium and may resemble Fenton chemistry.18 To better understand these
processes the oxidation states of the osmium species formed during reaction
with H2O2 need to be determined. X-ray Absorption Near Edge Spectroscopy
(XANES) can be utilised to analyse the oxidation states of a metal centre in a
given solid or solution.19 Furthermore, gases were released when complexes 8,
10-OH and 11 reacted with H2O2, as shown by the bubbles observed in the
EPR tubes (Chapter 6, Section 6.3.3.4). Identifying released gases could also
provide key insight into the mechanism of H2O2 degradation/HO· generation.
This could be achieved using GC analysis.20
Quantofix® peroxide test strips that were used for testing H2O2 levels in Chapter
6, Section 6.3.3.1, unfortunately only give semi-quantitative measurements.
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Quantifying the amount of H2O2 depleted by complexes could be achieved
using UV-Vis spectroscopy. H2O2 absorbs light at ~240 nm, which in phosphate
buffer solution lies too close to the solvent cut-off point for reliable
measurements. However, ammonium heptamolybdate tetrahydrate can be used
as a H2O2 indicator. It interacts with H2O2 to yield a species with strong
absorption at 405 nm.21 Os(II) arene AZPY complexes also absorb light at 405
nm, but complex concentrations can be lowered to minimise interference.
Furthermore, to better understand the impact of complexes on H2O2 levels in
vitro, cellular H2O2 assay kits that are available commercially could be utilised to
determine the effectiveness of complexes in a real cancer cell environment with
physiological H2O2 concentrations and low levels of complex resembling sub
IC50 concentrations. Assays for the determination of cellular H2O2 content utilise
highly fluorescent probes, specific to the detection of H2O2 where it is possible
to observe very small changes in fluorescence.22
7.5.2. Glutathione (GSH)
The binding studies of complexes 11 and FY026 with 100 mol. equiv. of GSH
were conducted in aerobic conditions and formed both thiolato- and sulfenato-
adducts. Previous studies showed that a ruthenium complex, [Ru(ɳ6-
bip)(en)I]PF6, was also able to form a sulfenato-adduct with GSH in the
presence of air, which was inhibited in an Ar atmosphere.23 Further studies of
complexes 11 and FY026 in anaerobic conditions (achieved by bubbling
samples with Ar or N2) are required to prove that the oxidation of thiolato- to
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sulfenato-adducts is caused by O2 exposure. Conducting experiments in
reduced levels of O2 also resembles more closely the hypoxic environment of
cancer cells, which in theory could inhibit the formation of sulfenato-adducts as
with [Ru(ɳ6-bip)(en)I]PF6. However, there are other species present in cancer
cells (such as H2O2) that may be capable of oxidising thiolato species. As
discussed in Chapter 6, Section 6.4.3, an Ir(III) Cpxbip complex was capable of
forming a thiolato-adduct with GSH, which formed sulfenato and sulfinato
species upon reaction with H2O2.24 Mimicking these reactions for 11-SG and
FY026-SG with small amounts of H2O2 could provide further insights into the
role of these species in anti-cancer activity.
Furthermore, no study was conducted to determine whether complex 10 is
capable of catalytically oxidising GSH to GSSG. In Chapter 4, Section 4.3.12, it
was shown that the first reduction potential of 10 is -0.26 V (lying well within the
biologically relevant range). It demonstrates that 10 is even more easily
reducible than [Ru(ɳ6-p-cym)(AZPY-NMe2)I]+ (first reduction potential = -0.40
V), which is a known catalyst for GSH oxidation. Based on the hypothesis
outlined by Dougan et al,25 that M(II) arene AZPY complexes (where M = Ru or
Os) with low and accessible reduction potentials can mediate redox reactions
via their azo-bonds, 10 may be capable of such processes that are inaccessible
for analogous complexes like FY026 (first reduction potential = -0.64 V).26
7.5.3. Nicotinamide adenine dinucleotide (NADH)
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It is suspected that the mechanism for the reaction between 10-OH and NADH
involves the transfer of hydride from NADH to Os(II), similarly to Os(II) arene
IMPY complexes.27 Further experiments are required to confirm the presence of
the Os-H bond formed in-situ. Formation of the hydride species was previously
confirmed via 1H NMR for [Os(ɳ6-p-cym)(IMPY-NMe2)I]+, yielding a resonance
at -4.2 ppm when it was incubated with 4 mol. equiv. NADH.27 The presence of
H2O2 was observed during the reaction between 10-OH and NADH. This
provides limited evidence that under aerobic conditions, O2 may react with a
Os-H species to regenerate the catalyst and release H2O2 in a similar manner to
[Os(ɳ6-p-cym)(IMPY-NMe2)I]+. Further experiments are required to determine
whether the reaction occurs catalytically (as it does with [Os(ɳ6-p-cym)(IMPY-
NMe2)I]+), and to determine whether the oxidation of NADH still proceeds under
the hypoxic conditions of cancerous cells, by performing reaction under
anaerobic conditions. Osmium-bound hydride may be released via alternative
pathways such as the generation of H2, which was observed by GC for some
Ir(III) Cp complexes.20
7.6. Chiral resolution of complexes
Ever since the Thalidamide disaster in 1957 when the (S)-enantiomer of the
morning sickness drug caused children to be born with phocomelia, all chiral
drugs are now subject to compulsory isolation and purification of enantiomers to
identify their toxicities. 3-Legged piano stool osmium(II) arene complexes
containing a monodentate halide ligand and a bidentate AZPY ligand all have
chiral metal centres, owing to the in
ligands. They crystallise as racemates (an
enantiomers), which is clearly observable in the X
complex
Figure 7.3.
EtO-AZPY)I]PF
ions and solvent molecules have been omitted for clarity.
∆-Trisphat is a chiral anion and an efficient NMR chiral shift reagent for chiral
cationic comp
pairs that have different chemical shifts. Hence, the resolution of enantiomers
can be observed by
splitting of
proximity to the chiral centre
10 reported in Chapter 4, Section
Two enantiomers observed in the X
6). Ellipsoids are shown at the 50% probability level and all hy
ounds.
several peaks,
28,29 On addition to complex
1H NMR
particularly those corresponding to protons in c
.
(see Figure 7.4
-equivalent N
4.3.3 (see
-ray crystal structure of
10
)
-binding groups in AZPY
equimolar mixture of two
-ray crystal structure of
Figure 7.3).
, it forms diastereomeric ion
. The spectrum revealed the
10 ([Os(ɳ
drogens, counter
Chapter 7
335
6-p-cym)(5-
lose
Figure 7.4.
(A) After the addition of
the splitting of several aromatic peaks that correspond to protons residing close to the Os chiral
centre.
An attempt was made to chirally resolve complex
CHIRALPAK ID chiral HPLC column with a mobile phase of EtOH (0.3% TFA,
0.5% TEA) at a
with retention times of 3.70 and 3.83 min, however, the latter peak is
approximately double the size of the former suggesting that the enantiomers
were not fully resolved (Figure 7.5
required
also required to isolate the two enantiomers and test them for racemisation
under physiological conditions. Stable enantiomers should be studied
(A)
(B)
Part of the aromatic region of the
flow rate of 2.2 mL/min. The chromatogram shows two peaks
to obtain complete resolution of the two enantiomers. Further work is
∆-Trisphat
1
. (B) Before the addition of
). Optimisation
H NMR spectrum of complex
∆-Trisphat
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of HPLC conditions are
10 in methanol
. After addition shows
by HPLC using a
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individually for anti-proliferative activity. Most isomers of chiral drugs in the clinic
exhibit marked differences in biological activity.30 However, Os(II) arene AZPY
complexes are not designed for targeted therapy and so differences in activities
between enantiomers are not considered likely. Nonetheless, chiral separation
and analysis of racemic drugs are vital prerequisites within the pharmaceutical
industry and a key safety measure for moving into clinical trials.
Figure 7.5. Chromatogram of the partial resolution of the enantiomers of 10, using a
CHIRALPAK ID chiral HPLC column, a mobile phase of EtOH (0.3% TFA, 0.5% TEA), and flow
rate of 2.2 mL/min.
7.7. Complexes incorporating BCL-XL inhibitors
The pro-survival BCL-2 family of proteins are responsible for regulating cell
death by suppressing the induction of apoptosis. However, in cancer cells
certain BCL-2 proteins such as BCL-XL are over-expressed, rendering
malignant tumour cells resistant to anti-cancer agents.31 One proposed idea is
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to incorporate a known BCL-XL inhibitor pharmacophore onto an Os(II) arene
AZPY complex, hence producing a dual functional metal complex capable of
targeting a biologically active site. BCL-XL is known to reside inside
mitochondria of cancer cells, which provides a strong advantage since Os(II)
arene AZPY complexes are believed to target mitochondria.16
In Chapter 1, Section 1.2.2, a lipophilic BCL-XL inhibitor (WEHI-539) was
described with the capability of docking into a hydrophobic groove on the active
site. It may be possible to attach pharmacophores like WEHI-539 onto an AZPY
ligand utilising the glycol side chains reported in Chapter 4, Section 4.3.1.1
(Figure 7.6). The length of the glycol linkage can be tailored so as to allow the
metal centre to sit on the surface of the protein and exert its multiple
mechanisms of elevating cellular ROS levels, whilst the WEHI-539 moiety fulfils
its role of inhibiting BCL-XL. Such modifications have the potential to improve
cancer cell selectivity of Os(II) arene AZPY complexes, an issue highlighted in
Chapter 4, Section 4.4.1 which requires addressing. At the same time it would
fulfil an industry demand for targeted chemotherapies, whilst still retaining the
desirable properties associated with organometallic drugs such as multiple
mechanisms of activity. A synthetic scheme is proposed for the attachment of
BCL-XL inhibiting molecules to Os(II) arene AZPY complexes in Scheme 7.2.
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Scheme 7.2. Proposed synthesis scheme for the attachment of BCL-XL inhibitors to Os(II)
arene AZPY complexes with glycol substituents.
Figure 7.6. The structure of BCL-XL inhibitor, WEHI-539, and proposed Os(II) arene AZPY
complex with a WEHI-539 pharmacophore attached to the AZPY ligand via a glycol chain
linkage.
WEHI-539
[Os(ɳ6-p-cym)(5-WEHI-539-O-{CH2CH2O}n-AZPY)I]PF6
BCL-XL inhibitor
Variable glycol
chain linkage
Redox active Os(II)
metal centre
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8. Appendices
8.1. Chapter 3 complexes
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8.2. Chapter 4 complexes
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8.3. Chapter 5 complexes
8.4. Chapter 6 complexes
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